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Huntington’s disease (HD) is an autosomal dominantly inherited, neurodegenerative disorder 
caused by an expanded cytosine-adenine-guanine (CAG) repeat within the Huntingtin gene on 
the short arm of chromosome 4.1;2 The classic HD symptom triad including motor dysfunction 
(chorea and hypokinesia), cognitive decline and neuropsychiatric symptoms will develop when 
there are 36 or more CAG repeats within the HTT gene. Symptoms and signs of HD usually start 
to become manifest between the ages of 30 and 50,3 with an average disease duration of 20 
years.1 Although the clinical diagnosis of HD is usually based on the manifestation of motor 
signs, neuropsychiatric symptoms can already occur before the onset of motor dysfuction4-6 
and are the first manifestation of the disease in 24–79% of the mutation carriers.7 These 
symptoms have a substantial impact on the activities of daily living,4;8;9 independent of the 
presence of motor and cognitive deficits.8
Psychopathology in HD
The most frequently reported neuropsychiatric symptoms in HD are depressed mood 
(prevalence: 33–69%),10;11 anxiety (prevalence: 13–71%),11;12 irritability (prevalence: 38–73%),10;11 
apathy (prevalence: 34–76%)10;11 and obsessive-compulsive behaviours (prevalence: 10–
52%).10;11 Reported prevalence numbers vary widely depending on for example the definition 
and assessment method of the neuropsychiatric symptoms and disease stage of the study 
population.10
Degeneration of the striatum and impaired functioning of the frontostriatal circuits, already 
affected in early HD, have been proposed as important factors in the aetiology of the 
neuropsychiatric symptoms in HD.10;13-17 This is supported by studies that showed a higher 
frequency of these symptoms in both pre-motor and motor symptomatic mutation carriers 
than in first-degree non-carriers.4;5 Also environmental factors, like the psychological stress of 
being at risk and growing up in an HD family, most likely contribute to the neuropsychiatric 
symptoms.10;14
Prevalence of suicidal ideation, suicide attempts and completed 
suicide in HD
Suicide is one other common psychiatric phenomenon in HD mutation carriers, which was 
already described in 1872 by George Huntington. He noticed that “the tendency to insanity, 
and sometimes that form of insanity which leads to suicide, is marked.”18 Also today, suicide, 
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after pneumonia, is considered to be one of the most frequent causes of death in HD.3;19 Several 
recent studies showed that the suicide risk in HD is higher than in the general population, with 
up to 11% of all deaths in diagnosed motor symptomatic HD patients being due to suicide 
(Figure 1A).19-38 Compared with the general population, the risk of dying by suicide was 2 
to 8 times higher in HD,19;22;23;26 with the point estimate from a meta-analysis showing a 2.9 
times increased risk.39;40 Also in persons at 50% risk of HD, an increased suicide risk has been 
reported,19;22 with 4.5% of the deaths in this group due to suicide.22
Having a medical illness itself is a strong predictor of suicide.40;41 Compared with other somatic 
medical illnesses, the standardised mortality ratio (SMR) for suicide in HD (being 2.9) is similar 
to multiple sclerosis (SMR = 2.4), but higher SMRs for suicide were reported for several other 
diseases like HIV/aids (SMR = 6.6) and lower SMRs for suicide were reported for some other 
diseases like malignant neoplasm (SMR = 1.8).40 For most mental illnesses higher SMRs for 
suicide were found than in HD (SMRs ranging from 3.3–87).39 In contrast, the risk of suicide in 
other forms of dementia is lower than or equal to that of the general population.42
Also, high prevalence numbers for suicidal ideation and suicide attempts (together referred to 
as ‘suicidality’) have been reported in both pre-motor and motor symptomatic HD mutation 
carriers. Lifetime suicide attempts were reported in 3.2–17.7% of the diagnosed motor 
symptomatic HD patients (Figure 1B).14;20;23-25;27;31;37;43-46 One of the lowest numbers (4.8%) was 
reported in a study that considered only severe attempts which required hospitalization.25 
Also in the PREDICT-HD study, a longitudinal multi-site study investigating markers of HD prior 
to the onset of motor symptoms, 7.2% of the pre-motor symptomatic HD mutation carriers 
attempted suicide during their lives.47 These numbers are higher than reported in the general 
population from 17 different countries worldwide, in which 2.7% of the individuals ever 
attempted suicide, with substantial variability across different countries.48 Lifetime suicidal 
ideation was reported in up to 34% of the diagnosed motor symptomatic HD patients,43;45;49 
while in the worldwide general population 9.2% of the individuals reported lifetime suicidal 
ideation.48 In studies with both pre-motor and motor symptomatic mutation carriers50;51 and in 
studies with only motor symptomatic mutation carriers,9;43;45;52 a high number of participants 
indicated suicidal ideation in the month prior to the interview, ranging from 843–34%52 (Figure 
1C). The large variation in numbers can for example be explained by varying definitions and 
measurement instruments: the highest prevalence numbers were reported in studies where 
the presence of suicidal ideation was defined as a score > 0 on the suicidal ideation item of 
the Unified Huntington’s Disease Rating Scale (UHDRS),53 which implies that questionable 
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Suicidal ideation and suicide attempts are an important field of study as suicidal patients have 
a lower quality of life.54;55 However, while attempted suicide is a well-established risk factor for 
subsequent completed suicide, the importance of suicidal ideation in the prediction of suicide 
is still debatable.56
Suicidality and suicide in relation to predictive testing for HD
Given the increased suicide risk in both pre-motor and motor symptomatic HD mutation 
carriers, significant concern has been raised about the impact of predictive genetic testing,57 
especially since there is no cure for HD despite symptomatic treatment options. Predictive 
testing for HD using linkage analysis has been available since 1983 and in 1993, when the 
expanded CAG repeat in the HTT gene was first described,2 direct testing of the mutation 
became available.3
Suicidality is not uncommon before predictive testing,42;58-60 as up to 50% of the at-risk persons 
who requested predictive testing reported suicidal ideation58;59 and up to 12% reported a 
suicide attempt before receiving the test result.59;60 There was no difference in these prevalence 
numbers between at-risk participants who later turned out to carry the mutation and non-
carriers.58;59 After disclosure of the test result, the HD mutation carriers, compared with non-
carriers, reported suicidal thoughts significantly more often over time,59 with 23% of the carriers 
reporting suicidal ideation within 2 months after receiving the test result, compared with 2% in 
non-carriers.59 Results with regard to attempted and completed suicide after predictive testing 
are inconsistent.42 Some studies reported no attempted or completed suicide after predictive 
testing,61-66 others reported higher rates in carriers than in non-carriers,59;67 or comparable 
rates between these two groups,68 and one other study reported suicide attempts in the non-
carrier group only while there were no attempts in the carrier group.69 A worldwide survey on 
catastrophic events after predictive testing67 reported a suicide rate that was 10 times higher 
than that in the general population,67;70 but showed that all of those who died by suicide 
after predictive testing had motor signs at the time of their suicide.67 Despite this conflicting 
evidence,42 a review on predictive testing in HD concluded that, although carriers experienced 
increased distress in the first period after testing, it did not result in increased serious adverse 
events like completed suicide.71 Also after predictive testing for other neurodegenerative 





Associations of suicidality and suicide in HD
Several mechanisms for the increased occurrence of suicidality and suicide in HD could be 
proposed. As suicidality and suicide also occur more frequently in pre-motor symptomatic 
mutation carriers and persons at 50% risk of HD, it could be hypothesised that environmental 
factors contribute to its aetiology. In addition, its increased occurrence might be related to 
affected brain structures and the emotional distress of having an incurable disease with a 
devastating course. Another possibly important factor in the aetiology of suicidality and suicide 
is the psychopathology, especially depression, that is common in HD10 and that is one of the 
most important risk factors for suicidality and suicide in general.73;74 It has also been suggested 
that some cases of suicide in HD might be “a rational but extreme response to an intolerable 
situation.”23 While the aetiology of suicidality and suicide in HD remains poorly understood,75 
previous studies tried to identify particular characteristics of HD mutation carriers who were 
most likely to think of, attempt, or die by suicide.
Sociodemographic associations
A few studies focused on sociodemographic characteristics and reported that male HD patients 
were 3-4 times more likely to die by suicide than females,22;26 while female HD mutation carriers 
were more likely to attempt suicide during follow-up than males.47 Having no offspring was 
found as another important association of completed suicide,76 whereas other investigated 
sociodemographic characteristics, like being unmarried or living alone, were not.76 Also, 
no other investigated sociodemographic factors, like age or education, were significantly 
associated with current suicidal ideation45 or future suicidal attempts.47
Clinical associations
Most studies that described associations of suicidality and suicide in HD focused on the 
relationship with disease stage. HD patients who died by suicide had a younger age and a 
shorter disease duration than those who died by other causes.19;21-23 However, HD patients who 
died by suicide still had a disease duration of 9–12 years,22;23 indicating suicide occurs most 
frequently in early to middle disease stages.23 For suicidal ideation two critical periods, one in 
early-stage HD and the other in middle-stage HD, have been identified. The first critical period 
occurs when at-risk persons start to experience the first symptoms of HD and the second 
when patients become more dependent on others for activities of daily living.50 Apart from 
disease stage, other disease progression related variables including age of onset, total motor 
score, and cognitive function were not significantly associated with suicidal ideation,45 suicide 
attempts47;49 or completed suicide.21-23
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Only one study assessed the association of psychiatric symptoms with completed suicide in 
HD76 and found a higher prevalence of depression in HD patients who died by suicide than in 
those who died by other causes.76 Studies that focused on suicidality reported depression (or a 
combined factor of depression and anxiety) to be the strongest association of suicidal ideation 
and suicide attempts in HD.14;45;47;49 Also, depression and a previous suicide attempt were 
significantly associated with future suicide attempts in a cohort of pre-motor symptomatic 
mutation carriers.47 In addition, motor symptomatic HD patients with aggression45 and 
obsessive and compulsive symptoms46 were significantly more likely to report suicidal ideation. 
Other psychiatric symptoms that frequently occur in HD like apathy or irritability have been 
reported not to be associated with suicide attempts.47;49
Biological associations
So far, only one HD study investigated biological associations of suicidality in HD and 
reported no association between total cholesterol levels and suicidal ideation.52 In non-
HD populations, several studies have identified biological associations of suicidality and 
suicide, like inflammation77-80 and dysfunction of the hypothalamic-pituitary-adrenal (HPA) 
axis, in particular dexamethasone non-suppression.81-83 While in HD populations increased 
inflammatory activity in the central nervous system and peripheral tissues84-89 and hypothalamic 
changes and disturbed HPA axis functioning have been reported compared with controls,90-98 
associations between these biological parameters and suicidality or suicide in HD have not 
been investigated.
Limitations of previous studies
Many of the aforementioned studies on associations of suicidality and suicide in pre-motor 
and motor symptomatic HD mutation carriers were cross-sectional.14;21-23;26;45;46;49;50 These 
studies for example investigated which mutation carriers were most likely to have thought of 
or attempted14;49 suicide in the past. However, for clinical practice, it is particularly relevant to 
know which mutation carriers are most likely to currently experience suicidality and develop 
suicidality or die by suicide in the future. Despite the high suicide risk in HD, only one prospective 
cohort study with limited statistical power, which investigated predictors of suicide attempts 
in pre-motor symptomatic HD mutation carriers, has been carried out to date.47
Treatment of suicidal HD mutation carriers
Given the high frequency of suicidality and suicide in HD, adequate support and treatment 




risk of developing suicidality in the future. Currently, there are only a few case reports on 
the pharmacologic treatment of suicidal HD mutation carriers indicating positive effects of 
mirtazapine,99 lithium100 and lamotrigine.101 Apart from pharmacological treatment, several 
psychosocial interventions are also recommended in treatment guidelines for non-HD suicidal 
patients. There are currently no treatment recommendations specifically for suicidal HD 
patients and it is unknown whether the treatment of suicidal HD patients should be different 
from other, non-HD, suicidal patients, given the in advance known devastating course of the 
disease.
Aims of this thesis
The primary aims of this thesis were to investigate the prevalence and incidence and 
sociodemographic, clinical, and biological associations of suicidality in HD and to explore which 
coping styles and support strategies can help suicidal HD mutation carriers. An additional aim 
was to examine whether the expression of suicidal ideation predicts subsequent completed 
suicide in various populations.
First, we studied the prevalence and incidence of suicidal ideation and suicide attempts in 
HD and both its cross-sectional and longitudinal sociodemographic and clinical associations 
(Chapter 2 and 3). The study described in chapter 2 was conducted within the PsychHD study,5 
a Dutch prospective cohort study that followed both pre-motor and motor symptomatic 
HD mutation carriers and controls. The study described in chapter 3 was conducted within 
the REGISTRY study, a large prospective cohort study of the European Huntington’s Disease 
Network (EHDN).102
We also aimed to assess biological associations of suicidality within the PsychHD study. 
We investigated the associations between two markers of inflammation, C-reactive 
protein (CRP) and albumin, and several clinical characteristics, including suicidality, in HD 
(Chapter 4). Additionally, we studied whether different parameters of HPA axis activity, 
including dexamethasone non-suppression, were associated with the severity of depressive 
symptoms and suicidality in HD (Chapter 5). 
Furthermore, in a qualitative study, we explored how HD mutation carriers coped with suicidal 
ideation or previous suicide attempts and we investigated ideas and wishes of HD mutation 
carriers regarding how relatives and healthcare professionals can help them cope with 
suicidality. Additionally, we explored how spouses of HD mutation carriers supported their 
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partners with regard to suicidality (Chapter 6).
Suicidal ideation, sometimes combined with attempted suicide, was the outcome in all 
our studies. In a meta-analysis we investigated whether the expression of suicidal ideation 
predicted subsequent completed suicide in various populations, including both psychiatric 
and non-psychiatric populations (Chapter 7).
The final chapter (Chapter 8) provides an overview of the results of this thesis and a general 
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Suicidality in Huntington’s disease




Background: In Huntington’s disease (HD) the risk of suicide is increased. Since suicidality may 
precede suicide, this study investigates prevalence, clinical associations and predictors of 
suicidality in HD.
Methods: Suicidality was investigated in 152 mutation carriers and 56 non-carriers, and was 
considered present if the score on the item ‘suicidal ideation’ of the Problem Behaviours 
Assessment (PBA) was >1 point. After 2 years, 100 mutation carriers who were free of suicidality 
at baseline were re-assessed. Associations and predictors of suicidality were analysed using 
multivariate logistic regression analysis.
Results: Eleven (20%) pre-motor and 20 (20%) motor symptomatic mutation carriers were 
considered suicidal compared to none of the non-carriers. Cross-sectionally, suicidal mutation 
carriers were more likely to use antidepressants (odds ratio = 5.3), were more often apathetic 
(OR = 2.8), more often had a depressed mood according to the PBA (OR = 5.9), and were more 
often diagnosed with a DSM-IV depression diagnosis (OR = 4.7). Independent associations 
were more frequent use of antidepressants (OR = 4.0) and presence of a depressed mood 
(OR = 4.2). Longitudinally, depressed mood (OR = 10.6) at baseline was the only independent 
predictor of suicidality at follow-up.
Limitations: Selection bias might have occurred which could have affected the suicidality 
prevalence and incidence.
Conclusion: It is important to screen both pre-motor and motor symptomatic HD mutation 
carriers for suicidality. The presence of a depressed mood is both associated with and predictive 
of suicidality in HD and assessment of depressed mood can help to identify individuals with 





Huntington’s disease (HD) is a neurodegenerative, autosomal dominantly inherited disease.1 An 
expanded CAG repeat on the short arm of chromosome 4 causes an expanded polyglutamine 
chain in the huntingtin protein.2 Motor disorders, cognitive decline and both behavioural 
problems and psychiatric disorders are part of the clinical presentation of HD, with progression 
of symptoms over time. Some of these symptoms can be treated but the disease cannot be 
cured.
Behavioural problems and psychiatric disorders are major constituents of the clinical spectrum 
of HD;3 many patients and their relatives consider these problems to be the most distressing 
aspect of the disease.4 An important clinical aspect of HD is the increased risk of suicide, as was 
described by George Huntington in 1872.5 Patients with HD were shown to commit suicide four 
to eight times more often than the general population.6-8 A suicide risk of 5.7 suicides per 100 
deaths has been reported in HD,6 whereas the suicide risk in the general Dutch population is 
about 1 suicide per 100 deaths.9 A study investigating suicidality over the previous thirty days 
reported a relatively high prevalence of 19% in motor symptomatic HD mutation carriers,10 
whereas the lifetime prevalence of suicidality in a mixed population of both pre-motor and 
motor symptomatic HD mutation carriers was 20%.11 In comparison, 11% of the general Dutch 
population, aged 18 to 64 years, ever considered suicide and 3% ever performed a suicide 
attempt.12 The increased prevalence of suicidality and suicide may be related to the emotional 
distress of having an incurable disease as well as the psychopathology that is common in HD.
In the HD population, sociodemographic and clinical characteristics such as having no 
offspring,13;14 being unemployed,15 the presence of a depressed mood10;11;16 and a psychiatric 
history15 were found to be of importance for suicidality and suicide. However, most studies 
investigating suicidality or suicide in HD were retrospective,14 or cross-sectional10;11;13 or they 
focused on persons undergoing predictive testing for HD.6;7;15 The only prospective study 
investigating suicidality in HD focused on suicidal behaviour in prodromal HD.16 Some studies 
used survey data obtained from family members17 or included a low number of participants.14 
Also, several studies focused on completed suicide,13;14;17 rather than on suicidal thoughts and 
attempts, whereas suicidal ideation may be of particular importance because it is a strong risk 
factor for and antecedent of completed suicide.18;19 
The present study aimed to assess the prevalence of suicidality, defined as the presence of 
suicidal ideation or suicide attempt in the month preceding the interview, in HD mutation 
carriers and a control group of non-carriers. Cross-sectionally, we wanted to investigate possible 
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sociodemographic and clinical characteristics associated with suicidality and longitudinally we 
analysed the possible baseline predictors of suicidality at 2-year follow-up. We hypothesised 




Between May 2004 and August 2006, 343 potential participants at initial 50% risk of HD 
were contacted through the departments of Neurology and Clinical Genetics of the Leiden 
University Medical Center and a nursing home specialised in the daily care of HD patients. 
Of these, 192 were willing and able to participate in this study. In addition, 16 participants 
were enrolled via the Dutch HD patients’ association after posting an announcement on their 
internet site and in their quarterly. Finally, 152 mutation carriers (CAG repeat length ≥ 36) and 
56 non-carriers were included in the cross-sectional analysis. The design of this study has been 
described in detail elsewhere.20
Two years after their initial visit, all participants were approached for a second measurement. 
Follow-up data from mutation carriers who were free of suicidality at baseline (n = 121) were 
used in the longitudinal analyses. Of them, 21 (17.4%) dropped out due to a variety of reasons. 
One person was deceased and one person was untraceable, whereas eight were excluded 
because of inability to speak, too severe symptomatology or other medical conditions. The 
remaining 11 persons refused to participate because they did not feel like it, or due to private 
circumstances. This resulted in 100 eligible mutation carriers for follow-up assessment (Figure 
1).
This study was approved by the Medical Ethical Committee of the Leiden University Medical 
Center. Written informed consent was obtained from all participants. Because many 
institutionalised participants had cognitive deficiencies, special attention was paid to this 
important issue by contacting their physicians and asking them to thoroughly discuss study 






Suicidality was assessed using the validated Problem Behaviours Assessment (PBA).21 The 
PBA is a semi-structured interview specifically designed for patients with HD, assessing the 
frequency and severity of 36 common behavioural problems. The interrater reliability of the 
PBA (Dutch translation) is 0.82 for severity scores and 0.73 for frequency scores.22
Severity and frequency of suicidality in the month preceding the interview were assessed 
with the item ‘suicidal ideation’ of the PBA (question 8) (Figure 2A). The total suicidality score 
is computed by multiplying the severity and frequency scores of this item, resulting in total 
scores ranging from 0 through 16. Based on clinical experience, a total (multiplied) suicidality 
score > 1 point was used to characterise suicidality (Figure 2B), meaning that participants 





n = 121 (80%)
Suicidal





n = 93 (93%)
Suicidal ideation 
n = 7 (7%)
 
 21 (17.4%) drop-out:
1 deceased
1 untraceable
3 inability to speak
3 too severe symptomatology
2 other medical conditions






























































































































































































































































































   
   
















   
   


















































































































































































































































































































































































































































































































































































































































































scoring a total score of 1 on the ‘suicidal ideation’ item were not considered suicidal, since 
suicidal ideation is then ‘questionable and seldom’ present according to the participant or 
interviewer. When participants were very pessimistic with fleeting suicidal thoughts, although 
‘seldom’ (less than once a week), they scored 2 points on the ‘suicidal ideation’ item. These 
participants were categorised as being suicidal. The cut-off value also implies that participants 
who were not actively suicidal at the time of assessment, but ‘sometimes’ (at least once a week) 
considered suicide as an option for a later date, were categorised as being suicidal.
Sociodemographic and clinical characteristics
Information on sociodemographics and clinical characteristics, and use of psychotropics was 
collected using a standardised interview.
Total Functioning Capacity (TFC) subscale of the Unified Huntington’s Disease Rating Scale 
(UHDRS) was used to assess global functioning.23 Scores range from 0 through 13 points, with 
lower scores indicating poorer global functioning.24
Motor function was assessed by an experienced neurologist using the motor scale of the 
UHDRS.23 This scale includes the rating of 15 motor symptoms on a scale from 0 (normal) to 
4 (severe). The total UHDRS motor score is the sum of these 15 individual items. Total scores 
range from 0 through 124 points, with higher scores indicating worse motor functioning. The 
diagnostic Confidence Level (CL) of this UHDRS motor scale23 was used to define mutation 
carriers as pre-motor symptomatic (CL score 0 or 1 point) or motor symptomatic (CL score 2 
through 4 points).
Neuropsychiatric characteristics
Apathy was assessed using the Apathy Scale (AS).25 This semi-structured interview consists of 
14 questions to determine the level of apathy, with scores ranging from 0 through 3, with a 
maximum total score of 42 points. A cutoff score ≥ 14 points was used to indicate presence of 
apathy.25;26 
The item ‘depressed mood’ from the PBA21 was used to assess severity and frequency of a 
depressed mood in the month preceding the interview, with both severity and frequency 
scores ranging from 0 (normal/never) to 4 (severe/always). Based on clinical experience, a 
total (multiplied) depressed mood score > 1 point was used to characterise the participant as 
having a depressed mood, since a total score of 1 on the ‘depressed mood’ item is scored when 




The Dutch translation of the computerised version of the Composite International Diagnostic 
Interview (CIDI, Version 2.1)27 was used to assess the presence of a psychiatric disorder 
according to the criteria of the Diagnostic Statistical Manual (DSM) of mental disorders, version 
IV.28 The CIDI is a completely structured and standardised psychiatric diagnostic interview. 
The CIDI was not administered in participants scoring < 18 points on the Mini-Mental State 
Examination, since the CIDI cannot be reliably administered in participants with such severe 
cognitive dysfunction.
Cognitive characteristics
The Mini-Mental State Examination (MMSE) was used to determine global cognitive 
functioning. The ExCog was used as a measure for executive cognitive function. This composite 
variable was obtained by averaging the standardised z-scores of the cognitive subscales of the 
UHDRS,23 including the Verbal Fluency Test (VFT),29 the Symbol Digit Modalities Test (SDMT)30 
and the Stroop tests.31
Statistical analyses
Data are presented as n (%), mean (±SD) or median (interquartile range, IQR) when appropriate. 
Sociodemographic and clinical characteristics of HD mutation carriers and non-carriers were 
compared by chi-squared tests for categorical data, t-tests for independent samples with 
normal distributions, or non-parametric Whitney-U tests for continuous variables without 
normal distributions.
Suicidal mutation carriers were compared with non-suicidal mutation carriers using univariate 
logistic regression analysis. Scores on the independent variables TFC, UHDRS-motor, MMSE 
and ExCog were dichotomised at the median. The independent cross-sectional associations 
of suicidality in HD were determined by multiple forward logistic regression analysis. Variables 
included in this analysis had a p-value ≤ 0.10 in the univariate logistic regression and we 
also adjusted for sex and age (being forced into the model). The overall use of psychotropic 
medication was not included in the analysis because of overlap with the use of antidepressants. 
The presence of a formal DSM-IV diagnosis of depression according to the CIDI was not 
included in the original models because the CIDI could not be administered in 12 participants 
scoring < 18 points on the MMSE.
Non-suicidal mutation carriers at baseline, who became suicidal at follow-up, were compared 
with those mutation carriers who did not become suicidal at follow-up using univariate logistic 
regression analyses. Since only 7 mutation carriers had incident suicidality at the 2-year follow-




using the longitudinal data in which the significant associations of suicidality in the cross-
sectional model (use of antidepressants and presence of a depressed mood according to the 
PBA) and sex and age were entered. A p-value < 0.05 was considered statistically significant. 
SPSS version 16.0 was used.
Results
Mutations carriers versus non-carriers
Compared with the 56 non-carriers, the 152 mutation carriers were significantly older and 
more often had a depressed mood according to the PBA, although there was no significant 
difference in the presence of a formal DSM-IV diagnosis of depression. Mutation carriers also 
had worse cognitive scores on all cognitive tests compared with non-carriers (data not shown). 
Suicidality was only present in mutation carriers (Figure 2C). 
Comparison of Huntington’s disease mutation carriers with and without suicidality
At baseline, 31 mutation carriers (20%) were considered suicidal according to the PBA, 
whereas 121 mutation carriers (80%) were not (Table 1, Figure 2B, C). There was no significant 
difference in the prevalence of suicidality between pre-motor symptomatic (CL ≤ 1) and motor 
symptomatic (CL ≥ 2) mutation carriers (Figure 2C). Also, there was no significant difference in 
presence of suicidality between participants who received their genetic test result in the year 
preceding the interview and those who received their genetic test result more than a year prior 
to the interview (data not shown). 
Univariate analyses showed a significantly higher use of psychotropics (specifically 
antidepressants) in suicidal mutation carriers compared with non-suicidal mutation carriers. 
Suicidal mutation carriers were more often apathetic, more often had a depressed mood 
according to the PBA, and were more often diagnosed with a formal DSM-IV diagnosis 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Using multivariate analyses, the use of antidepressants (odds ratio (OR) = 3.96; 95% confidence 
interval (CI) = 1.59–9.87) and the presence of a depressed mood according to the PBA (OR = 
4.17; 95% CI = 1.52–11.5) were independently associated with suicidality (Table 2). 
In addition, sensitivity analyses were conducted to evaluate the robustness of the model. All 
participants scoring 1 (non-suicidal) or 2 (suicidal) on the suicidality item were excluded from 
the analysis. This sensitivity analysis confirmed our findings with higher OR on the covariates, 
whereas the TFC score (OR = 2.88; 95% CI = 1.04–7.95) and use of benzodiazepines (OR = 3.14; 
95% CI = 1.18–8.37) also showed a significant difference between the suicidal and non-suicidal 
groups (data not shown). In the multivariate model, the presence of a depressed mood and 
use of antidepressants remained the only independent associations of suicidality (data not 
shown).
Next, the DSM-IV diagnosis of depression was forced into the cross-sectional multivariate model. 
The presence of a depressed mood and use of antidepressants remained the independent 
associations of suicidality (data not shown).
Table 1 shows that 8 participants had a formal DSM-IV diagnosis of depression (4 in the non-
suicidal and 4 in the suicidal group). After exclusion of these 8 participants, the presence of a 
depressed mood according to the PBA and use of antidepressants again remained the only 
independent associations of suicidality (data not shown).
Predictors of suicidality at follow-up
Of the 121 participants free of suicidality at baseline (all had a suicidality score of 0), 100 were 
available for re-assessment after 2 years. The 21 drop-outs (17.4%) showed no significant 
differences on any of the baseline variables compared with the 100 participants that were 
followed up (data not shown). Seven (7%) of these 100 participants were suicidal at follow-up. 
Four of these 7 mutation carriers scored ≥ 4 on the suicidality item at follow-up, indicating 
moderate to severe suicidality. At baseline, these suicidal mutation carriers more often had a 
depressed mood according to the PBA (OR = 10.4; 95% CI = 1.20–90.2) and a formal DSM-IV 
psychiatric diagnosis (OR = 6.58; 95% CI = 1.27–34.2), although not particularly of depression 
(data not shown). Assessment of the CIDI at baseline was not possible in 5 of the 100 participants 
who were followed up because of severe cognitive impairment.
Using multivariate analysis in which sex, age, use of antidepressants and depressed mood were 
entered, depressed mood (OR = 10.6; 95% CI = 1.17–97.0) was the only significant independent 




Table 2. Independent associations and predictors of suicidality in Huntington’s disease 
mutation carriers.
Cross-sectional analysis (n = 152) 
(31/152 were suicidal at baseline)
Baseline variable Odds Ratioa 95% CIa p-valuea
Male gender 0.82 0.34 – 1.99 0.66
Age (years) 0.99 0.96 – 1.03 0.67
Use of antidepressants 3.96 1.59 – 9.87 0.003
Depressed moodb 4.17 1.52 – 11.5 0.006
Longitudinal analysis (n = 100) 
(7/100 were suicidal at follow-up)
Baseline variable Odds Ratioa 95% CIa p-valuea
Male gender 0.16 0.02 – 1.54 0.11
Age (years) 1.01 0.94 – 1.09 0.71
Use of antidepressants 1.33 0.21 – 8.48 0.76
Depressed moodb 10.6 1.17 – 97.0 0.04
Covariates cross-sectional analysis (forward model): use of antidepressants, use of benzodiazepines, Apathy Scale 
score, and depressed mood according to the PBA. Adjustment for sex and age. 
Entered longitudinal analysis (enter model): sex, age, use of antidepressants, and depressed mood according to 
the PBA. 
a Odds ratio, 95% CI and p-value by binary logistic regression. 
b Depressed mood score of the Problem Behaviours Assessment (question 1), consisting of the severity and 




The results of this study confirm that suicidality frequently occurred in this HD study group 
with a prevalence of 20% in mutation carriers compared with 0% in non-carriers. No difference 
was found in suicidality prevalence between pre-motor symptomatic and motor symptomatic 
mutation carriers. Cross-sectionally, suicidal mutation carriers were more likely to be depressed 
than non-suicidal mutation carriers, as shown by the higher use of antidepressants, the higher 
prevalence of apathy, possibly being a symptom of depression, the increased prevalence of 
a depressed mood according to the PBA and a more frequent formal DSM-IV diagnosis of 
depression. Longitudinally, these results were confirmed since the presence of a depressed 
mood was the only predictor of suicidality.
The prevalence of 20% suicidality among mutation carriers as found in our study is in 
accordance with a recent multi-site HD study reporting a suicidality month prevalence of 
19% among motor symptomatic HD carriers, while the suicidality prevalence among pre-
motor symptomatic mutation carriers was not investigated.10 A large European cross-sectional 
study (Registry) also reported a suicidality prevalence of 19.9% among pre-motor and motor 
symptomatic mutation carriers.11 However, the Registry study reported lifetime prevalence 
of suicidal ideation or suicidal attempts, assessed as present or absent, whereas our study 
focused on suicidality prevalence in the previous month, assessed by a score ranging from 0 
through 16. This lifetime prevalence in the Registry study may be an underestimation of the 
true suicidality prevalence in HD due to recall bias in that study, and because the presence 
of suicidality was not investigated in a detailed psychopathology interview but in a general 
questionnaire on medical history.
Remarkably, both in pre-motor symptomatic and motor symptomatic mutation carriers the 
baseline suicidality prevalence was 20%. This is in line with previous studies that suggested 
two critical periods of suicide risk in HD. This first critical period for suicidality occurs when 
genetically at-risk individuals are in the period immediately before diagnosis when they start to 
experience symptoms of HD,8;17;32 while they only have non-specific neurological signs and not 
yet unequivocal signs of HD.32 Suicidal pre-motor symptomatic mutation carriers in our study 
population belong to this first critical period of suicidality. A similar suicidality prevalence was 
found among motor symptomatic mutation carriers, who belonged to the second critical period 
for suicide risk occurring when patients with unequivocal motor symptoms of HD become 
more dependent on others for daily activities, as assessed by the TFC.32 In contrast to others,32 
we found no relationship between TFC and suicidality. Various phenomena may contribute to 




in the present study. First, before motor symptoms even appear, psychopathology (in particular 
depression) often arises.22;33 This may contribute to the relatively high prevalence of suicidality 
in pre-motor symptomatic mutation carriers since the presence of a depressed mood seems 
to be the most important predictor of suicidality. Furthermore, the emotional distress of 
having an incurable disease with a devastating course might also contribute to the relatively 
high suicidality prevalence already in pre-motor symptomatic mutation carriers. Moreover, 
diminished support from and increased mortality rates among affected family members could 
also lead to complicated grief, depression and suicidality.
The most important correlate and predictor of suicidality in HD mutation carriers was the 
presence of a depressed mood according to the PBA, despite that not all these participants 
had a formal DSM-IV diagnosis of depression. Cross-sectionally, an association between a 
depression subscale and suicidality was found in the Registry study and the multi-site HD study, 
whereas in these studies motor and cognitive subscores of the UHDRS were not associated 
with suicidality.10;11 Longitudinally, depressed mood was found to be predictive of suicidal 
attempts and completed suicide in prodromal HD.16 Both our cross-sectional and longitudinal 
findings are in line with these latter results.
Besides having a depressed mood, suicidal mutation carriers were cross-sectionally more likely 
to use antidepressants. The percentage of participants using antidepressants was much higher 
than the percentage of participants officially diagnosed with a DSM-IV diagnosis of depression. 
However, antidepressants may already be prescribed before a patient meets the official criteria 
of a DSM-IV diagnosis of depression, or because of a depression in remission. Furthermore, in 
HD antidepressants are also prescribed for anxiety and irritability.3 Since use of antidepressants 
was only associated with suicidality in the cross-sectional analysis, it is unlikely that the use of 
antidepressants causes suicidality.
The strengths of this study are the combination of cross-sectional and longitudinal analyses, 
the use of a comparison group (consisting of first-degree non-carriers at risk for HD), and the 
use of specific and validated measurement tools in a standardised interview.
Some limitations also warrant discussion. First, the study population available for follow-up was 
relatively small since HD is a rare disease; the use of larger databases will improve reliability. 
Despite the relatively small number of participants, all analyses consistently indicated a strong 
relationship of suicidality with depressed mood. Further, many of the variables included in this 
study were dichotomised because of their skewed distributions, which adversely affected the 
statistical power. Third, variables previously found to be associated with suicidality in HD, like 
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pessimism, hopelessness,7 aggression,10 unemployment15 and a history of suicide attempt,16 
were not included in our analyses. Finally, selection bias might have occurred since suicidal 
and/or depressed participants might have been more likely to refuse participation, which may 
have caused an underestimation of the true suicidality prevalence and incidence in HD.
Given the elevated suicidality prevalence in the HD population, it is important to regularly 
screen both pre-motor and motor symptomatic HD mutation carriers for suicidal ideation 
during clinical assessment. We found that the presence of a depressed mood was the main 
risk factor for suicidality in HD. Assessment of suicidal ideation is a priority in those with a 
depressed mood, and strategies of support and treatment should certainly be available for this 
subgroup of patients.
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Background: Previous studies indicate increased prevalences of suicidal ideation, suicide 
attempts, and completed suicide in Huntington’s disease (HD) compared with the general 
population. This study investigates correlates and predictors of suicidal ideation in HD.
Methods: The study cohort consisted of 2106 HD mutation carriers, all participating in the 
REGISTRY study of the European Huntington’s Disease Network. Of the 1937 participants 
without suicidal ideation at baseline, 945 had one or more follow-up measurements. 
Participants were assessed for suicidal ideation by the behavioural subscale of the Unified 
Huntington’s Disease Rating Scale (UHDRS). Correlates of suicidal ideation were analysed using 
logistic regression analysis and predictors were analysed using Cox regression analysis.
Results: At baseline, 169 (8.0%) mutation carriers endorsed suicidal ideation. Disease duration 
(odds ratio [OR] = 0.96; 95% confidence interval [CI] = 0.9–1.0), anxiety (OR = 2.14; 95% CI = 1.4–
3.3), aggression (OR = 2.41; 95% CI = 1.5–3.8), a previous suicide attempt (OR = 3.95; 95% CI = 
2.4–6.6), and a depressed mood (OR = 13.71; 95% CI = 6.7–28.0) were independently correlated 
to suicidal ideation at baseline. The 4-year cumulative incidence of suicidal ideation was 9.9%. 
Longitudinally, the presence of a depressed mood (hazard ratio [HR] = 2.05; 95% CI = 1.1–
4.0) and use of benzodiazepines (HR = 2.44; 95% CI = 1.2–5.0) at baseline were independent 
predictors of incident suicidal ideation, whereas a previous suicide attempt was not predictive.
Limitations: As suicidal ideation was assessed by only one item, and participants were a selection 
of all HD mutation carriers, the prevalence of suicidal ideation was likely underestimated.
Conclusions: Suicidal ideation in HD frequently occurs. Assessment of suicidal ideation is a 
priority in mutation carriers with a depressed mood and in those using benzodiazepines.




Huntington’s disease (HD) is an autosomal dominant progressive neurodegenerative disease.1 
The underlying genetic defect is an unstable and expanded CAG repeat on the short arm of 
chromosome 4, which causes an expanded polyglutamine chain in the huntingtin protein.2 
The disease is characterised by motor abnormalities, cognitive decline, and both behavioural 
problems and psychiatric disorders. George Huntington first described the tendency to suicide 
as an important aspect of the disease in 1872.3 Recent studies have reported that completed 
suicide rates among HD mutation carriers are four to eight times higher compared with the 
general population,4-6 and increased prevalences of suicidal ideation and attempted suicide, of 
up to 20%, have been reported.7;8
Previous cross-sectional studies have shown that both sociodemographic characteristics 
such as having no offspring9;10 or being unemployed,11 and clinical characteristics such as the 
presence of a depressed mood,7;8 aggression,8 or having a psychiatric history11 are associated 
with suicidal ideation, suicide attempts, or completed suicide in HD. Some of these studies 
only included a small number of participants10 or used data obtained from family members12. 
Also, several of these studies only investigated the effect of undergoing genetic testing on 
suicide risk,4;5;11 without investigating correlates or predictors of suicidal ideation during 
disease progression.
Despite the high suicide risk in HD, only two prospective studies have been carried out.7;13 
One study investigating both suicide attempts and completed suicide in 735 prodromal HD 
mutation carriers during a median follow-up of 3.5 years, reported presence of depression and 
a history of suicide attempts as relevant predictors.13 However, there were only 13 incident 
events, which limited study power.13 The other longitudinal study, in which 100 mutation 
carriers were assessed for both suicidal ideation and suicide attempts, reported 7 participants 
who developed suicidal ideation or attempted suicide after two years follow-up. This study 
also found depressed mood as a predictor of suicidal ideation and attempts in HD.7
The present study aimed to identify correlates and predictors of suicidal ideation in a large 





The study cohort consisted of 2106 European HD mutation carriers participating in the 
REGISTRY study prior to February 2011. Our study included only monitored data of REGISTRY 
participants who had a Unified Huntington’s Disease Rating Scale (UHDRS)14 behavioural 
assessment. REGISTRY is a large prospective, observational study of the European Huntington’s 
Disease Network (EHDN) describing the natural course of HD in many European countries.15 
More detailed information can be found at http://www.euro-hd.net/html/registry. 
In the study cohort, participants from 15 European countries were included: Austria (n = 58), 
Belgium (n = 3), Czech Republic (n = 29), Finland (n = 23), France (n = 158), Germany (n = 
493), Italy (n = 181), the Netherlands (n = 215), Norway (n = 74), Poland (n = 222), Portugal 
(n = 65), Spain (n = 160), Sweden (n = 18), Switzerland (n = 21) and the United Kingdom (n = 
386). Full ethical approval for REGISTRY was obtained in each of the participating countries 
and all participants gave written informed consent after the study procedure had been fully 
explained. The first behavioural assessment according to the behavioural subscale of the 
Unified Huntington’s Disease Rating Scale (UHDRS-b)14 was taken as baseline visit. Follow-up 
data from mutation carriers free of suicidal ideation at baseline (n = 1937) were used in the 
longitudinal analyses. Of these mutation carriers, 992 participants dropped out because they 
had no follow-up measurements. This resulted in 945 eligible mutation carriers for follow-up 
assessment (Figure 1).
Instruments
Assessment of suicidal ideation
Suicidal ideation was examined using the UHDRS-b.14 The behavioural subscale of the UHDRS 
assesses frequency and severity of 11 neuropsychiatric symptoms.14 The item ‘suicidal thoughts’ 
of the UHDRS-b14 measures frequency and severity of suicidal thoughts in the month preceding 
the interview. The frequency score ranges from 0 through 4: a score of 0 indicates suicidal 
thoughts are never present, a score of 1 indicates seldom presence, a score of 2 indicates 
suicidal thoughts are sometimes present, a score of 3 indicates frequent presence, and a 
score of 4 indicates suicidal thoughts are often present. The severity score also ranges from 0 
through 4: a score of 0 indicates absence of suicidal ideation, a score of 1 indicates there are no 
current suicidal thoughts, but the participant considers suicide as a potential option, a score of 
2 indicates presence of fleeting suicidal ideation, a score of 3 indicates the participant seriously 
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992 (51.2%) no follow-up (drop-out)*
Suicidal ideation at baseline
No suicidal ideation
n = 1937 (92%)
Suicidal ideation 
n = 169 (8.0%)
Mutation carriers
n = 945





Figure 1. Flowchart of drops-outs.
* drop-outs had a significantly longer estimated duration of disease, lower Total Functioning Capacity (TFC) 
score and higher Unified Huntington’s Disease Rating Scale (UHDRS)-motor score. No significant difference in 
any of the neuropsychiatric characteristics.
considered suicide but has no plan, and a severity score of 4 indicates the participant has a plan 
and is actively preparing.14 The total score was computed by multiplying the frequency and 
severity scores (range 0–16 points).8 Based on clinical experience, a total score > 1 point on this 
item was used to characterise presence of suicidal ideation, meaning that participants scoring 
a total score of 1 on the ‘suicidal ideation’ item were not considered to have suicidal ideation, 
since suicidal ideation is then ‘not currently and seldom’ present according to the participant 
or interviewer. When participants had fleeting suicidal thoughts, although ‘seldom’ (less than 
once per month), they scored 2 points on the ‘suicidal ideation’ item, and were considered to 
have suicidal ideation. This cut-off value also implies that participants that consider suicide as 
a potential option for the future, and ‘seldom’ think about this, were not considered to have 
suicidal ideation.
Assessment of neuropsychiatric characteristics
The presence of depressed mood, anxiety, apathy, irritability, and aggression was also assessed 
with the UHDRS-b.14 Total scores for these separate items were computed by multiplying 
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their severity (range 0–4 points) and frequency (range 0–4 points) scores. Based on clinical 
experience, a total score > 1 point on such an item was used to characterise presence of that 
particular neuropsychiatric characteristic.
Assessment of sociodemographic and clinical characteristics
Data on sociodemographic and clinical characteristics were collected using detailed electronic 
case report forms. Participants were examined by clinicians with longstanding experience in 
HD.16
The estimated disease duration was calculated by the current age minus the estimated age of 
onset, calculated using the formula of Vassos et al.17
Global functioning was assessed with the Total Functioning Capacity (TFC)14 with scores 
ranging from 0 through 13 points. Higher scores indicate better global functioning.18 Disease 
stage was derived from TFC scores.19
A trained neurologist assessed motor functioning according to the motor subscale of the 
UHDRS (UHDRS-m)14 with scores ranging from 0 through 124 points. Higher scores indicate 
worse motor functioning.14 Mutation carriers were considered motor symptomatic if the total 
score on the UHDRS-m was > 4 points.
Medication use at baseline was determined based on the provided start and stop dates. 
If medication use at baseline could not be unequivocally determined, this variable was 
considered missing.
Statistical analyses 
Data are presented as n (%), mean (± SD), or median (interquartile range [IQR]) when 
appropriate. Characteristics of mutation carriers with and without suicidal ideation were 
compared by chi-squared tests for categorical data, two-tailed t-tests for independent samples 
with normal distribution, or non-parametric Whitney-U tests.
The significant univariate cross-sectional correlates were included in a multivariate logistic 
regression analysis, while forcing sex, age, and country in the model, to yield independent 
correlates of suicidal ideation. The overall use of psychotropic medication was not included 
in the multivariate analysis because of overlap with use of the different component kinds of 
psychotropics.
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Mutation carriers free of suicidal ideation at baseline were followed-up until they developed 
suicidal ideation (incident cases). If participants did not develop suicidal ideation within 
four years from baseline, they were censored. Incident cases were compared with mutation 
carriers who did not develop suicidal ideation using univariate Cox regression analysis. The 
significant univariate longitudinal predictors were included in a multivariate Cox regression 
analysis, while forcing sex, age, and country in the model, to yield the independent predictors 
of suicidal ideation. Additional sensitivity analyses were conducted in which missing data were 
imputed by either 0 or 1. Furthermore, a sensitivity analysis using only a severity score of the 
UHDRS suicidal ideation item > 1 point to classify participants as having suicidal ideation was 
carried out. In this way, participants who had no current suicidal thoughts and only considered 
suicide as a potential option for the future were no longer classified as having suicidal ideation, 
while all participants with current suicidal ideation were, irrespective of the frequency of those 
thoughts. A p-value < 0.05 was considered statistically significant. SPSS version 20.0 was used.
Results
The 2106 participants were both male (50.9%) and female (49.1%) with a mean (± SD) age of 
50.3 (± 12.4) years. The study population included mostly motor symptomatic (98%) mutation 
carriers. The mean (± SD) estimated disease duration was 5.7 (± 8.1) years. The study cohort 
consisted of mutation carriers from all TFC stages: stage 1: n = 701 (33.3%), stage 2: n = 694 
(33.0%), stage 3: n = 537 (25.5%), stage 4: n = 148 (7.0%), stage 5: n = 26 (1.2%). Psychotropics 
were used by 1189 (56.5%) mutation carriers: 740 (35.1%) participants used antidepressants, 
709 (33.7%) antipsychotics, 348 (16.5%) benzodiazepines, and 151 (7.2%) mood stabilizers/
anti-epileptics (data not shown). At baseline, 169 (8.0%) mutation carriers endorsed suicidal 
ideation, whereas 1937 (92.0%) did not (Figure 1). The prevalences of suicidal ideation in the 
three largest participating countries were 6.9% in Germany, 7.5% in the United Kingdom, and 
10.4% in Poland (data not shown). 
Suicidal ideation at baseline
Mutation carriers with suicidal ideation at baseline had a significantly shorter estimated 
disease duration and a significantly higher use of psychotropics (specifically antidepressants, 
benzodiazepines, and mood stabilizers/anti-epileptics) compared with mutation carriers 
without suicidal ideation. Furthermore, the baseline presence of a depressed mood, anxiety, 
apathy, irritability, aggression, and also the presence of a suicide attempt in the past were all 
significantly correlated with suicidal ideation (Table 1). 
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Table 1. Correlates of suicidal ideation in Huntington’s disease mutation carriers at baseline.
HD mutation  
carriers without si  
(n = 1937)
HD mutation  




Male gender 994 (51.3%) 78 (46.2%) 0.20
Age (years) 50.5 ± 12.4 48.7 ± 11.3 0.08
Clinical characteristics
CAG repeats (number) 44.6 ± 4.4 44.4 ± 4.2 0.59
Estimated duration of disease (years) 5.9 ± 8.1 3.7 ± 8.0 0.001
TFC score 8.0 (5 – 12) 8.0 (6 – 11) 0.73
UHDRS-motor score 35.3 ± 19.7 33.1 ± 20.4 0.18
Pre-motor symptomatic 38 (2.0%) 6 (3.6%) 0.16
Psychotropic medication 
Any psychotropic medication 1080 (59.0%) 109 (68.1%) 0.03
Antidepressant use 660 (35.6%) 80 (50.0%) <0.001
Antipsychotic use 645 (34.5%) 64 (38.8%) 0.27
Benzodiazepine use 303 (16.2%) 45 (29.0%) <0.001
Mood stabilizer/anti-epileptic use 132 (6.9%) 19 (11.4%) 0.03
Tetrabenazine use 96 (5.0%) 10 (6.0%) 0.59
Neuropsychiatric characteristics 
Depressed mood 771 (39.8%) 159 (94.1%) <0.001
Anxiety 641 (33.1%) 114 (67.5%) <0.001
Apathy 881 (45.7%) 123 (73.7%) <0.001
Irritability 775 (40.4%) 105 (63.3%) <0.001
Aggression 395 (20.5%) 79 (47.0%) <0.001
Suicide attempt in past 123 (6.4%) 45 (26.6%) <0.001
Data are presented as n (%), mean (± SD) or median (interquartile range [IQR]) when appropriate. HD denotes 
Huntington’s disease; si, suicidal ideation; TFC, total functional capacity; UHDRS, unified Huntington’s disease 
rating scale. 117 missing values for use of psychotropic medication; 91 missing values for antidepressant use; 
72 missing values for antipsychotic use; 81 missing values for benzodiazepine use; 21 missing values for mood 
stabilizer/anti-epileptic use; 33 missing values for tetrabenazine use; 1 missing value for presence of anxiety; 
12 missing values for presence of apathy; 21 missing values for presence of irritability; 12 missing values for 
presence of aggression. 
a P-values by chi-square tests for categorical data, by unpaired t-tests for independent samples with normal 
distribution, or non-parametric Mann–Whitney U test for continuous variables without normal distributions.
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Table 2. Independent correlates of suicidal ideation in Huntington’s disease mutation carriers 
at baseline.
Cross-sectional logistic regression (n = 1916)a 
(144/1916 had suicidal ideation at baseline)
Baseline variable





Sociodemographic and clinical characteristics
Male gender 1.16 (0.79 – 1.71) 0.56 0.46
Age (years) 1.02 (0.99 – 1.04) 2.12 0.15
Estimated duration of disease (years) 0.96 (0.93 – 0.99) 6.27 0.01
Psychotropic medication
Antidepressant use 0.93 (0.62 – 1.40) 0.12 0.73
Benzodiazepine use 1.48 (0.93 – 2.37) 2.67 0.10
Mood stabilizers/anti-epileptic use 1.18 (0.64 – 2.18) 0.27 0.60
Neuropsychiatric characteristics
Depressed mood 13.71 (6.71 – 28.00) 51.55 <0.001
Anxiety 2.14 (1.40 – 3.26) 12.54 <0.001
Apathy 1.42 (0.92 – 2.20) 2.47 0.12
Irritability 0.87 (0.55 – 1.37) 0.39 0.53
Aggression 2.41 (1.53 – 3.80) 14.43 <0.001
Suicide attempt in past 3.95 (2.36 – 6.60) 27.51 <0.001
Covariates cross-sectional analysis (enter model): all variables with p-value ≤ 0.05 in the univariate analysis 
were entered (estimated duration of disease, use of antidepressants, use of benzodiazepines, use of mood 
stabilizers/anti-epileptics, presence of depressed mood, presence of anxiety, presence of apathy, presence of 
irritability, presence of aggression, and suicide attempt in the past) and sex, age, and country were forced into 
the model. 
a 190 cases excluded due to missing values. 
b Odds ratio, 95% confidence interval (CI), Wald statistic, degrees of freedom (df ), and p-value by binary logistic 
regression.
Using multivariate analyses, the estimated disease duration (odds ratio [OR] = 0.96; 95% 
confidence interval [CI] = 0.93-0.99), presence of depressed mood (OR = 13.71; 95% CI = 
6.71–28.00), anxiety (OR = 2.14; 95% CI = 1.40–3.26), aggression (OR 2.41; 95% CI = 1.53–3.80), 
and previous suicide attempt (OR = 3.95; 95% CI = 2.36–6.60) were significant independent 
correlates of suicidal ideation (Table 2). As 190 cases were excluded from the multivariate 
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analysis due to missing data, two additional sensitivity analyses were conducted in which 
missing data were imputed by either 0 or 1. Both of these sensitivity analyses yielded similar 
results, with comparable odds ratios for all correlates (data not shown).
To see whether correlates of suicidal ideation remained the same when only using the severity 
score of the ‘suicidal ideation’ item of the UHDRS-b, we carried out a multinomial regression 
analysis, comparing mutation carriers with a severity score of 0 on the suicidal ideation 
item to mutation carriers with a severity score of 1 and to mutation carriers with a severity 
score > 1. This sensitivity analysis confirmed most of the previous results, with higher or 
comparable odds ratios in the group mutation carriers with a severity score > 1 for all 
neuropsychiatric correlates and increasing odds ratios as the severity score rose. Only the 
estimated disease duration became a weaker correlate (data not shown).
Suicidal ideation at follow-up
Of the 1937 mutation carriers free of suicidal ideation at baseline, 945 were followed up for 
a median (IQR) period of 2.0 (1.1–3.0) years. The 992 drop-outs, had a significantly longer 
estimated disease duration (p = 0.040), lower TFC score (p < 0.001), and higher UHDRS-m 
score (p < 0.001). When comparing neuropsychiatric characteristics, the drop-outs did not 
differ significantly from the participants that were included in the follow-up analyses (data not 
shown).
After four years of follow-up 9.9% of the mutation carriers had developed suicidal thoughts. 
These mutation carriers had significantly higher hazard ratios for the use of benzodiazepines 
and mood stabilizers/anti-epileptics at baseline. Also, they had significantly higher hazard 
ratios for the presence of a depressed mood, anxiety, and apathy at baseline (Table 3).
Using multivariate Cox regression analysis, the use of benzodiazepines at baseline (hazard 
ratio [HR] = 2.44; 95% CI = 1.20–4.97) and the presence of a depressed mood at baseline 
(HR = 2.05; 95% CI = 1.06–3.96) were independent predictors of suicidal ideation at follow-up 
(Table 4 and Figure 2). As 57 cases were excluded from the multivariate Cox regression analysis 
due to missing data, again two additional sensitivity analyses were conducted imputing either 
0 or 1 for the missing data. These sensitivity analyses confirmed our results, with comparable 
hazard ratios for all predictors (data not shown).
To see whether predictors of suicidal ideation remained the same when only using the severity 
score of the ‘suicidal ideation’ item of the UHDRS-b, we carried out a multivariate Cox regression 
analysis comparing mutation carriers with a severity score < 1 on the suicidal ideation item to 
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Table 3. Predictors of suicidal ideation at follow-up in Huntington’s disease mutation carriers.
Univariate Cox regression (n = 942)a 
(52/942 had suicidal ideation at follow-up)





Male gender 0.91 (0.53 – 1.57) 0.11 0.74
Age (years) 1.00 (0.98 – 1.02) 0.01 0.95
Clinical characteristics
CAG repeats (number) 0.98 (0.92 – 1.05) 0.25 0.62
Estimated duration of disease (years) 0.99 (0.96 – 1.03) 0.25 0.62
TFC score (points) 0.99 (0.91 – 1.07) 0.10 0.76
UHDRS-motor score (points) 1.00 (0.98 – 1.01) 0.08 0.78
Pre-motor symptomatic 1.78 (0.55 – 5.72) 0.94 0.33
Psychotropic medication
Antidepressant use 1.72 (0.98 – 3.02) 3.59 0.06
Antipsychotic use 1.69 (0.95 – 3.01) 3.16 0.08
Benzodiazepine use 2.78 (1.48 – 5.22) 10.14 0.001
Mood stabilizer/anti-epileptic use 2.80 (1.36 – 5.76) 7.85 0.005
Tetrabenazine use 2.43 (0.59 – 10.03) 1.50 0.22
Neuropsychiatric characteristics
Depressed mood 2.73 (1.57 – 4.76) 12.58 <0.001
Anxiety 1.99 (1.15 – 3.42) 6.11 0.01
Apathy 2.27 (1.30 – 3.96) 8.22 0.004
Irritability 1.48 (0.86 – 2.55) 1.99 0.16
Aggression 1.58 (0.85 – 2.92) 2.10 0.15
Suicide attempt in past 2.32 (0.92 – 5.84) 3.19 0.07
TFC denotes total functional capacity; UHDRS, unified Huntington’s disease rating scale. 49 missing values 
for antidepressant use; 39 missing values for antipsychotic use; 44 missing values for benzodiazepine use; 12 
missing values for mood stabilizer/anti-epileptic use; 26 missing values for tetrabenazine use; 1 missing value 
for presence of anxiety; 8 missing values for presence of apathy; 5 missing values for presence of irritability; 9 
missing values for presence of aggression. 
a Three cases were censored before the earliest event in the stratum. 




mutation carriers with a severity score > 1. This sensitivity analysis mostly confirmed previous 
results, with a comparable hazard ratio for the predictor depressed mood. Although the hazard 
ratio for benzodiazepine use decreased, it remained > 2 (data not shown).
Table 4. Independent predictors of suicidal ideation at follow-up in Huntington’s disease 
mutation carriers.
Multivariate Cox regression (n = 885)a 








Male gender 1.03 (0.57 – 1.84) 0.01 0.94
Age (years) 1.00 (0.97 – 1.02) 0.12 0.73
Psychotropic medication
Benzodiazepine use 2.44 (1.20 – 4.97) 6.00 0.01
Mood stabilizer/anti-epileptic use 1.96 (0.88 – 4.35) 2.71 0.10
Neuropsychiatric characteristics
Depressed mood 2.05 (1.06 – 3.96) 4.50 0.03
Anxiety 0.97 (0.50 – 1.88) 0.01 0.93
Apathy 1.67 (0.87 – 3.20) 2.35 0.13
Covariates Cox regression analysis (enter model): all variables with p-value ≤ 0.05 in the univariate Cox regression 
analysis were entered (use of benzodiazepines, use of mood stabilizers/anti-epileptics, presence of depressed 
mood, presence of anxiety, and presence of apathy) and sex, age, and country were forced into the model. 
a Three cases were censored before the earliest event in the stratum and there were 57 cases excluded due to 
missing values. 
b Hazard ratio, 95% confidence interval (CI), Wald statistic, degrees of freedom (df ), and p-value by multivariate 
Cox regression analysis.
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A Suicidal ideation at follow-up according to baseline depressed mood
No. at Risk (n = 901*)
Benzodiazepine use
No benzodiazepine use
Suicidal ideation at follow-up according to baseline benzodiazepine use
*: 44 missings due to unknown benzodiazepine use
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HR = 2.73; 95% CI: .57-4.76
P < 0.001
Figure 2. 
Hazard ratio (HR), 95% confidence interval (CI), and p-value by univariate Cox regression analysis. Kaplan–Meier 
curves showing cumulativef incidence of suicidal ideation according to baseline presence of a depressed mood 




The results of this study demonstrate that mutation carriers with suicidal ideation at baseline, 
more often had a depressed mood, were more often anxious and aggressive, more often 
attempted suicide in the past, and had a shorter estimated disease duration compared with 
mutation carriers free of suicidal ideation. Longitudinally, a depressed mood and use of 
benzodiazepines at baseline predicted suicidal ideation at follow-up. 
The presence of a depressed mood was the most important correlate and predictor of suicidal 
ideation. This association was previously found among both pre-motor and motor symptomatic 
HD mutation carriers.7 Besides depressed mood, we also found an association between the 
presence of anxiety and suicidal ideation. In a previous study, the depression/anxiety factor 
of the UHDRS-b was found to be a correlate of suicidal ideation in HD.8 Longitudinally, these 
results were confirmed as presence of depressed mood at baseline predicted suicidal ideation 
at follow-up, in line with two previous longitudinal studies, which reported depressed mood 
as a predictor of suicidal thoughts7 and attempts.7;13
Moreover, aggression and a suicide attempt in the past were correlates of suicidal ideation. 
A previous multi-site study also found aggression as a correlate of suicidal ideation in HD.8 
Although a previous suicide attempt did not independently predict suicidal ideation at follow-
up in our study, it was previously found as a predictor of suicide attempts among prodromal 
HD mutation carriers13 and it is one of the strongest risk factors for completed suicide in 
the general population.20 Although attempted suicide is a well-established risk factor for 
completed suicide, it is debatable whether or not suicidal ideation itself is a risk factor for 
completed suicide.21 Therefore, future studies need to investigate and describe trajectories of 
suicidality in HD, and determine whether and to what extend suicidal ideation is a clinically 
relevant predictor of completed suicide.
Furthermore, a shorter estimated disease duration was correlated to suicidal ideation. Several 
authors have previously suggested that completed suicide occurs more frequently in the early 
stages of HD.4;6;10;12 One study described two critical periods of suicidal ideation in HD: one when 
at-risk persons start to experience the first symptoms of HD, and one when patients become 
more dependent on others for daily functioning.22 Both critical periods are in a relatively early 
course of the disease.
The use of benzodiazepines at baseline also predicted suicidal ideation at follow-up. It is 
known among patients with other disorders that use of benzodiazepines may lead to a 
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paradoxical reaction with behavioural disinhibition, especially in those with impulse control 
problems and pre-existing neurological disorders.23 Since HD mutation carriers often have 
difficulty with impulse control already as result of disruption of frontal-subcortical circuitry,8;24 
they may indeed be at higher risk for paradoxical reactions to benzodiazepine use. Previous 
studies in other populations did not only show an association between impulsivity and 
suicidal behaviour,25;26 but also suggested that benzodiazepine use may be associated with 
attempted suicide.27;28 In our predictive study, there was no information regarding impulsivity 
and attempted and completed suicide during the study period, and we did not investigate 
which participants still used benzodiazepines at follow-up. Therefore, future research on 
the relationship between benzodiazepine use, impulsivity, and suicidality is necessary. 
Furthermore, the relationship between benzodiazepine use and suicidal ideation might be 
due to confounding by indication, as benzodiazepines are prescribed mainly to patients with 
symptoms of anxiety, which was a correlate of suicidal ideation in this study, and irritability 
and insomnia, which were correlates of suicidal ideation in other populations.29;30 Also other 
unmeasured neuropsychiatric characteristics, like personality traits or coping styles, could 
be the reason for both more prevalent suicidal ideation and the use of benzodiazepines. 
Confounding by indication was considered the most likely explanation in a previous study that 
reported an association between benzodiazepine use and suicide attempts.27
Although there was variance in suicidal ideation prevalences among countries, baseline 
suicidal ideation prevalences in the three largest participating countries (Germany, United 
Kingdom, and Poland) were around 8.0%. It is unclear whether the variance between other 
countries corresponded to true differences or whether this may be explained by measurement 
error (country-specific over- and underestimation of the true prevalences), as assessment and 
expression of suicidal ideation between countries might differ depending on the cultural 
context and professional traditions. Since the distribution of prevalence numbers did not 
correspond with the distribution of prevalence numbers in the general populations of the 
different European countries,31 our analyses focused on correlates and predictors of suicidal 
ideation irrespective of the country. It is reasonable to assume that correlates and predictors 
found in this study generalise to the entire European HD population, since previous research 
showed consistent risk factors in European countries despite important variation in country 
prevalences.31
The strength of this European cohort study is the large size and the high quality of monitored 
data, the use of structured electronic case report forms, the annual training of the study site 
raters, and the combination of cross-sectional and longitudinal analyses.
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This study has several limitations that warrant discussion. Our prevalence of 8.0% is much 
lower than a recent study that found a prevalence of 20%.7 However, in this study, assessment 
of suicidal ideation was done by psychiatrists through a detailed psychopathology interview.7 
A prevalence of 19% has been found using the UHDRS-b, but this study also categorised 
participants with a total score of 1 point as suicidal.8 Another study using the severity score of 
the ‘suicidal thoughts’ item of the UHDRS-b to assess participants for suicidal ideation reported 
a prevalence of 17.5%.22 However, when all mildly suicidal participants (severity score of 1) 
were excluded, the prevalence dropped to 10.3%,22 which is much more in accordance with the 
prevalence found in our study. Although the suicidal ideation prevalence found in our study 
is lower than reported in previous studies, a suicidal ideation one-month prevalence of 8.0% 
among HD mutation carriers is still much higher compared with the one-month prevalence 
of 0.0% recently found among non-HD controls7 and the twelve-month prevalence of 2.0% in 
the general population.32 The lower prevalence found in our study compared with previous 
HD studies may be explained by the design of REGISTRY, which measured a lot of motor and 
cognitive symptoms, while the assessment of neuropsychiatric symptoms is rather sparse. A 
detailed and extensive psychopathology interview is probably more sensitive to detect suicidal 
ideation in HD, as was previously recommended by the authors of a multi-site HD study.8 
Additionally, psychiatrists may be better trained than neurologists in detecting subtle suicidal 
thoughts, as assessing suicidality is an important part of their psychiatric training. Furthermore, 
a selection of HD mutation carriers who were stable enough at the time of enrolment and 
subsequent follow-up visits participated in this study. HD patients attending REGISTRY clinics 
might be less disturbed and better treated; and, there was a substantial number of drop-
outs, which may have caused attrition bias. This may have resulted in limited generalizability 
of the prevalence and incidence found in this study, as it probably is an underestimation of 
the prevalence and incidence in the general HD population. Another important limitation of 
this study is that only one item of the UDHRS-b was used to assess suicidal ideation. Finally, 
only predictors of suicidal ideation could emerge from this observational study and we cannot 
conclude whether these are causal relationships.
Because of the high prevalence of suicidal ideation in HD, it is important to regularly screen 
mutation carriers for the presence of suicidal ideation. In depressed HD mutation carriers 
assessment of suicidal ideation is a priority, especially since depressed mood is a potential 
treatable risk factor. Furthermore, clinicians should be aware when mutation carriers are using 
benzodiazepines, since use of benzodiazepines predicted suicidal ideation at follow-up.
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Activation of the innate immune system has been postulated in the pathogenesis of 
Huntington’s disease (HD). We studied serum concentrations of C-reactive protein (CRP) and 
albumin as positive and negative acute-phase proteins in HD. Multivariate linear and logistic 
regression was used to study the association between acute-phase protein levels in relation to 
clinical, neuropsychiatric, cognitive, and psychotropic use characteristics in a cohort consisting 
of 122 HD mutation carriers and 42 controls at first biomarker measurement, and 85 HD 
mutation carriers and 32 controls at second biomarker measurement. Significant associations 
were found between acute-phase protein levels and Total Functioning Capacity (TFC) score, 
severity of apathy, cognitive impairment, and the use of antipsychotics. Interestingly, all 
significant results with neuropsychiatric symptoms disappeared after additional adjusting for 
antipsychotic use. High sensitivity CRP levels were highest and albumin levels were lowest in 
mutation carriers who continuously used antipsychotics during follow-up versus those who 
had never used antipsychotics (mean difference for CRP 1.4 SE mg/L; p = 0.04; mean difference 
for albumin 3 SE g/L; p < 0.001). The associations found between acute-phase proteins and TFC 
score, apathy, and cognitive impairment could mainly be attributed to the use of antipsychotics. 
This study provides evidence that HD mutation carriers who use antipsychotics are prone to 
develop an acute-phase response.




Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease, characterised 
by motor abnormalities, cognitive dysfunction, and neuropsychiatric symptoms1 including 
depressed mood,2 apathy,3;4 and irritability.5 Although the mean age of onset is 40 years, 
there is a wide range in age at onset, severity, and symptomatology of HD. HD is caused by an 
expanded trinucleotide cytosine-adenine-guanine (CAG) repeat on chromosome 4 coding for 
the mutant huntingtin protein.6 Although the genetic defect has been elucidated, its role in 
the pathogenesis of HD remains unclear.
There is increasing evidence that the immune system may be involved in the pathogenesis 
of HD. Increased activation of components of the innate and adaptive immune systems has 
been found in the central nervous system (CNS)7-9 and peripheral tissues of HD patients.10 In 
particular, increased concentrations of tumor necrosis factor (TNF)-α and interleukin (IL)-6, have 
been found in plasma of HD mutation carriers when compared to controls.11 Physiologically, 
TNF-α and IL-6 are pro-inflammatory cytokines which are released in the bloodstream as part 
of the acute-phase response.12;13 C-reactive protein (CRP) synthesis is upregulated in the liver 
under regulation of IL-6,14 whereas the synthesis of other proteins such as albumin is down-
regulated. Since in the acute-phase response CRP levels increase, CRP can be thought of as a 
positive acute-phase protein and since albumin levels decrease, albumin can be thought of as 
a negative acute-phase protein.
Previously, CRP levels have been reported to be significantly increased in HD mutation carriers 
in advanced disease stage when compared to controls.15 Levels of CRP were significantly 
higher in a group of 13 HD mutation carriers when compared to 10 healthy controls. Also, 
levels of CRP were higher in HD mutation carriers with more advanced disease.16 A large set of 
markers for inflammation and innate immunity was measured in a recent study that included 
two cohorts comprising 81 HD mutation carriers and 40 controls, but none of the more than 20 
plasma constituents were significantly different between the groups.17 Nevertheless, post-hoc 
tests revealed significantly lower CRP levels in HD mutation carriers with early disease versus 
controls, whereas premanifest HD had similar levels compared with controls.
In various other populations, there are reports indicating an association between CRP18-20 and 
albumin21-24 levels on the one hand, and both cognitive dysfunction and neuropsychiatric 
symptoms on the other hand. In a systematic review assessing the association between 
CRP level and stroke, cognitive disorders, and depression,18 raised CRP concentrations were 
associated with cognitive decline and increased risk of dementia. Low albumin levels were 
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associated with cognitive dysfunction in two large population-based studies of the non-
demented elderly.21;22 In a large longitudinal study with 73,131 participants from the general 
population, a positive association was found between CRP levels and depressive symptoms.19 
Also, a meta-analysis showed a positive correlation between CRP levels and depression (d = 
0.15; 95% confidence interval [CI] 0.10–0.21).20 Low albumin levels were found in depressed 
patients compared to healthy controls.23;24 Cross-sectionally, a significant association was 
found between CRP levels and apathy in elderly individuals.25 Longitudinally, however, higher 
CRP levels were not associated with an increased risk of apathy in individuals aged 85 years 
and over.26
Antipsychotics are frequently prescribed for symptomatic treatment of chorea and 
neuropsychiatric symptoms in HD.27 It has become apparent that the use of antipsychotics 
may adversely affect CRP levels.23;28;29 In addition, weight gain is a well-known side-effect of 
treatment with atypical antipsychotics,30 which is associated with an increase of IL-6 and other 
proteins associated with low-grade inflammation.31 The effects of antipsychotics on levels of 
albumin have not been thoroughly studied, although serum albumin was decreased in a group 
of schizophrenic patients when compared with healthy controls. However, no significant effect 
of the use of antipsychotics was demonstrated.32
This study aims to investigate CRP levels as a positive acute-phase protein and albumin levels 
as a negative acute-phase protein in relation to clinical, neuropsychiatric, and cognitive 
characteristics in a cohort of HD mutation carriers. For this, we took into account factors that 
might have confounded or otherwise influenced these associations, in particular the use of 
antipsychotics. Our hypothesis was that, with disease progression, inflammatory activity 
would increase leading to higher CRP levels and lower albumin levels, associated with a higher 
prevalence of cognitive impairment and neuropsychiatric symptoms.
Experimental procedures
Population
Between May 2004 and August 2006, 152 HD mutation carriers and 56 controls were recruited 
for participation. Sources for recruitment were the outpatient departments of Neurology and 
Clinical Genetics of the Leiden University Medical Center (LUMC) and a regional nursing home 
specialised in care for HD patients. Besides HD mutation carriers, verified first-degree non-
carriers participated in the study as controls. The study design is described in detail elsewhere.33 
A second measurement was conducted two years after the baseline visit (including 128 
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mutation carriers and 42 controls) and a third measurement two years thereafter (including 
94 HD mutation carriers and 32 controls). Blood samples suitable for the determination of 
high sensitivity CRP (hsCRP) and albumin levels were available at the second and the third 
measurement. Since 6 participants did not give blood at the first biomarker measurement 
(defined as t1) they were excluded from the analyses, which resulted in 122 mutation carriers 
at t1. At the second biomarker measurement (defined as t2), 9 participants did not give blood, 
which resulted in 85 mutation carriers at t2.
Sample withdrawal and biochemical analyses
At t1 and t2 EDTA blood was withdrawn between the years 2008 and 2012 and subsequently 
stored at -80 ºC within 2 h. Blood samples were stored until measurement of hsCRP and albumin 
levels in the fall of 2012. hsCRP was determined in EDTA plasma with an IFCC standardised 
method (Cat. no. 04628918190) on a COBAS INTEGRA 800 analyser from Roche Diagnostics, 
according to the instructions of the manufacturer. The expected reference range for hsCRP 
in adult males and females is < 5 mg/L. Between-run coefficients of variation (CVs) during 
the study period (12 runs) were 5.8% at 4.09 mg/L, and 5.7% at 12.81 mg/L. Albumin in EDTA 
plasma was determined with an IFCC standardised method (Cat. no. 11970909216) on Modular 
P systems from Roche Diagnostics, using a BCG-based colorimetric assay with endpoint 
detection. This method has been standardised against the CRM 470 reference preparation. The 
reference range for serum albumin in adult males and females is 34–48 g/L. CVs during the 
study period (7 runs) were 2.94% at 37.5 g/L and 1.01% at 55.0 g/L.
Sociodemographic and clinical characteristics
Information on sociodemographic and clinical characteristics, including the potential 
confounders like current smoking, high alcohol consumption (defined as drinking more 
than 14 standardised units of alcohol a week), body weight and height, and medication 
use, was collected using a standardised interview. Use of antipsychotics was divided in 
different categories: typical antipsychotics, atypical antipsychotics, and tiapride. Tiapride was 
considered a separate category as it was used by many participants and cannot be classified 
unambiguously within one of the other categories. The estimated duration of disease was 
calculated by the current age minus the estimated age of onset according to the equation of 
Vassos.34 The Total Functional Capacity (TFC) scale of the Unified Huntington’s Disease Rating 
Scale (UHDRS)35 was used to assess global daily functioning and disease stage.36 Total scores 
range from 0 through 13 points, with higher scores indicating better global functioning.37
Motor functioning was assessed by a trained neurologist using the motor scale of the UHDRS.35 
Total scores range from 0 through 124, with higher scores indicating worse motor functioning. 
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The diagnostic Confidence Level (CL) of the UHDRS motor scale was used to define mutation 
carriers as pre-motor symptomatic (CL 0 or 1 point) or motor symptomatic (CL 2 through 4 
points).
Neuropsychiatric characteristics
Neuropsychiatric characteristics were assessed by the Dutch version of the Problem Behaviours 
Assessment (PBA),38 a semi-structured interview, assessing the frequency and severity of 36 
potential behavioural problems in HD. The inter-rater reliability of the Dutch version of the PBA 
is 0.82 for severity scores and 0.73 for frequency scores.39 In this study we used symptom factors 
that were previously estimated by factor analysis of the PBA, which resulted in three factors: 
apathy (range 0–64), irritability (range 0–80), and depression (range 0–80).39 Additionally, 
suicidality was assessed with the PBA38 by multiplying the severity and frequency score of 
the item ‘suicidal ideation’. As done before, a total score > 1 point on this item was used to 
characterise the presence of suicidality.40
Cognitive characteristics
The Mini-Mental State Examination (MMSE) was used to assess global cognitive functioning. 
Total scores range from 0 through 30 points, with higher scores indicating better global 
cognitive functioning.41 The cognitive scales of the UHDRS,35 including the Verbal Fluency Test 
(VFT),42 the Symbol Digit Modalities Test (SDMT),43 and the Stroop tests,44 were used to assess 
executive cognitive functioning. For all cognitive scales, higher scores indicate better executive 
functioning. The ExCog, a composite variable obtained by averaging the standardised z-scores 
of the other executive cognitive subscales, was used as a measure for executive cognitive 
functioning.
Statistical analyses
Data are presented as n (%), mean (± standard deviation [SD]), mean (95% CI), or median 
(interquartile range [IQR]) when appropriate.
Because of their positively skewed distribution, hsCRP levels were log transformed before 
being used in statistical analyses. Characteristics of HD mutation carriers and controls at t1 
were compared by chi-squared tests for categorical data, t-tests for independent samples with 
normal distributions, or non-parametric Whitney-U tests for continuous variables without 
normal distributions.
Associations between hsCRP and albumin levels and clinical, neuropsychiatric, and cognitive 
characteristics were determined by linear regression analysis for continuous outcomes and 
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logistic regression analysis for dichotomous outcomes. Apart from the crude model, we 
adjusted in the first multivariate models for the potential confounders sex, age, body mass 
index (BMI), smoking, and alcohol consumption at t1. Since previous literature indicated that 
the use of antipsychotics may affect CRP levels,23;28;29 a second model was built, including the 
variables from the adjusted model and the use of antipsychotics. Furthermore, analysis of 
covariance (ANCOVA) was used to compare acute-phase protein levels between participants 
who did not use antipsychotics, participants who started using antipsychotics during the study 
period, and participants who continuously used antipsychotics, with adjustment for sex, age, 
BMI, smoking, and alcohol consumption at t1. In an additional model comparing acute-phase 
protein levels at t2 between the different groups, we additionally adjusted for acute-phase 
protein levels at t1. As a sensitivity analysis, this ANCOVA was repeated without participants 
whose hsCRP level was above 10 mg/L, due to their possible association with acute infectious 
diseases. Since almost all participants who used antipsychotics were in later disease stages 
and disease stage may also be related to the acute-phase response, we performed a sensitivity 
analysis which only included the participants with a disease stage > 2 (TFC score < 7) at t1. 
As previous research showed that the effect of antipsychotic use on CRP levels is different 
for different kinds of antipsychotics,28 we performed a mixed model analysis (i.e., multilevel 
regression analysis) with adjustment for age, sex, BMI, smoking, and alcohol consumption 
at t1, to evaluate associations between the different categories of antipsychotics and acute-
phase protein levels.
A p-value < 0.05 was considered statistically significant. P-values presented were not corrected 
for multiple comparisons, since we interpreted the overall pattern of diminishing effect sizes 
and p-values after additional adjustment for the use of antipsychotics in multivariable models. 
SPSS version 20.0 was used.
Results
Characteristics of mutation carriers versus controls
At t1, mutation carriers more often used psychotropic medication, had higher scores on the 
apathy, irritability, and depression factors of the PBA and worse scores on all cognitive tests, 
compared with controls (Table 1). When comparing acute-phase proteins, the hsCRP level of 
the mutation carriers at t1 was non-significantly higher in mutation carriers compared with 
controls (Table 1). At t2, the hsCRP level of mutation carriers was significantly higher compared 
with controls (mean = 1.94; 95% CI = 1.50–2.51 versus 0.99; 95% CI = 0.64–1.52, respectively; 
p = 0.002) (data not shown). There was a significant trend of increasing hsCRP levels across 
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Male gender 54 (44%) 19 (45%) 0.91
Age (years) 49.2 ± 11.5 41.0 ± 11.2 <0.001
BMI (kg/m2) 25.6 ± 5.1 25.1 ± 4.3 0.62
Smoking 30 (26%) 12 (29%) 0.73
High alcohol consumption 11 (9%) 1 (2%) 0.30
Biological characteristics
Albumin (mean in g/L, 95% CI) 47.1 (46.5 – 47.7) 48.5 (47.6 – 49.5) 0.01
hsCRPb (mean in mg/L, 95% CI) 1.49 (1.20 – 1.86) 1.23 (0.85 – 1.79) 0.39
Clinical characteristics
CAG repeats (number) 44.1 ± 3.2 21.6 ± 4.2 <0.001
Estimated disease duration (years) 3.8 ± 11.4 NA NA
TFC score 8 (3 – 13) 13 (13 – 13) <0.001
UHDRS motor score 19 (5 – 48) NA NA
Pre-motor symptomatic 33 (28%) NA NA
Antidepressant use 44 (36%) 1 (2%) <0.001
Benzodiazepine use 25 (21%) 0 (0%) 0.001
Antipsychotic use 35 (29%) 0 (0%) <0.001
Neuropsychiatric characteristics
PBA apathy factor score 2 (0 – 18) 0 (0 – 0) <0.001
PBA irritability factor score 4 (0 – 15) 0 (0 – 2) <0.001
PBA depression factor score 4 (0 – 12) 0 (0 – 6) 0.04
PBA suicidality 14 (12%) 1 (2%) 0.08
Table continued on the next page.
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MMSE score 28 (24 – 29) 29 (29 – 30) <0.001
SDMT score 35 (12 – 50) 53 (47 – 58) <0.001
VFT score 20 (10 – 30) 29 (25 – 37) <0.001
Stroop colour score 50 (33 – 71) 76 (69 – 87) <0.001
Stroop word score 71 (41 – 98) 99 (99 – 100) <0.001
Stroop interference score 29 (16 – 40) 44 (39 – 47) <0.001
ExCog -0.20 ± 0.9 0.68 ± 0.3 <0.001
Data are presented as n (%), mean (± SD), or median (interquartile range [IQR]), unless otherwise specified. 
BMI denotes Body Mass Index; hsCRP, high sensitivity C-reactive protein; CI, confidence interval; NA, applicable; 
TFC, total functional capacity; UHDRS, Unified Huntington’s Disease Rating Scale; PBA, Problem Behaviour 
Assessment; MMSE, Mini Mental State Examination; SDMT, Symbol-Digit Modalities Test; VFT, Verbal Fluency 
Test. 
a P-values by chi-squared test for categorical data, by t-test for independent samples with normal distributions, 
or non-parametric Whitney-U tests for independent samples without normal distributions. 
b Because of its skewed distribution, hsCRP was log transformed before the analyses.
increasing disease stages at t1 and t2 (Suppl. Table 1). The albumin level of the mutation carriers 
was significantly lower compared with controls, both at t1 (Table 1) and t2 (mean = 46.4; 95% CI 
= 45.8–47.1 versus 47.6; 95% CI = 46.5–48.7, respectively; p = 0.03) (data not shown). However, 
after correction for potential confounders (sex, age, BMI, smoking, and alcohol consumption) 
only the hsCRP level at t2 remained significantly different between mutation carriers and 
controls. There was a significant trend of decreasing albumin levels across increasing disease 
stages at t1 and t2 (Suppl. Table 1).
Associations between acute-phase proteins and clinical characteristics at t1
Serum hsCRP level was significantly associated with TFC score, apathy score (Table 2), 
benzodiazepine use, and antipsychotic use (Table 3). Using multivariate linear regression 
analyses, with adjustment for potential confounders, the hsCRP level remained significantly 
associated with apathy score, Stroop interference test, and ExCog (Table 2). However, after 
additional adjustment for use of antipsychotics, all these associations lost their statistical 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Serum albumin level was independently associated with TFC score, apathy score, SDMT 
score, the Stroop test scores, ExCog (Table 2), MMSE score, use of benzodiazepines, and use 
of antipsychotics (Table 3). Likewise, after additional adjustment for use of antipsychotics, all 
these associations lost their statistical significance (Tables 2 and 3). 
Associations between acute-phase proteins and clinical characteristics at t2
When analysing cross-sectional associations between hsCRP and albumin levels on the one 
hand and clinical, neuropsychiatric, and cognitive characteristics on the other hand at t2, 
similar associations were found as at t1. Once more, significant associations disappeared after 
additionally adjusting for antipsychotic use (data not shown).
Use of antipsychotics and acute-phase proteins
When comparing mutation carriers who started using antipsychotics during the study period 
with mutation carriers who did not use antipsychotics during the study period, the hsCRP 
level of starters at t1 was not significantly different from non-users. At t2, however, the hsCRP 
level of starters had increased and was higher compared with non-users, although statistical 
significance disappeared after adjustment for the hsCRP level at t1 (Figure 1 and Suppl. Table 
2). Compared with non-users, mutation carriers who continuously used antipsychotics had 
significantly higher hsCRP levels at both measurements and also had a larger increase in hsCRP 
level between the two measurements (Figure 1 and Suppl. Table 2). 
Likewise, serum albumin levels of antipsychotic starters tended to decline, but the comparison 
with non-users was not significant at both measurements (Figure 1 and Suppl. Table 2). 
Albumin levels of continuous users were significantly lower compared with non-users at both 
t1 and t2, even after adjustment for the albumin level at t1 (Figure 1 and Suppl. Table 2). 
After excluding participants with an hsCRP level above 10 mg/L, differences in hsCRP and 
albumin levels between non-users and starters and between non-users and continuous users 
at t1 persisted. At t2, continuous users had significantly more often hsCRP levels above 10 
mg/L than non-users (21.1% versus 4.1%, respectively; p = 0.03). hsCRP levels remained higher 
and albumin levels lower in starters and continuous users compared with non-users, although 
the absolute differences substantially attenuated.
When repeating the analysis only in participants with a disease stage > 2, the differences that 
were found between continuous users and non-users at both t1 and t2 were comparable to 
those in the original analysis, while this was not the case for the differences between starters 
and non-users.
























































































































































































































































































































































































































Using linear mixed models analyses, with adjustment for potential confounders, all three 
categories of antipsychotics were positively associated with hsCRP levels. Effect estimates 
indicated a rather similar effect sizes for typical antipsychotics (n = 32; ß = 0.42), atypical 
antipsychotics (n = 26; ß = 0.25), and tiapride (n = 28; ß = 0.30). Likewise, inverse associations 
were found with albumin: typical antipsychotics (n = 32; ß = -0.47), atypical antipsychotic (n = 
26; ß = -0.53), and tiapride (n = 28; ß = -0.36) (data not shown).
Discussion
We found strong associations between the use of antipsychotics and an elevated acute-phase 
response in HD. Other associations between hsCRP and albumin levels on the one hand and 
TFC score, apathy, and cognitive impairment on the other hand, disappeared when adjusting 
for the use of antipsychotics. Also, mutation carriers who continuously used antipsychotics had 
significantly higher hsCRP levels and lower albumin levels compared with mutation carriers 
who did not use antipsychotics during the study period.
Increases in CRP levels have previously been found in HD mutation carriers when compared 
to controls and one study also found a correlation between disease stage and CRP levels.15;16 
In contrast, we only found a significant increasing trend of CRP across increasing disease 
stages but no differences in CRP levels between the whole group of HD mutation carriers and 
controls. The relatively low number of HD mutation carriers in more advanced disease stages 
in our cohort may have accounted for this finding. This idea is in line with the finding of a study 
reporting that premanifest and early-stage HD mutation carriers, who are in lower disease 
stages, had similar or lower CRP levels respectively, when compared with controls.17
Previous publications offer several mechanisms that could explain our finding of an 
elevated acute-phase reaction in mutation carriers who used antipsychotics. First, the use 
of antipsychotics may cause symptoms associated with the metabolic syndrome which in 
turn induces an acute-phase response. Atypical antipsychotics are strongly associated with 
the development of metabolic syndrome, which is characterised by abdominal obesity, 
dyslipidaemia, hypertension, and insulin resistance. Obesity,45 dyslipidaemia,31 and insulin 
resistance46 may induce low-grade inflammation reflected in increased CRP levels. In rats, it 
has been shown that treatment with olanzapine induces weight gain and increased adipose 
tissue. In addition, the adipose tissue of olanzapine-treated rats had become infiltrated with 
macrophages and there was a 2-fold increase in the expression of the TNF-α, both indicative 
of low-grade inflammation.47 Second, the use of antipsychotics may directly induce low-grade 
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inflammation through their hepatic impact since antipsychotics are eliminated predominantly 
by hepatic metabolism. In the CATIE trial,28 increased CRP levels were indicative of having 
more signs of the metabolic syndrome but were also independently associated with the use 
of atypical antipsychotics, in particular olanzapine. In a smaller open-label study, with 111 
patients randomised to haloperidol, olanzapine, and risperidone, patients on haloperidol 
showed the strongest increase in CRP levels after three months of treatment.29
Since the effects in our study were largely unaffected by adjustment for BMI, we assume that 
the use of antipsychotics directly induced an acute-phase response. Atypical antipsychotics 
are most often implicated in induction of inflammation but in our mixed-model analyses, we 
did not find a differential role for atypical antipsychotics, typical antipsychotics, and tiapride. 
Therefore these groups were combined.
Immune activation in HD is widespread48 and is known to positively correlate with disease 
stage. IL-6, a cytokine that plays a main role in the innate immune response, was shown to be 
up-regulated both centrally and peripherally in HD.11 One of its functions is to initiate the acute-
phase response, thus subsequently increasing the synthesis of CRP while decreasing albumin 
levels. Neuroinflammation leads to neuronal degeneration through several mechanisms, 
and neuronal degeneration in the striatum is one of the key histopathological features of 
HD that is associated with movement abnormalities, cognitive and several neuropsychiatric 
symptoms. Our findings may therefore also be explained by reverse causation meaning that 
neuroinflammation has caused movement abnormalities and neuropsychiatric symptoms, 
which in turn has led to the prescription of antipsychotics.
Although influenced by the use of antipsychotics, we did find associations between levels of 
acute-phase proteins and several clinical variables. We found an association for TFC, apathy, 
and cognitive impairment. Previous studies in non-HD populations also found associations 
between levels of acute-phase proteins and both apathy25 and cognitive impairment.18;21;22 
In contrast to our study, these studies did not investigate the role of antipsychotics in these 
associations. In our study, the elevated acute-phase reaction was strongly associated with the 
use of antipsychotics and all associations between acute-phase proteins and clinical variables 
disappeared when adjusting for antipsychotics. As previously argued, we hypothesise that 
the use of antipsychotics induced an acute-phase response which in turn was associated 
with several neuropsychiatric symptoms and cognitive impairment. But associations between 
acute-phase proteins on the one hand and TFC, apathy, and cognitive impairment on the other 
hand, may have been confounded by the use of antipsychotics. Alternatively, confounding by 
indication may explain our results.
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To our knowledge, this is the first study investigating the role of the acute-phase response in 
the occurrence of neuropsychiatric symptoms and cognitive dysfunction in HD. Strengths of 
this study are the use of a comparison group (consisting of first-degree non-carriers), the use 
of validated measurement tools in a standardised interview, and the adjustment for potential 
confounders, including antipsychotic use, in the analyses. There are several limitations that 
warrant discussion. Since inflammation is associated with the neurodegenerative process 
in HD, relationships found in this study might not be generalised to other disorders and the 
general population. Given the observational rather than experimental nature of our study, it is 
impossible to make causal inferences about our findings.
Future research on the role of antipsychotic use on the acute-phase reaction is necessary, both 
in HD and in other populations. We found strong evidence for a role of antipsychotics in inducing 
an acute-phase response in HD mutation carriers. Although we could not make inferences 
regarding the direction of causation, HD mutation carriers who receive antipsychotics may be 
prone to the development of low-grade inflammation, which may subsequently increase their 
risk of cardiovascular morbidity, lower functioning capacity, apathy, and cognitive dysfunction.
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Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis has been reported in Huntington’s 
disease (HD). In non-HD populations, alterations in HPA axis activity have been associated with 
depression and suicidality. The present study aims to compare HPA axis activity between HD 
mutation carriers and controls, and examine its association with depressive symptoms and 
suicidality. To this end, salivary cortisol concentrations at seven time points, as well as depressive 
symptoms and suicidality, were assessed in 49 pre-motor, 102 motor symptomatic mutation 
carriers and 55 controls, at baseline and follow-up combined. Differences in parameters of HPA 
axis activity between these three groups, and their associations with depressive symptoms and 
suicidality in HD mutation carriers, were analysed using multilevel regression analyses. There 
were no differences in parameters of HPA axis activity between mutation carriers and controls, 
whereas pre-motor symptomatic mutation carriers had a significantly higher area under the 
curve to the increase (AUCi) compared to motor symptomatic mutation carriers. In the entire 
HD cohort, HPA axis activity was not associated with depressive symptoms or suicidality. 
After stratifying mutation carriers into pre-motor, early and advanced disease stages, β values 
differed between these groups. Remarkably, a higher AUCi was significantly associated with 
depressive symptoms in pre-motor and early disease stage mutation carriers, with a reverse 
non-significant association in advanced disease stage mutation carriers. The lower AUCi in 
motor symptomatic mutation carriers and the varying associations with depressive symptoms 
and suicidality in pre-motor, early and advanced disease stages could possibly be explained by 
exhaustion of the HPA axis after prolonged stress-induced HPA axis hyperactivity and deserves 
further longitudinal study.




Huntington’s disease (HD) is an autosomal dominant, neurodegenerative disease caused by 
a CAG expansion in the HTT gene on chromosome 4. The disease is characterised by motor 
symptoms, cognitive decline, behavioural symptoms and psychiatric disorders.1
Depression is a common psychiatric disorder in HD,2 which can precede the onset of motor 
abnormalities.3 The prevalence of a depressed mood is reported to range from 33% to 69%, 
depending on the disease stage and assessment method used.2 The presence of a depressed 
mood in HD is an important predictor of suicidal ideation4;5 and suicidal behaviour.5,6 Previous 
studies showed that completed suicide rates among HD mutation carriers are four- to eight-fold 
higher compared to the general population,7,8 with increased suicidality prevalences (including 
both suicidal ideation and attempts) of up to 20% in the previous month in both pre-motor 
and motor symptomatic mutation carriers.5 Although some of the psychiatric symptoms in 
HD might be attributed to environmental factors, pathophysiological mechanisms may also 
be involved, such as dysfunction in the caudate nucleus,2;9 which is one of the brain structures 
with prominent cell loss in HD.1
In non-HD populations, the presence of depression and suicidality has also been associated 
with disturbed functioning of the hypothalamic-pituitary-adrenal (HPA) axis. Although several 
studies indicated hyperactivity of the HPA axis in depressed patients or in those developing 
depression compared to non-depressed controls,10-15 other studies have reported normal16;17 or 
even lower HPA axis activity in depressed patients or those developing depression compared 
to non-depressed controls.18-20 These inconsistent results might partly be explained by the 
existence of a non-linear association between HPA axis activity and depression, which implies 
that both hyper- and hypoactivity of the HPA axis can be associated with depression.21
Also, an association between dysfunction of the HPA axis (most commonly dexamethasone 
non-suppression) and completed suicide has repeatedly been described, mainly in depressed 
patients.22-24 A meta-analysis showed that non-suppressors of the dexamethasone suppression 
test (DST) are 4.7 times more likely to commit suicide than suppressors.25 Evidence for a 
relationship between HPA axis functioning and suicidal ideation or attempted suicide is 
less consistent22,24,26 (i.e. some studies reported hyperactivity of the HPA axis in those with 
suicidal ideation or attempts, whereas others found no association or reported a reverse 
association).22;24;26-28
Hypothalamic changes and hyperactivity of the HPA axis have been reported in HD mouse 
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models and in HD mutation carriers compared to controls.29-38 Both alterations have been 
reported in early disease stages30;34;37 and elevated salivary cortisol concentrations were found 
in pre-motor symptomatic HD mutation carriers compared to diagnosed HD patients.39;40 
Elevated cortisol concentrations in an early stage of HD could indicate that psychiatric 
symptoms in this stage are related to a perturbed HPA axis30 and it has been suggested that 
HPA axis alterations may contribute to depressive symptoms in HD.41 A recent study reported 
higher salivary morning cortisol concentrations in early disease stage mutation carriers with 
mild to severe depressive symptoms compared to non-depressed early disease stage mutation 
carriers,40 whereas other studies found no significant relationship between HPA axis activity 
and depression scores,30;42 the presence of a major depressive disorder (MDD) or dysthymia,38 or 
a history of MDD.31 So far, studies investigating the relationship between HPA axis functioning 
and psychiatric symptoms in HD were limited to the presence of depression and did not 
investigate suicidality. Furthermore, these studies were small (≤ 56 mutation carriers) and 
reported contradicting results.
In a previous cross-sectional study conducted by our group,39 in contrast to earlier studies, 
no significant differences were found in overall parameters of HPA axis activity between 
HD mutation carriers and controls. For the present study, additional follow-up data was 
collected, and we aimed to compare HPA axis functioning, as measured by salivary cortisol 
concentrations at different time points during the day, between HD mutation carriers and 
controls at both baseline and follow-up measurements combined. We hypothesised that HPA 
axis activity would be elevated in both pre-motor and motor symptomatic mutation carriers 
compared to controls. We also aimed to assess the change in parameters of HPA axis activity 
between baseline and follow-up and expected to find a decrease in HPA axis functioning with 
disease progression. In addition, we aimed to investigate whether elevated HPA axis activity 
was associated with severity of depressive symptoms and suicidality within the cohort of HD 
mutation carriers and we expected to find higher depressive symptom and suicidality scores 
in mutation carriers with elevated parameters of HPA axis activity.
Materials and methods
Participants
Between May 2004 and August 2006, 152 HD mutation carriers were recruited for participation 
through the outpatient departments of Neurology and Clinical Genetics of the Leiden University 
Medical Center (LUMC) and a regional nursing home specialised in care for HD patients. In 
addition, 56 relatives, who initially had a 50% risk for the mutation but tested negative for the 
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HD mutation, were recruited as a control group. The study design and recruitment procedure 
have been described in detail elsewhere.43
A second measurement was made between 2006 and 2008; in this period, 128 mutation carriers 
and 42 non-carriers continued to participate. A third measurement was made between 2009 
and 2011, which included 94 mutation carriers and 32 non-carriers. Biomarker measurements, 
including cortisol measurements at seven different time points during two consecutive days 
to assess HPA axis functioning, were made at the second and third measurements. Because 
several participants refused saliva collection or insufficient saliva was collected, only 97 
mutation carriers and 33 controls could participate at the first cortisol measurement (2006–
2008; baseline for this substudy) and 55 mutation carriers and 22 controls could participate at 
the second cortisol measurement (2009–2011; follow-up) (Figure 1). 
Data from the first cortisol measurement were also used in a previous study investigating HPA 
axis functioning in HD compared to controls;39 however, this latter study was limited to cross-
sectional analyses with baseline data only. After the analyses for the previous study, additional 
data on baseline HPA axis activity were acquired in 13 mutation carriers and five controls and 
follow-up data on HPA axis activity were acquired in 55 mutation carriers and 22 controls. Also, 
the previous study did not investigate the change in parameters of HPA axis activity between 
baseline and follow-up and did not investigate the association between HPA axis functioning 
on the one hand and depressive symptoms and suicidality on the other. In addition, for the 
present study, all salivary cortisol samples used in the previous article were re-assayed using an 
improved re-standardised cortisol in saliva assay that guarantees accurate values in the 5–50 
nmol/l range. Correlation coefficients between cortisol concentrations at the different times 
throughout the day, as determined by the former and the improved assay, ranged from 0.96 to 
1.00. This improved assay was also used to assess the newly collected salivary cortisol samples.
The study was approved by the Medical Ethical Committee of the LUMC and all participants 
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Assessment of HPA axis functioning
HPA axis functioning was assessed by measuring cortisol concentrations in saliva samples. All 
participants received an oral and written instruction that asked them to collect saliva on two 
consecutive days. Instructions provided by the manufacturer were used. The participants had 
to place cotton wads from a saliva collection tube (Salivettes, catalogue no. 1.1534, Sarstedt AG 
& Co., Nümbrecht, Germany) in their mouth and chew until the cotton was saturated. To avoid 
contamination of the saliva with food or blood, participants were asked to refrain from eating, 
drinking or brushing their teeth before sampling. The participants were free to wake up on the 
basis of their own time schedule.
The day curve of cortisol concentrations was assessed by collecting the saliva on six different 
times throughout the day: at the time of awakening, 30 min after awakening, 45 min after 
awakening, 60 min after awakening, and at 22.00 and 23.00 h. In addition, the saliva cortisol 
concentrations after the DST were measured at the time of awakening on day two. Participants 
were also asked to record the date and time of collection. We assumed cortisol concentrations 
≥ 100 nmol/l to be physiologically unlikely (e.g. as a result of bleeding gums) and these 
values were excluded. One or more cortisol values were excluded for this reason in two 
control participants (3.6%), two pre-motor symptomatic (4.1%) and five motor symptomatic 
mutation carriers (4.9%). When one to four cortisol values were missing, loge-transformed 
cortisol concentrations were imputed using multiple imputation (five times), in which other 
known characteristics of the participant were used: the remaining loge-transformed cortisol 
concentrations, time of awakening at day 1, time of awakening at day 2, season, sex, age, 
smoking, high alcohol use, body mass index (BMI), loge-transformed Total Functional Capacity 
(TFC) score, loge-transformed depressive symptom score, loge-transformed suicidality score, 
use of psychotropics, and time of measurement (baseline/follow-up). In total, from both 
baseline and follow-up combined, 63 of the 1449 (4.3%) cortisol values were imputed.
Two indicators of the cortisol awakening response (CAR), the area under the curve to the ground 
(AUCg) and the area under the curve to the increase (AUCi), were calculated using the first four 
time points, according to the trapezoid formula.44 The mean evening cortisol was assessed by 
the mean of the two evening measurements on day 1, at 22.00 and 23.00 h. Physiologically, 
the DST results in a decrease in the morning cortisol concentration because of the inhibition of 
ACTH secretion. On the evening of day 1, the participants were instructed to orally take a low-
dose dexamethasone tablet (0.5 mg). The dexamethasone suppression rate was determined 
by the cortisol concentration at time of awakening on day 1/the cortisol concentration at time 
of awakening on day 2 (post DST).
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After collecting all seven saliva samples, participants returned their samples through the 
regular postal service. Upon arrival, saliva was harvested by centrifuging the Salivettes during 
5 min at 10°C and 3309 g. Saliva was stored at -80 °C until analysis. Determination of cortisol 
in saliva was performed with a competitive electrochemoluminescent immunoassay using a 
Modular Analytics E170 immunoassay analyser (Roche Diagnostics, Mannheim, Germany). For 
the determination, a cortisol reagent (catalogue number 11875116 122/lot number 00168267) 
and calibrator (catalogue number 11875124 122/lot number 00169356: expiration date 
December 2013) were used.
The functional sensitivity for salivary cortisol is < 8.5 nmol/l, with a lower limit of detection of 0.5 
nmol/l (source: Roche Diagnostics product insert). The internal quality control was monitored 
using home-made controls of saliva pools manufactured in an ISO-certified production facility 
(ISO 13485:2003). During the measurements, the mean ± SD was 8.04 ± 0.57 nmol/l for pool 
1/20111281 (inter-run coefficient of variation [CV] = 7.11%; n = 28) and 20.70 ± 0.97 nmol/l 
(inter-run CV = 4.69%; n = 28) for pool 2/20111282.
Sociodemographic and clinical characteristics
Information on sociodemographic and clinical characteristics (e.g. height and weight, current 
smoking, high alcohol consumption [defined as drinking > 14 standardised units of alcohol 
a week] and medication use) was collected using a standardised interview. The estimated 
duration of disease was calculated by the current age minus the estimated age of onset 
according to the equation of Vassos et al.45 Global daily functioning and disease stage46 were 
assessed by the TFC scale47 of the Unified Huntington’s Disease Rating Scale (UHDRS),48 and 
motor functioning was assessed by a trained neurologist using the motor scale of the UHDRS.48 
The confidence level (CL) of the UHDRS motor scale48 was used to characterise mutation carriers 
as pre-motor (CL 0–1 points) or motor symptomatic (CL 2-4 points). 
Assessment of depressive symptoms and suicidality
Depressive symptoms and suicidality were assessed using the Dutch version of the Problem 
Behaviours Assessment (PBA). The PBA is a semi-structured interview designed to assess 
the frequency and severity of 36 common behavioural symptoms in HD.49;50 Total scores for 
the separate items of the PBA are computed by multiplying severity (range 0–4 points) and 
frequency (range 0–4 points) scores (range 0–16 points). Depressive symptoms in the previous 
month were assessed using the depressive symptoms cluster that was previously reported.50 
This depression subscale (range 0-80 points) consists of five items: ‘depressed mood’, ‘depressive 
cognitions’, ‘anxiety’, ‘tension’, and ‘suicidal ideation’.50 In addition, the ‘suicidal ideation’ item of 
the PBA (range 0–16 points) was used to assess the presence of suicidal ideation and suicide 
HPA axis in relation to depression and suicidality in HD
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attempts in the month preceding the interview.
Statistical analysis
Because of their positively skewed distributions, parameters of HPA axis activity, depressive 
symptom scores and suicidality scores were loge-transformed before being analysed. Data are 
presented as n (%), mean (± SD) or geometric back-transformed mean (i.e. back-transforming 
the mean of logarithmic values) (95% confidence intervals [CI]) when appropriate.
Sociodemographic and clinical characteristics of controls and pre-motor and motor 
symptomatic mutation carriers at baseline were compared using chi-squared tests for 
categorical data and one-way between-groups analysis of variance (ANOVA) for continuous 
data. Post-hoc comparisons were made using a chi-squared test for categorical data and 
Tukey’s honestly significant difference test for continuous data.
Parameters of HPA axis activity of controls and pre-motor and motor symptomatic mutation 
carriers, both at baseline and follow-up combined, were compared using multilevel regression 
analyses (i.e. linear mixed models), with additional adjustment for potential confounders (sex, 
age, and time of measurement [baseline/follow-up]). An unstructured covariance matrix was 
used to account for the repeated measurements within a participant. Additionally, changes in 
the parameters of HPA axis activity between baseline and follow-up were compared between 
controls and pre-motor and motor symptomatic mutation carriers, using ANOVA. Analysis of 
covariance (ANCOVA) was used to adjust for sex and age.
The associations between continuous parameters of HPA axis activity on the one hand, and 
continuous depressive symptom and suicidality scores on the other, in HD mutation carriers 
at both baseline and follow-up combined were analysed using multilevel regression analyses 
with an unstructured covariance matrix. Analyses were adjusted for the potential confounders 
sex, age, season, smoking and time of measurement (baseline/follow-up). Because a previous 
study reported a relationship between HPA axis functioning and depression only in early 
symptomatic HD mutation carriers,40 we stratified the mutation carriers into pre-motor 
symptomatic, early disease stage (motor symptomatic and disease stage 1 or 2)46 and advanced 
disease stage (motor symptomatic and disease stage 3–5)46 and repeated the analyses to 
explore whether the associations varied between these different disease stages.
In additional sensitivity analyses, BMI and alcohol use were added to the models of the original 
analyses. Also, analyses were restricted to those who woke up at, or before, 09.00 h and to 
those who reported the time of saliva collection and did not violate the prescribed time for 
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saliva collection by more than 5 min. For the DST, we considered participants with more than 
60 min between time of awakening on day 1 and time of awakening on day 2 as time protocol 
violators.
For illustrative purposes only, scores on the outcome measures (depressive symptom and 
suicidality scores) were categorised into quartiles of parameters of HPA axis activity in the 
tables and figures, whereas statistical tests were solely based on the appropriate continuous 
data. P < 0.05 (two-tailed) was considered statistically significant. SPSS, version 20.0 (IBM Corp., 
Armonk, NY, USA) was used for the analyses.
Results
Baseline characteristics of pre-motor and motor symptomatic mutation carriers versus controls
At baseline, the study population consisted of 33 controls, 30 pre-motor symptomatic mutation 
carriers and 67 motor symptomatic mutation carriers (Table 1). Motor symptomatic mutation 
carriers were significantly older compared to pre-motor symptomatic mutation carriers and 
controls, and also had lower TFC scores. In addition, the use of psychotropic medication 
showed a significant difference between the three groups. Depressive symptom scores were 
higher in both pre-motor and motor symptomatic HD mutation carriers compared to controls. 
Also, suicidality scores in pre-motor and motor symptomatic mutation carriers were higher 
compared to controls; however, these differences were not significant (Table 1). 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































Parameters of HPA axis activity in HD mutation carriers versus controls
Comparison of the parameters of HPA axis activity between controls and pre-motor symptomatic 
and motor symptomatic mutation carriers, at both baseline and follow-up combined, showed 
that the only significant difference was a higher AUCi in pre-motor symptomatic mutation 
carriers compared to motor symptomatic mutation carriers (Table 2a); this difference remained 
significant after adjustment for sex and age. Although the AUCg was also higher in pre-motor 
symptomatic mutation carriers compared to motor symptomatic mutation carriers and 
controls, this difference was not significant. Also, the mean evening cortisol and the cortisol 
suppression ratio showed no significant difference between controls and pre-motor and motor 
symptomatic mutation carriers, in both the crude and adjusted models (Figure 2 and Table 2a).
The largest change in parameters of HPA axis activity from baseline to follow-up was observed 
for the AUCi (> 9% decrease in all groups). However, the changes in parameters of HPA axis 
activity between baseline and follow-up showed no significant difference between controls 
and pre-motor and motor symptomatic mutation carriers, in both the crude and adjusted 




















Controls (55 observations) 
Pre-motor symptomatic HD (49 observations)
Motorsymptomatic HD (102 observations) 
Figure 2.
Geometric mean cortisol concentrations (i.e. back-transforming the mean of logarithmic values) (95% 
confidence interval) at the different sampling times for controls and pre-motor and motor symptomatic HD 
mutation carriers at both baseline and follow-up combined. For one observation, a motor assessment was 
missing, which resulted in 55 control and 151 mutation carrier observations. 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Associations between parameters of HPA axis activity and depressive symptoms and suicidality 
Analyses of the associations between parameters of HPA axis activity and PBA depressive 
symptom score (Table 3) showed that the strongest but non-significant association was with 
the AUCi. No associations were found between the AUCg, mean evening cortisol and cortisol 
suppression ratio (CSR) on the one hand and depressive symptom score on the other. After 
adjustment for potential confounders, the β values remained similar or became smaller 
compared to those in the crude model (Figure 3 and Table 3).
Analyses of the associations between parameters of HPA axis activity and suicidality showed 
that the AUCg, AUCi, mean evening cortisol and the CSR were not associated with suicidality 
score, either in the crude or in the adjusted model (Figure 3 and Table 3).
Associations in pre-motor symptomatic, early and advanced disease stages
When exploring associations separately in pre-motor symptomatic (49 observations), early 
disease stage (48 observations) and advanced disease stage (53 observations) mutation 
carriers, both the crude and adjusted β values differed for all parameters of HPA axis activity 
between the three groups (data not shown). For the depressive symptom score, the difference 
between the adjusted β values was largest for the AUCi. A higher AUCi was associated with 
depressive symptoms in both pre-motor symptomatic (βadjusted = 0.27, 95% CI = 0.04 to 0.51) 
and early disease stage mutation carriers (βadjusted = 0.44, 95% CI = 0.21 to 0.67), whereas a 
reverse association was found in advanced disease stage mutation carriers (βadjusted = -0.09, 95% 
CI = -0.38 to 0.21). Regarding suicidality, the difference between adjusted β values was largest 
for the CSR. A lower CSR was associated with suicidality in the pre-motor symptomatic group 
(βadjusted = -0.19, 95% CI = -0.43 to 0.06). This association was weaker in the early disease stage 
group (βadjusted = -0.04, 95% CI = -0.36 to 0.28) and was reversed in the advanced disease stage 
group (βadjusted = 0.15, 95% CI = -0.23 to 0.53).
Sensitivity analyses
For both the depressive symptom and suicidality analyses in the entire group of HD mutation 
carriers, additional adjustments for BMI and alcohol use resulted in comparable or smaller β 
values compared to the original adjusted models, which differed no more than 0.05 points 
from those of the original analyses. Also, when restricting the analyses to those mutation 
carriers who woke up at, or before, 09.00 h, the crude and adjusted β values for both depressive 
symptoms and suicidality differed no more than 0.05 points from those of the original analyses. 
When time protocol violators were excluded from the analyses, the crude and adjusted β 
values for both depressive symptoms and suicidality differed no more than 0.04 points from 
those of the original analyses (data not shown).
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The present study examined HPA axis activity in HD and revealed a significantly higher AUCi in 
pre-motor symptomatic mutation carriers compared to motor symptomatic mutation carriers. 
By contrast to our hypothesis, we found no differences in HPA axis activity between both pre-
motor and motor symptomatic mutation carriers and controls. Also, no overall statistically 
significant or clinically relevant associations were found between parameters of HPA axis 
activity on the one hand, and depressive symptoms or suicidality on the other. Nevertheless, 
when the population was stratified in pre-motor symptomatic, early and advanced disease 
stages, the associations varied between the different stages, and the AUCi was significantly 
associated with depressive symptoms in mutation carriers from both pre-motor symptomatic 
and early disease stages.
By contrast to previous studies,29-33;38 we found no hyperactivity of the HPA axis in HD mutation 
carriers compared to controls. However, the previous studies differed from our study by 
including controls who did not grow up in a HD family.29-31;33;38 There is increasing evidence that, 
as a result of epigenetic mechanisms, an unfavourable environment during childhood can 
influence important genes in stress regulation that can affect HPA axis functioning.22;23;51 The 
stress of growing up in an HD family, and the fear of being an HD mutation carrier, was most 
probably also experienced by our control group, which may explain why, compared to non-
depressed controls from the general Dutch population,10 the salivary cortisol concentrations 
of the controls in the present study were higher at every measured time point (on average 2.65 
nmol/l higher).
In addition, these contrasting studies assessed HPA axis functioning by measuring cortisol in 
serum,30-33 urine,29 or cerebrospinal fluid (CSF),38 whereas the present study, as well as another 
study that found no differences in HPA axis activity between mutation carriers and controls,40 
assessed HPA axis functioning by measuring salivary cortisol. Most of these measures only 
indirectly assess central HPA axis functioning and all reflect partially different information 
regarding its activity, which can lead to different results.52
When comparing HPA axis activity within HD mutation carriers, we found a lower CAR in motor 
symptomatic mutation carriers compared to pre-motor symptomatic mutation carriers, which 
is in line with previous results from this cohort,39 and with another study reporting higher 
morning salivary cortisol concentrations in pre-diagnosed mutation carriers compared to 
early HD.40 Long-lasting periods of elevated HPA axis activity in the earlier phases of HD may 
lead to reduced HPA axis activity53 in later phases as a result of volume reduction or impaired 
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functioning of the hippocampus,26 resulting in a blunted CAR.21
The elevated activity preceding down-regulation or exhaustion of the HPA axis in HD might 
be explained by loss of HPA axis feedback mechanisms as a result of brain pathology, such 
as hypothalamic alterations, which occur before clinical diagnosis.34;37 In addition, a loss of 
GABAergic neurons can result in disinhibition of the HPA axis,31 and the experience of different 
kinds of stress because of the presence of HD in their family might have resulted in elevated 
morning cortisol concentrations. The hypothesis of reduced HPA axis activity after prolonged 
exposure to stress and elevated parameters of HPA axis activity was also proposed in a 
depression and anxiety population.21 Within the HD population, this hypothesis is supported 
by a postmortem study reporting decreased corticotropin-releasing hormone (CRH) 
immunoreactivity in the striatum of symptomatic HD patients.54 Furthermore, the finding 
that pre-motor symptomatic mutation carriers showed no decrease in parameters of HPA axis 
activity over time does not support this hypothesis. However, the pre-motor symptomatic 
group is a heterogeneous population with varying estimated times until motor onset and the 
individual changes in the CAR from baseline to follow-up differed substantially.
Overall, we found no statistical significant or clinically relevant associations between HPA axis 
activity and depressive symptoms which is in line with previous HD studies that investigated 
HPA axis functioning in CSF,38 blood,30;31;42 and saliva.40 However, after stratifying the population 
of this latter study according to disease stage, salivary morning cortisol concentrations were 
found to be higher in early HD mutation carriers with mild to severe depressive symptoms 
compared to non-depressed early HD mutation carriers;40 this finding is in line with the results 
of our subgroup analyses. It is possible that, in different stages of HD, disturbed HPA axis 
functioning may have a different influence on the complex aetiology of depression, for which 
several mechanisms, both neuropathological and environmental, have been proposed.2;9
Although these are only exploratory analyses in small subgroups, the subgroup analyses 
for the AUCi do support the hypothesis of hyperactivation of the HPA axis in depressed 
mutation carriers in earlier disease stages, with exhaustion or down-regulation of the HPA axis 
after a longer period of stress-induced HPA axis hyperactivity,21 as indicated by the reverse 
association in advanced stage motor symptomatic mutation carriers. Two other previous small 
HD studies that only included early symptomatic mutation carriers (n = 830 and n = 56)38 did 
find higher HPA axis activity in depressed mutation carriers, although these associations were 
not significant. This might be the result of a lack of power, or because one of these studies 
focused on mean 24-h plasma cortisol concentrations30 and the other on the afternoon CSF 




This is the first study to investigate the relationship between HPA axis activity and suicidality 
in HD, finding no associations in the entire group of HD mutation carriers. First, the overall null 
finding might be explained by different associations in different disease stages, especially for 
the CSR, which was also most commonly associated with suicidality in non-HD populations.22-24 
In addition, previous non-HD studies showed that the relationship between HPA axis and 
suicidality is most consistent for completed suicide, whereas the results of studies investigating 
suicide attempts or suicidal ideation are less consistent22;24;26-28 and might be dependent on the 
suicidality severity.26 Because suicidal ideation, attempts, and completed suicides are separate 
phenotypes with probably only partly shared aetiology,51 the relatively mild suicidality scores 
and lack of completed suicides in this cohort might also explain the lack of association in this 
HD population.
Furthermore, inconsistencies in results from non-HD studies on the association between HPA 
axis functioning and suicidality have been attributed to the presence of a deleterious childhood 
environment in study participants,22;23;51 with early-life stress being a possible confounder in 
this relationship. It is possible that HD mutation carriers, regardless of whether they do or do 
not become suicidal, experienced some form of early-life stress. Unfortunately, we did not 
assess the extent of early-life stress experienced in our study population.
Several limitations of the present study limit causal inference from our results. First, because 
of the limited number of incident depression and suicidality cases, we focused on cross-
sectional analyses. Because timing is crucial in the investigation of HPA axis functioning 
and the direction of possible relationships cannot be determined in cross-sectional studies, 
longitudinal studies are needed to investigate changes in the HPA axis preceding the onset 
of behavioural symptoms. Second, many different mechanisms can result in either hyper- or 
hypoactivity of the HPA axis, some of which might be associated with depression or suicidality, 
whereas others might not. This lack of consistency makes it impossible to disentangle the 
complex causal relationship between HPA axis functioning and behavioural symptoms in 
an observational study.55 Third, unknown and unmeasured negative confounding may have 
prevented us from finding potentially causal associations. Furthermore, the stratified analyses 
were only explorative in relatively small groups. Another limitation of the present study is the 
use of peripheral markers that do not necessarily reflect all regulatory processes of central 
activation of the HPA axis. The sophisticated physical feedback regulation systems might keep 
peripheral cortisol concentrations at normal levels whereas hormones in the brain regulating 
peripheral cortisol concentrations might be dysregulated. Also, the relatively mild depressive 
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symptom and suicidality scores in this population may limit external generalisability of our 
findings because the associations in more severely affected populations might be different.
Previously, antiglucocorticoid therapy was suggested, for example, for the treatment of 
behavioural symptoms in HD.30 However, because of the limitations of this observational 
study, only a randomised clinical trial with antiglucocorticoid therapy could lead to causal 
conclusions on the effectiveness of such therapy. However, in line with previous HD studies, 
the present study, with several strong aspects such as a relatively large HD population, the 
assessment of multiple parameters of HPA axis activity and adjustment for various confounders, 
found no evidence for an association between HPA axis activity and behavioural symptoms 
in HD. The associations between HPA axis activity and depression and suicidality appear 
to vary in different HD stages, which might be explained by the exhaustion of the HPA axis 
after prolonged stress-induced HPA axis hyperactivity. Exhaustion of the HPA axis might also 
explain the diminished concentrations of morning cortisol in motor symptomatic mutation 
carriers. However, further longitudinal studies are needed to determine the course of HPA axis 
functioning during disease progression.
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Suicidality in Huntington’s disease: a 
qualitative study on coping styles and 
support strategies




Background: Huntington’s disease (HD) mutation carriers are at increased risk of suicidal 
ideation, suicide attempts, and completed suicide. However, research is lacking on coping 
strategies and treatment options that can be offered to suicidal HD mutation carriers. This 
study explores how HD mutation carriers cope with suicidality, how their partners support 
them, and their ideas and wishes regarding how relatives and healthcare professionals can 
help them in coping with suicidality.
Methods: This qualitative study included 11 HD mutation carriers who experienced suicidal 
ideation or attempted suicide and 3 of their partners. They participated in a focus group 
discussion or an individual in-depth interview. Two independent researchers fragmented the 
transcribed interviews, coded these fragments, and grouped them under themes.
Results: HD mutation carriers used four main strategies to cope with suicidality, including 
talking about suicidality, employing self-management activities, using medication, and 
discussing end-of-life wishes. Partners, relatives, and healthcare professionals can support 
suicidal HD mutation carriers in each of those four strategies.
Limitations: Although data saturation was reached within this sample, we included only a 
limited and selected group of HD mutation carriers and their partners.
Conclusion: Despite the absence of a turnkey solution for suicidality in HD, healthcare 
professionals can play an important role in supporting suicidal HD mutation carriers by 
providing an opportunity to talk about suicidality, providing psychoeducation on self-
management, prescribing medication, and discussing end-of-life wishes. Future HD-specific 
intervention studies could investigate the effect of combining these treatment strategies into 
one holistic approach.




Huntington’s disease (HD) is an autosomal dominant progressive neurodegenerative disease.1 
An expanded CAG repeat on the short arm of chromosome 4 causes a mutant polyglutamine 
chain in the huntingtin protein.2 The disease is characterised by motor dysfunction, cognitive 
decline, and neuropsychiatric symptoms. Although some of these symptoms can be treated, 
the disease cannot be cured.3
An important psychiatric sign of HD is the increased risk of suicide, as first described by George 
Huntington in 1872.4 More recent studies showed that HD patients were 2-8 times more likely 
to die by suicide than individuals from the general population,5-8 which accounts for up to 
11.4% of all deaths in motor symptomatic HD patients.5-24 In addition, lifetime suicide attempts 
have been reported by 3.2-17.7%7;9;10;12;13;17;18;25-31 of the mutation carriers, compared with only 
2.7% in the general population.32 Furthermore, 8-34% of the HD mutation carriers experienced 
some form of suicidal ideation in the month prior to the interview,25;28;31;33-36 compared with 0% 
of the first-degree non-carrier relatives.33 These numbers emphasise the frequent occurrence 
of suicidal ideation and suicide attempts (together referred to as ‘suicidality’) in HD. Suicidality 
is associated with lower quality of life37;38 and an increased occurrence of completed suicide.39;40
Both suicidal ideation and completed suicide occur most frequently in early-to-middle 
disease stages.5;7;8;11;31;34 In addition, depression is reported to be the strongest association of 
suicidality in HD.26;28;29;31;33;41 Mutation carriers with other psychiatric symptoms like irritability/
aggression,28;31 obsessive and compulsive symptoms,30 and a previous suicide attempt31;41 
as well as those who used antidepressants33 or benzodiazepines,31 were also more likely to 
experience or develop suicidality.
Despite the high frequency of suicidality in HD, limited information is available about coping 
with or the treatment of suicidality in HD, comprising only a few case descriptions of suicidal 
HD patients who were pharmacologically treated.42-44
Therefore, we conducted a qualitative study among HD mutation carriers who had experienced 
suicidal ideation or attempted suicide and among their partners. The primary aim was to 
examine how HD mutation carriers cope with suicidality and their ideas and wishes regarding 
how relatives and healthcare professionals can help them cope with suicidality. An additional 





Recruitment procedure and participants
This qualitative study was conducted among HD mutation carriers recruited between February 
and May 2014 and who had previously participated in a Dutch prospective cohort study on 
behavioural problems and psychiatric disorders in HD.45
Of all mutation carriers who 1) had participated in the last follow-up measurement of the 
aforementioned cohort study, 2) had given consent to be contacted for future research, and 
3) were known not to have died (n = 90), 40 had reported the presence of thoughts of death, 
suicidal ideation or a previous suicide attempt at one of the measurements of the cohort 
study. Of these 40 HD mutation carriers, 11 consented to participate in the present qualitative 
study (Figure 1). If possible, participation in a focus group discussion was the preferred study 
method.46;47 Eight mutation carriers participated in a focus group discussion (divided over 2 
groups of 4 participants each) and 3 in an individual in-depth interview.
The focus group discussions were analysed first, followed by the individual interviews. Data 
saturation was reached after these focus group discussions, as no new understandings/
information on support strategies emerged from the individual interviews.46
All participants were asked whether they had a partner and, if so, whether he/she knew about 
their suicidal thoughts. After consent, we contacted their partner for participation in a focus 
group discussion. Of the 4 partners of participants that we could contact, 3 were willing to 
participate. 
This study was approved by the Medical Ethical Committee of the LUMC and all participants 
provided written informed consent.
Focus group/individual interview for HD participants
Before the focus group discussion/individual interview, each HD participant had an individual 
intake appointment to explain: the purpose of the study, the topic list, and the course of 
the focus group discussion/individual interview. In addition, the presence and severity of 
depressed mood and suicidality in the last month were assessed by the items ‘depressed mood’ 
and ‘suicidal ideation’ of the Problem Behaviours Assessment (PBA).25 Also, lifetime suicidality 
was assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS).48
The actual focus group discussions/individual interviews were conducted by a psychiatrist 
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Mutation carriers who participated at the last follow-up 
measurement of the cohort study,45 gave consent to be contacted 
and were not known to have died
 n = 90
Study participants
n = 11




Deceased: n = 6
Too severe illness: n = 4
No thoughts of death: n = 5
Refusal: n = 8
Untraceable: n = 1







Lack of verbal/cognitive 
capacities to participate
n = 5
Reported thoughts of 
death or suicide 
n = 40
Figure 1. Selection of HD study participants 
a Two participants were considered too ill to participate in a focus group interview and one participant did not 
want to talk about her experiences in a group.
(moderator/interviewer) with longstanding experience in the study and treatment of HD 
mutation carriers (EvD). This researcher was specifically trained in moderating focus groups for 
the present study. He was also the treating psychiatrist of one of the participants of the focus 
group discussion. The first author (AAMH), who is experienced in interviewing HD mutation 
carriers, conducted the intake appointment and was present as note taker during the focus 
groups and individual interviews. The focus groups lasted 1.5-2 h (including a short break), 
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and the individual interviews lasted 15-60 min each. During the focus groups and individual 
interviews, we mainly referred to ‘thoughts of death’, and explained that this term could cover 
the whole spectrum of suicidal thoughts: ranging from not wanting to live anymore should 
the disease become more severe, to actual suicide attempts. The moderator/interviewer 
ensured that the whole range of thoughts of death was discussed. To introduce this sensitive 
topic, the focus group discussion/individual interview started with an open question about 
how participants felt about this study actually being conducted. Subsequent questions were 
based on what the participants said themselves. A topic list was used as a reminder for the 
moderator/interviewer and consisted of 3 main items: how the mutation carriers themselves 
coped with suicidality; how relatives could support suicidal mutation carriers; and how 
healthcare professionals could help suicidal mutation carriers. 
Focus group for partners
The focus group discussion for partners lasted ± 80 min (including a short break). The 
session started with an open question regarding how participants felt about this study being 
conducted and subsequent questions depended on the participants’ responses. The topic 
list was based on results of the mutation carrier focus groups and individual interviews, and 
covered the following items: discussion of suicidal thoughts with partner; support of suicidal 
partner; and advice for future partners of suicidal HD mutation carriers.
Data analysis
All focus group discussions and individual interviews were recorded on tape and transcribed 
ad verbatim. The analyses started with fragmenting the transcripts of the HD mutation carriers 
and open coding of the fragments by two independent researchers (AAMH: medical PhD 
student and AH: physician). The initial code list included only 3 codes: coping themselves, 
support from relatives, and help from healthcare professionals, as these were the items on the 
topic list. Codes were grouped into themes; this involved independent and close examination 
and comparison of the transcripts by the two researchers. After the coding of each transcript, 
these researchers discussed their fragments, codes, and themes until consensus was reached, 
constantly taking into account the previous transcripts. Examples of new codes emerging 
from the data were ‘listening’ and ‘trust’ which were grouped as ‘factors influencing talking’, 
which was grouped under the major category ‘talking about suicidality’. Having discussed 
all the transcripts of the HD participants, both researchers independently recognised that all 
codes and themes which described coping and support strategies could be grouped into four 
major categories. Subsequently, they independently read and interpreted the fragments that 
belonged to these four categories. Thereafter, the partner focus group transcripts were coded 
and interpretive reading was conducted to analyse what the partners had said about these 
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four major categories. Atlas.ti 7.5 (Scientific Software Development GmbH, Berlin, Germany) 
was used to code the interviews.
Results
Study population
The disease stage of the participants ranged from self-reported pre-motor symptomatic to 
participants who had to live in a nursing home. There were three male mutation carriers and 
one male partner, the age of the participants ranged from 32-71 years, and the number of CAG 
repeats ranged from 41-47. Table 1 presents the scores on the ‘depressed mood’ and ‘suicidality’ 
items of the PBA.





















M1 yes yes no no 0 0
M2 yes yes no no 2 1
M3 yes yes yes no 2 0
M4 yes yes no no 3 1
M5 yes yes yes yes 0 0
M6 yes yes yes yes 3 1
M7 yes yes no no 3 1
M8 yes yes no no 3 0
M9 yes yes no no 0 0
M10 yes yes no no 3 3
M11 yes no no no 0 0
M indicates mutation carrier; PBA, Problem Behaviour Assessment 
a Lifetime thoughts of death, thoughts of suicide, suicide plan, and attempts as assessed by the Columbia 
Suicide Severity Rating Scale lifetime.48 
b PBA depressed mood and suicidality severity scores in the last month (range 0-4), with higher scores 
indicating more severe depressed mood or suicidality.25
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Support strategies for suicidality in HD
First of all, participants indicated that there is no turnkey solution for suicidality in HD. They 
mentioned several ways of support that can be grouped in the following categories: 1) talking 
about suicidality, 2) self-management, 3) medication use, and 4) discussing end-of-life wishes.
1. Talking about suicidality
All participants stressed that they had a great need to talk about their suicidality, even though 
this was considered difficult and the threshold to do so was high. This is illustrated by one of 
the participants who said: “Someone who thinks about death already has difficulty expressing 
this ... and has feelings of self-disapproval because of this thought [….] But my experience is that it 
really helps when you eventually do talk about everything - with all your sorrows and misery. This 
always gives relief.”
Table 2 shows factors that, according to the participants, could facilitate or complicate talking 
about suicidality. Listening, taking the thoughts seriously and not trivialising these thoughts 
were the most important factors in helping them to express their feelings to a relative or 
healthcare professional. The preferred person to talk to varied per participant and included 
their partner, a family member, friend, care manager, psychologist, or hypnotherapist. Some 
participants stressed that this person should not be too close, and they preferred someone 
who is “a relative outsider”, because they did not want to hurt their partner or children by telling 
them about their suicidal thoughts. However, the spouses mentioned that they did want 
their partner to tell them about suicidal ideation, as was stated by a female spouse: “I don’t 
want him to think about that all on his own - I think that’s far too lonely”, although the spouses 
admitted that their partner’s expression of suicidal ideation was also a burden on their own 
lives. When the person to talk to was less close (either a professional or a non-professional), a 
trustful relationship needed to be established before the mutation carriers felt ‘close’ enough 
to talk about suicidal ideation, although the extent of this relationship differed per participant. 
Furthermore, some participants found it difficult when family members who experienced 
the same disease process did not want to talk about the disease at all, as illustrated by one 
participant: “You’d think you’d have a good relationship with someone […] somebody who lives 
the same sort of life as you, but who’s really very different.”
Participants stated that positive experiences with talking to someone about suicidal thoughts 
resulted in a decrease of suicidal ideation, and in relief, improved self-esteem, and increased 
ability to see the positive things in life. A few participants who read up on the disease since the 
moment they became aware of their genetic status recognised that they had now learned to 
think more positively when they felt depressed for a longer period, or when someone pointed 
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out the good things in life. However, most other participants felt that the ‘helping person’ 
ignored their suicidal thoughts when they simply responded by pointing out the positive 
things in life. This difficulty experienced by persons trying to give support is illustrated by one 
of the partners who said: “If you even make a small reference to something positive […] this works 
in a counterproductive way [….] what you’re really trying to do is cheer the other person up” and 
sometimes it is better “not go into it” but “just be there [for your partner]”. Also, the mutation 
carriers themselves mentioned that non-verbal signs of support, like someone putting an arm 
around you, can be very helpful. Negative experiences with talking about suicidal ideation 
resulted, for example, in withdrawing from the contact “which made me feel lonely and yes, that 
made everything worse.” Others mentioned that they had a negative experience with too much 
talking about suicidality to too many different healthcare professionals. One mutation carrier 
attributed this to the fact that she had not yet learned “to let go”. The delicate balance between 
actively facing HD/suicidality on the one hand and taking your mind off suicidality/HD on the 
other was also important with regard to self-management.
Given the importance of talking about suicidality, the moderator specifically asked participants 
whether others should actively address the presence of suicidal thoughts. The mutation 
carriers pointed out that it is best to ask about their mood when others see that they are sad 
or doing less well; also, when the mutation carrier indicates a depressed mood, questions 
about suicidality could be asked (Table 2). Partners acknowledged that it is difficult to find the 
right moment to talk, e.g. due to a busy daily life, and because they did not want to introduce 
this painful topic when their partner was feeling well. Given the emotional burden for both 
mutation carriers and partners, one of the partners advised other partners to try and talk about 
the suicidality during multiple conversations, as a person can only handle a certain amount 
each time. One participant could talk with her partner about suicidality very well because he 
“allowed me to talk about it and he took the time to discuss it.” Talking about suicidality was also 
difficult for the partners themselves, particularly when they had to decide on the amount of 
control they wished to exercise in order to prevent suicide. Partners themselves also needed 
to talk about suicidality with others, which one partner did by joining a peer support group, 
whereas another partner had negative experiences with such a group because of all the 
unpleasant stories she heard about what was still to come.
Most participants agreed that healthcare professionals could (or even should) ask about suicidal 
thoughts, even though they might feel “taken by surprise”. This topic should be introduced 
delicately by asking about sad feelings and, if present, follow-up questions should be asked 
(Table 2). In case of suicidal thoughts, healthcare professionals should guarantee further 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































and spouses emphasised that healthcare professionals should have adequate knowledge 
on HD and “be familiar with the whole picture”. A combination of individual therapy for the 
mutation carrier and therapy sessions that partners could also attend was preferred by the 
participating spouses. 
2. Self-management
Participants mentioned many different activities that they used to cope with suicidality and 
with HD itself. These activities could result in increased self-esteem and decreased stress 
and thoughts of death. Most of these activities could be grouped as either 1) actively facing 
suicidality/HD (e.g. talking about suicidal ideation/HD, gaining information on HD, realising 
that you are not the only one, contacting an HD support centre, making a crisis plan, setting 
future goals, healthy living, and hypnotherapy), or 2) taking their mind off it, mainly by exercise 
and relaxation (e.g. yoga, meditation, going outside, cycling, walking, distraction, focusing on 
daily life, social contacts, family life, taking rest, and creative therapy). “The art” of “balancing” 
these elements was considered important, since activities on both sides of this spectrum could 
become too extreme (Figure 2) and then worsen their feelings. Reducing suicidal thoughts and 
getting back in balance after too much confrontation with HD or thoughts of death (e.g. in 
family, by rumination, listening to sad music or watching films or TV shows about death) could 
be achieved by taking medication, calling someone, taking rest, letting go, taking distance, 
focusing on yourself, or having someone who can take you out. At the same time, for some 
participants, negative experiences were induced by too much avoidance and not wanting 
to face the disease which resulted in destructive behaviour like taking drugs and alcohol, 
aggression, or isolating oneself. At that point, participants said they need people who can “pull 
you out of the mud, so to speak.” One of the participants gave the following advice: “Don’t stay 
at home worrying… It is a cliché, but it actually does help: go out for a walk with someone, or go 
cycling! Or … I don’t know … if you stay at home in front of the TV all day, or behind the computer 
… if you isolate yourself, in my experience, it’ll only get worse and worse.”
It was advised to employ such self-management strategies and create an environment of 
people you can talk to before the disease starts, as it is more difficult to do this when the 
disease becomes more severe or when someone is depressed. Coping styles witnessed in 
their own family also influenced how participants dealt with the disease themselves. Several 
participants criticised the coping styles of their family members, e.g. when they refused to talk 
about it and/or avoided everything that had to do with HD. 















































































































































































































































































































Almost all participants who used medication (mostly antidepressants) were positive about its 
effects on their mood and suicidal thoughts. Only one woman reported that she stopped using 
antidepressants because she always felt unwell after taking these pills. In her opinion the pills 
suppressed her feelings, and she emphasised that the “the instruction leaflet already states […] 
suicidal tendencies.”
The reluctance of some participants to start taking medication was recognised by the 
participants who were currently using medication from the period before they started. Reasons 
for this reluctance were: potential side-effects and being unable to separate these from disease 
symptoms, fear of emotional suppression, and “wanting to do it on your own strength”. Some 
participants needed time and discussion with relatives to decide about starting medication. 
Participants who used medication for a longer period of time mentioned that they did not 
want to quit, because of its effectiveness.
Many participants who used medication combined this with talking to someone: the 
importance of this was stressed by one participant who described an appointment with a 
neurologist as follows: “when I mention I feel depressed, [the neurologist says]: ‘Well - here’s the 
medication’, whereas in fact he could say something like: ‘Take this medication, and try and see 
a psychologist in a couple of days.’ People might not always want to do this, but offering this, 
yes that can help some people [….] I think it often helps to literally say these things out loud to a 
psychologist or psychiatrist.” Partners recognised the positive effects of medication for various 
HD symptoms, and one partner stated “without all of that [HD medication] I couldn’t have coped 
for so long.”
4. Discussing end-of-life wishes
Some participants had a wish and/or advance directive for euthanasia in case the disease 
became very severe: in the Netherlands, under strictly controlled conditions, this is legal. The 
prospect of such a way out could help in coping with suicidal thoughts, as explained by one of 
the participants: “I kind of made my own crisis plan: what to do if I think I want to jump in front of a 
train. Because … I don’t want to end up that way. So I made arrangements about this [euthanasia 
directive] and that helps.” Most participants had seen examples of HD in their family and clearly 
knew what they did not want to experience (such as admission to a nursing home), but some 
also mentioned that their views might change. Also, some participants in an early stage of the 
disease did not know whether or not they would want euthanasia, or had not yet thought 
about this. Some found it difficult to decide at what point you need to think about end-of-
life wishes: this was illustrated by one participant who was recently clinically diagnosed and 
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still fully occupied with accepting the functional decline he experienced: “When should I start 
thinking about that [euthanasia directive]? [….] I don’t want to face it yet, because I feel reasonably 
OK […] but there’s a point when you’ll go further downhill, and then … then you can’t properly 
think about it.” These participants did not want the doctor to actively address euthanasia, or 
they considered it a topic that should first be discussed with their partner. However, another 
participant, who had thought about euthanasia since her genetic diagnosis, would like the 
doctor to address this. Also, one partner thought it was normal that the doctor had asked 
about euthanasia when his wife was admitted to a nursing home, since they had discussed this 
together since the beginning of the disease.
Those who expressed a wish for euthanasia emphasised the importance of this being their 
own choice. One participant described both her positive and negative experiences with 
healthcare professionals as follows: “I was always used to the fact that healthcare professionals 
[…] are focused on making sure you won’t end your life [….] but at the moment it does help me that 
I can just be very honest about it and yes … that people understand. That maybe I don’t want to 
continue living at some point in time … and, yes that this is my own choice and not … not someone 
else’s.” The fact that the doctor might not want to carry out their request at the time they have 
reached this point, which some participants had witnessed in their close surroundings, worried 
them as “you have no guarantee”. Also, one partner expressed such doubts, but acknowledged 
she had no knowledge about the legal requirements for euthanasia. Once a participant had 
the confidence that his/her wish would be carried out, this provided some relief. Positive 
euthanasia experiences in the family strengthened this confidence, and further thoughts 
about end-of-life wishes were also influenced by family experiences. One participant realised 
that in an advanced disease stage he might not understand his situation and he wondered “So 
who is euthanasia most important for? For me? ... Or for my wife and children?”
Discussion
This qualitative study shows that HD mutation carriers use various strategies to cope with 
suicidality including talking about suicidality, employing self-management activities, using 
medication, and discussing end-of-life wishes. Relatives and healthcare professionals can 
support suicidal mutation carriers in each of those four strategies.
Coping styles and support strategies
In older non-HD populations with a death wish or suicidal ideation, physicians were less likely 
to consider treatment and avoided further conversations about it.49;50 They felt they could not 
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help50;51 and considered suicidal ideation in older people more normal and rational.50 Although 
healthcare professionals treating HD might have similar feelings, our study participants 
emphasised the urgent need to talk about their suicidality, either with a healthcare professional 
or a relative. They also stressed that questions about suicidality should be asked in case of 
a depressed mood, which is the most important association and predictor of suicidality in 
HD.26;28;29;31;33;41 Similar to non-HD populations, the majority of patients do not easily disclose 
their suicidal thoughts to healthcare professionals52;53 and general practitioners only asked 
questions about suicide in 36% of patients with depressive symptoms.54 Furthermore, both 
general practitioners and neurologists thought that less than 50% of the patients with suicidal 
ideation needed psychiatric assessment.55 It was previously suggested that suicidal persons 
communicate their thoughts more often to relatives than to healthcare professionals.56 The 
participating spouses stressed they wanted their partners to tell them about suicidal thoughts 
and wanted to be involved in the treatment. A two-hour education program for caregivers of 
suicidal patients was shown to result in improved caring ability, such as better communicative 
skills and a more positive attitude.57 Also, it was shown that the involvement of a significant 
other in the treatment of suicidal ideation resulted in greater improvement on suicidality, 
depression, and hopelessness measures.58
Applying self-managements strategies while keeping the balance between actively facing HD/
suicidality and taking one’s mind off, was another strategy that helped mutation carriers to 
cope with suicidality. Several of the self-management strategies mentioned by the participants 
(e.g. relaxation and exercise) have been shown effective in reducing suicidal ideation59-61 and/
or depressive symptoms62-66 in non-HD populations, including patients with a chronic illness.63 
Within HD, positive effects of relaxation67;68 and exercise69-72 on several clinical outcomes have 
been reported, including on depression.70
Case reports on treatment for suicidality in HD have only focused on pharmacotherapy;42-44 
positive effects were highlighted by our study participants who used medication. In non-HD 
populations, antidepressants (most frequently mentioned by our participants) have been 
shown effective in reducing suicidal ideation in patients with major depressive disorder.73 
Within HD, one case report showed that mirtazapine could reduce suicidal ideation43 and a 
HD case series demonstrated the effectiveness of lithium in reducing suicidality.42 Lithium 
was not specifically mentioned by our study participants, but in both non-HD unipolar and 
bipolar patients treatment with lithium resulted in a reduced suicide risk.74 Pharmacotherapy 
for depression is recommended in guidelines for non-HD suicidal patients,52;75 whereas in HD 
undertreatment of depression is likely76 and there is insufficient evidence to guide treatment 
choice.77
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Finally, discussing end-of-life wishes helped some participants to cope with suicidality; however, 
this is not one of the treatment strategies recommended in general non-HD guidelines on 
suicidality and, moreover, is illegal in many countries. It has been estimated that 7% of the 
affected HD patients in the Netherlands die by euthanasia or physician-assisted suicide.78 
In non-HD populations, euthanasia is often considered to be inconceivable for psychiatric 
patients with a death wish.79 It was previously recommended that HD physicians address end-
of-life wishes,80 even though they often do not initiate this conversation.81 In the present study, 
not all study participants wanted their physician to actively address euthanasia. As reported 
previously, 80;82;83 these patients do have thoughts about their future which are mainly based 
on experiences in their family82 and are usually discussed first with the family.80 It was beyond 
the scope of the present study to disentangle the best moment to address these thoughts. If 
a patient has a wish for euthanasia, a letter of intent,81 repeated conversations,80;84 a trusting 
relationship80 and informing patients about legal criteria/requirements80 were previously 
suggested strategies that could be offered by physicians. Although not specifically mentioned 
by participants in our study, this might have resulted in more peace of mind for some of our 
participants with a wish for euthanasia.
Strengths and limitations
This is the first study to investigate attitudes towards, and coping and support strategies for 
suicidality in HD, which included HD mutation carriers in various disease stages. Also, the 
use of focus group discussions facilitated the observation of differences of opinion between 
participants about the coping and support strategies that were proposed.
Some limitations need to be addressed. First, we included a small and selected group which 
limits the generalisability of the findings. Although data saturation was reached, some 
participants mentioned that their family members had more avoiding ways of dealing with 
the disease, but did not want to participate in research in general. Second, because only three 
partners participated, their data were used only to determine whether they had similar ideas 
about treatment strategies as the mutation carriers themselves. Third, the moderator and 
researchers who analysed the interviews had received medical education, which might have 
unintentionally focused their attention on strategies that are similar to those used in current 
clinical practice. Fourth, generalisability of the results to other countries might be limited, 
especially since (under specific circumstances) euthanasia is permissible in the Netherlands, 
whereas this is illegal in many other countries.
Clinical recommendations
Despite the absence of a turnkey solution for suicidality in HD, healthcare professionals can 
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play an important role in all four strategies, which are largely in line with general non-HD 
suicide guidelines. All healthcare professionals who treat HD mutation carriers should ask 
about suicidal ideation, especially when symptoms of depression are present, and refer them 
to a (preferably HD-related) psychologist or psychiatrist for regular sessions to talk about 
suicidality. Active and non-judgmental listening, and taking their thoughts seriously, will 
strongly facilitate talking about suicidality. The application of the different self-management 
strategies might be enhanced with psychoeducation, which should also address the frequent 
occurrence of suicidality in HD so that patients realise that they are ‘not the only one’. If the 
physician considers prescribing medication, this should always be combined with talking 
about suicidality. Furthermore, both the effectiveness and side-effects have to be addressed, 
and time should be allowed for the patient to decide on starting medication. Significant others 
should also be involved in the treatment and (often) need to receive psychoeducation from 
healthcare professionals,52;85 which must at least contain guidance on talking about suicidality 
and suggestions for support strategies for this person him or herself. If a patient has a wish for 
euthanasia, and euthanasia is permissible in their country, the healthcare professional should 
ensure repeated conversations about this topic and show a commitment of best intentions.80;81
Recommendations for further study
Future studies on the treatment of suicidality in HD should ideally investigate a combination 
of the proposed support strategies; this was shown to be effective in elderly populations86;87 in 
whom a program of psychoeducation, access to a care manager, behavioural activation, and 
pharmacotherapy or psychotherapy resulted in lower rates of suicidal ideation and improved 
quality of life compared with the treatment-as-usual group.87;88 Also, HD-specific studies should 
investigate whether involvement of a significant other in the experimental treatment leads to 
a greater decrease in suicidality for mutation carriers and less stress for caregivers.
Conclusion
This study indicates that the best practice for suicidality in HD is talking about suicidality, 
self-management strategies, using medication, and discussing end-of-life wishes. Future HD-
specific intervention studies should investigate a combined approach of these treatment 
strategies to establish clinical evidence and improve guidance for the treatment of suicidality 
in HD.
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Suicidal ideation and subsequent 
completed suicide in both psychiatric 
and non-psychiatric populations:  
a meta-analysis
AAM Hubers, S Moaddine, SHM Peersmann, T Stijnen, E van Duijn, RC van der Mast,  




Background: The association between suicidal ideation and subsequent completed suicide has 
not been firmly established in different populations and absolute suicide risks after expression 
are unknown.
Aim: To examine whether the expression of suicidal ideation predicted subsequent completed 
suicide in various populations. 
Method: A meta-analysis of 73 observational studies was conducted.
Results: The risk for completed suicide was clearly higher in people who had expressed suicidal 
ideation compared with people who had not, with substantial variation between the different 
populations: risk ratio 3.66 (95% CI = 2.88–4.65) for psychiatric populations and 7.46 (95% CI 
= 5.16–10.8) for non-psychiatric populations. In contrast, the suicide risk after expression of 
suicidal ideation in the first year of follow-up was higher in psychiatric patients (risk = 1.21%; 
95% CI = 0.64–2.28) than in non-psychiatric participants (risk = 0.26%; 95% CI = 0.10–0.73).
Conclusion: Expression of suicidal ideation in psychiatric patients should prompt secondary 
prevention strategies to reduce their substantial increased risk of suicide.




Almost 90% of those who died by suicide contacted a health care professional in the three 
months prior to their death.1 Of those who had contact with a health care professional in the four 
weeks before their death, 22% expressed suicidal intent.2 Several authors claim that expression 
of suicidal ideation is one of the most important predictors of completed suicide.3-5 However, 
the association between suicidal ideation and subsequent completed suicide has not been 
firmly established.6 Previous studies7-12 and meta-analyses13-18 that assessed this association 
were restricted to specific populations and reported varying results, with odds ratios obtained 
from the meta-analyses ranging from 1.5 in bipolar disorder16 to 29.8 in schizophrenia.15 For 
the general population and several other psychiatric populations the relationship between 
suicidal ideation and subsequent completed suicide remains unknown.6,19,20 As suicidal ideation 
is quite common, with a lifetime prevalence of almost 10% in the general population,21 it is 
important to know not only the relative risk but also the absolute risk of completed suicide for 
an individual who expresses suicidal ideation. The aforementioned meta-analyses13-18 did not 
assess absolute risks of completed suicide. Furthermore, suicidal ideation is strongly correlated 
with other predictors of completed suicide like the presence of previous suicide attempts22;23 
and has not been firmly established as an independent predictor of completed suicide.6
Therefore, we conducted a systematic review and meta-analysis to assess whether expression 
of suicidal ideation predicted subsequent completed suicide in various populations, including 
non-psychiatric and psychiatric populations. Secondly, we aimed to estimate the absolute risks 
of suicide after expression of suicidal ideation in these populations and to investigate whether 
the expression of suicidal ideation predicted subsequent completed suicide independent of 
the presence of past suicide attempts. 
Method
Search strategy
Ten electronic databases (PubMed, Embase, Web of science, PsycINFO, PsycARTICLES, 
Psychology and behavioural sciences collection, Cochrane, CINAHL, Academic search premier, 
and ScienceDirect) were searched until September 16, 2014, without language restrictions. 
A medical librarian was involved in formulating the search string (supplement S1) designed 
to identify studies assessing the association between the expression of suicidal ideation and 




Relevant articles fulfilling the following inclusion criteria were eligible for inclusion: 1) 
assessment of presence or absence of suicidal ideation as a distinct determinant (i.e. not 
combined with suicidal behaviour, so studies with determinants like suicidality or elevated 
suicide risk were not included). The presence of suicidal ideation was considered present when 
any form of ideation, ranging from death wish to suicide plans or threats, was expressed; 2) 
assessment of completed suicide (which could include open verdicts) as a distinct outcome 
measure; 3) comparison of suicidal ideation vs. no suicidal ideation with respect to risk of 
subsequent completed suicide 4) cohort or case-control study design; and 5) mean age of the 
study population ≥ 18 years.
Next, the following exclusion criteria were applied: 1) presence of suicidal ideation was 
assessed after a suicide attempt; 2) comparison of suicidal ideation versus suicide attempt as 
determinant in a cohort study; or 3) comparison of those who died by suicide and those who 
unsuccessfully attempted suicide as outcome in a case-control study.
For the assessment of the absolute risks of completed suicide, we included only cohort studies 
and nested case-control studies (with the size of the source population specified and random 
selection of controls from the source population) in which the number of suicides in the 
suicidal ideation group and the exposed person-time could be extracted or estimated.
To determine whether suicidal ideation predicted subsequent completed suicide independent 
of the presence of past suicide attempts, articles that assessed the effect of suicidal ideation on 
subsequent completed suicide adjusted for previous suicide attempts were selected. 
Study selection
All retrieved articles in the original search were screened independently by 2 of the 3 reviewers 
(AAMH, SM, and SHMP), first on title, then abstract and subsequently full-text evaluation to 
consider final eligibility. Disagreements with regard to final eligibility were discussed to reach 
consensus or, if necessary, another independent reviewer (EJG) got involved. In addition, 
the reference lists of eligible articles and relevant review articles identified by the search 
strategy were examined by one of the reviewers to search for eligible studies. When multiple 
publications used (partially) overlapping study populations only the largest study or, when 
similar, the most recent study was included. 
Data extraction
For each eligible article, 2 of the 3 reviewers (AAMH and SM or SHMP) independently extracted 
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data using a standardised form. Disagreements were discussed or another independent 
reviewer (EJG) got involved if needed. When information necessary to compute the effect 
size for the primary aim was missing, a request for the missing numbers was emailed to the 
corresponding author. In case of no response, the study was not included.
Risk of bias assessment
Two independent reviewers (AAMH and SM or SHMP) assessed four risk of bias aspects 
(selection of study population, assessment of suicidal ideation, assessment of completed 
suicide, and missing data) as adequate or inadequate or not reported (see supplement S2), 
judged on the basis of adapted items from the Newcastle-Ottawa scale24 and the internal 
validity assessment by Altman.25
Statistical analyses
The primary outcome of this meta-analysis was the pooled unadjusted risk ratio for the association 
between suicidal ideation and completed suicide in a random effects model according to the 
method of DerSimonian and Laird.26 Due to expected between study heterogeneity, e.g. due to 
the varying absolute risks of suicide among different populations,27 the pooling of risk ratios was 
stratified for the following populations: affective disorders (including both in & outpatients), 
(former) psychiatric inpatients (mixed diagnoses), schizophrenic patients (including both in 
& outpatients), other mixed psychiatric populations (including substance abusers, borderline 
patients, and mixed diagnosis psychiatric outpatients [sometimes combined with inpatients]), 
general population, and a residual category that included non-psychiatric study populations 
that could not be grouped in one of the other categories. Studies in each subgroup were 
combined using a random effects model with separate estimates of tau-squared.28 To pool 
results from different studies, odds ratios, risk ratios and incidence rate ratios were considered 
to approach the same value, which is reasonable given the low risk of completed suicide. When 
only chi-square values or p-values were given in combination with a direction of the effect, 
these were used to estimate risk ratios. If the given p-value was < 0.05, we assumed a p-value 
of 0.049. There were no eligible studies only reporting a p-value > 0.05. Since several articles 
reported on multiple suicidal ideation determinants (e.g. thoughts and plans separately) we 
computed a combined effect across these different determinants based on the mean of the 
related effect sizes,29 so each study only contributed one effect estimate to the meta-analysis.
With regard to the risk of suicide after expression of suicidal ideation, we were most interested 
in the suicide risk during the first year of follow-up. Since studies had varying follow-up times, 
and we did not expect a constant suicide rate over time, we conducted maximum likelihood 
meta-regression analyses with mean study follow-up time as determinant and loge-transformed 
Chapter 7
144
rates of completed suicide as outcome. The obtained intercept and regression coefficient were 
used to calculate the loge-transformed rate at 1-year follow-up which was back transformed 
to the suicide risk during the first year of follow-up. Given the limited number of studies per 
population subgroup, analyses were stratified for psychiatric and non-psychiatric populations 
only. When one article assessed suicidal ideation at multiple time points (e.g. current and 
lifetime), we only included the determinant that assessed suicidal ideation closest to baseline.
In order to assess whether suicidal ideation predicted completed suicide independently of 
previous attempts, the past suicide attempt-adjusted risk ratios were extracted and used for 
estimation.
To check the robustness of the results, we restricted the analyses to 1) studies with a low risk 
of bias (see supplement S2), 2) to cohort studies (for the primary research aim only), and 3) 
studies that assessed suicidal ideation at baseline or in the preceding month (for the secondary 
research aim only). In addition, we were interested in the results in different subgroups and 
stratified analyses of the primary outcome for studies with short (≤ 1-year) versus long (> 
1-year) timeframe between expression of suicidal ideation and completed suicide and suicidal 
ideation assessment method. Maximum likelihood meta-regression was applied to examine 
the effects of mean age and gender in the study populations.
Heterogeneity was assessed using the I2 statistic, publication bias by inspecting the funnel 
plot and Egger’s test for funnel plot asymmetry. A p-value < 0.05 was considered statistically 
significant. Statistical analyses were performed using Comprehensive Meta-analysis software 
version 2.0.064 (www.meta-analysis.com).
Results
Literature search and study characteristics
The literature search identified 4999 unique articles: 73 articles were finally included (Figure 1). 
Most studies (n = 20) investigated suicide in psychiatric inpatients (mixed diagnoses), others in 
schizophrenia (both in- and outpatients) (n =17), general population (n = 11), mixed psychiatric 
populations (n = 9; including 3 studies on substance abusers, 2 on borderline patients, 2 on 
mixed diagnosis psychiatric in & outpatients, and 2 on mixed diagnosis psychiatric outpatients), 
affective disorder (both in- and outpatients) (n = 8), or in the non-psychiatric residual category 
(n = 8; including 2 studies on military, 1 on veterans, 1 on stalkers, 1 study on HIV infected 
males, 1 on survivors of childhood cancer, 1 on prisoners, and 1 on emergency department 
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visitors) (Figure 1). Together these studies included 4,445,979 participants (median 203; range 
14–4,045,993), with a total of 7462 completed suicides (median 60; range 3–1429). Reported 
mean age ranged from 18.3–76.2 years, and studies included median 41.6% (range 0–67.5) 
females (see supplementary Table 1 in supplement S3).
The majority of included studies were (nested) case-control studies (n = 50, 68.5%). In only 
23 studies the absolute risk of completed suicide could be extracted. None of the 73 eligible 
articles assessed the effect of suicidal ideation on completed suicide with sole adjustment for 
Unique articles from 
searching 10 databases
    n = 4999
Full text examination




  - Psychiatric inpatients: n = 20
  - Schizophrenia: n = 17
  - General population: n = 11 
  - Mixed psychiatric patients: n = 9
  - Affective disorder: n = 8
  - Non-psychiatric residual: n = 8
Excluded on title: n = 2911 
Excluded on full text: n = 671
  - no si as determinant: n = 436
  - no cs as outcome: n = 147
  - no controls: n = 47
  - mean age < 18: n = 16 
  - overlap in population: n = 10
  - all participants si/sa: n = 6





n = 2088 Excluded on abstract: n = 1313
  - no si as determinant: n = 577
  - no cs as outcome: n = 570 
  - no controls: n = 86
  - mean age < 18: n = 68
  - overlap in population: n = 1
  - other: n = 11
n = 41 reviews
n = 10 
new articles
Figure 1. Flowchart of the study selection process.
Si denotes suicidal ideation; cs, completed suicide; sa, suicide attempts.
Databases searched: PubMed, Embase, Web of science, PsycINFO, PsycARTICLES, Psychology and behavioural 
sciences collection, Cochrane, CINAHL, Academic Search Premier, and Science Direct. Independent screening 
by 2 reviewers, disagreements with regard to final eligibility were discussed.
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previous suicide attempts. However, there were 42 studies that applied a multivariable model, 
but only 26 adjusted for previous attempts as a separate determinant in this model.
Association between suicidal ideation and subsequent completed suicide
For all population subgroups investigated in this meta-analysis, the pooled risk of suicide was 
significantly higher in study participants who had expressed suicidal ideation compared with 
study participants who had not. Whereas the overall risk ratio (RR) was 4.41 (95% CI = 3.44–
5.66), the risk ratios per population subgroup varied substantially. The risk ratio was highest in 
the non-psychiatric residual subgroup (RR = 8.00; 95% CI = 5.46–11.7), followed by the general 
population (RR = 6.85; 95% CI = 3.56–13.2), schizophrenia (RR = 5.80; 95% CI = 3.18–10.6), mixed 
psychiatric patients (RR = 5.64; 95% CI = 3.64–8.76), psychiatric inpatients (RR = 2.64; 95% CI 
= 2.00–3.50), and affective disorder (RR = 2.63; 95% CI = 1.49–4.67) (Figure 2). Overall, the risk 
ratio was 3.66 (95% CI = 2.88–4.65) in psychiatric populations and 7.46 (95% CI = 5.16–10.8) in 
non-psychiatric populations (data not shown).
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Bickley et al. 201338 2.14 (0.87-5.26)
Bioulac et al. 200039 1.38 (0.39-4.93)
Dingman and McGlashan 198640 2.79(1.26-6.15)
Dong et al. 200541 3.09(0.83-11.5)
Farberow et al. 196642 7.03 (4.10-12.1)
Flood and Seager 196843 0.63 (0.30-1.31)
Hunt et al. 200744 1.79 (0.93-3.44)
Hunt et al. 200945 2.90 (1.38-6.10)
Hunt et al. 201346 1.56 (0.67-3.61)
King et al. 200147 2.36 (1.11-5.01)
Lin et al. 201449 3.93 (1.77-8.71)
Park et al. 201350 2.69 (1.74-4.16)
Powell et al. 200051 7.68 (1.40-42.1)
Sani et al. 201152 2.14 (1.24-3.69)
Shah and Ganesvaran 199753 16.3 (4.75-55.8)
Spiessl et al. 200254 1.95 (0.89-4.27)
Wolfersdorf et al. 200355 22.8 (2.93-177)
Overall effect 2.64 (2.00-3.50)
Overall effect 2.63 (1.49-4.67)
Bradvik and Berglund 199311 1.30 (0.64-2.63)
King et al. 200148 1.93 (1.22-3.06)
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Figure 2. Forest plot showing the association between si and subsequent completed suicide. 
CI denotes confidence interval; si, suicidal ideation. 
a Authors provided additional data to compute effect size.
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Allebeck et al. 198756 2.34 (0.96-5.73)
Bertelsen et al. 200712 0.91 (0.10-8.04)
Cheng et al. 199057 8.52 (1.04-70.1)
De Hert et al. 200158 5.10 (2.33-11.2)
Drake and Cotton 198659 8.33 (1.78-39.1)
Dutta et al. 2011a, 60 1.74 (0.92-3.30)
Funahashi et al. 200061 81.0 (18.4-356)
Kasckow et al. 201062 26.8 (1.57-458)
Kelly et al. 200463 15.4 (2.83-83.4)
Li et al. 200864 10.1 (2.83-36.3)
Lui 200965 13.9 (3.29-58.6)
Nyman and Jonsson 198666 2.00 (1.00-4.03)
Stephens et al. 199969 5.54 (2.60-11.8)
18.9 (6.16-58.0)Taiminen et al. 20018
Wolfersdorf and Neher 200370 11.1 (2.44-50.4)
Overall effect 5.80 (3.18-10.6)
Brown et al. 200071 6.56 (3.61-11.9)
Bukstein et al. 199372 291 (12.0-7074)
Conlon et al. 200773 1.91 (0.51-7.16)
Kjelsberg et al. 199174 3.21 (0.97-10.6)
Kullgren 198875 5.00 (0.39-64.4)
Kuo et al. 201176 5.90 (1.79-19.4)
Murphy et al. 199277 7.26 (3.81-13.8)
Simon et al. 201378 3.77 (1.99-7.16)
Thong et al. 200879 11.7 (3.59-37.9)
5.64 (3.64-8.76)Overall effect
Appleby et al. 1999a, 80 7.46 (2.12-26.2)
Castle et al. 200481 13.2 (10.6-16.3)
De Leo et al. 20139 20.7 (10.7-39.9)
Didham et al. 200682 16.5 (3.66-74.4)
Jollant et al. 201410 0.15 (0.01-2.90)
Khang et al. 201083 2.59 (0.87-7.71)
Kleiman and Liu 201484 2.84 (0.61-13.2)
Mock et al. 199685 5.28 (0.14-196)
Palacio et al. 200786 15.4 (6.89-34.3)
Rowe et al. 200687 45.0 (1.80-1128)
Zonda 200688 1.99 (1.01-3.92)
Overall effect 6.85 (3.56-13.2)
Brinkman et al. 201489 3.49 (0.90-13.5)
Crandall et al. 200690 6.45 (4.82-8.63)
Fruehwald et al. 200491 14.9 (8.15-27.1)
Hyman 201292 10.5 (6.92-15.8)
Mahon et al. 200593 30.8 (1.78-533)
McEwan et al. 201094 4.89 (0.42-56.6)
McManus et al. 201495 7.88 (1.44-43.1)
Thoresen and Mehlum 200496 3.34 (1.11-10.0)
Overall effect 8.00 (5.46-11.7)
Roos et al. 199267 0.15 (0.03-0.81)
Salama 198868 23.9 (1.29-443)
Chapter 7
148
Risk of completed suicide
Although the psychiatric subgroups had the lowest risk ratios, meta-regression analyses 
showed the suicide risk was highest in the psychiatric subgroups who had expressed suicidal 
ideation (risk during first year of follow-up = 1.21%; 95% CI = 0.64–2.28). This was clearly 
higher than the suicide risk in psychiatric patients who had not expressed suicidal ideation 
(risk during first year of follow-up = 0.29%; 95% CI = 0.15–0.55). While the difference between 
study participants who had expressed suicidal ideation and study participants who had not 
was relatively larger in the non-psychiatric subgroups, the suicide risk in non-psychiatric 
populations was lower. The suicide risk during the first year of follow-up was 0.26% (95% CI 
= 0.10–0.73) in non-psychiatric study participants who had expressed suicidal ideation and 
0.05% (95% CI = 0.01–0.24) in non-psychiatric study participants who had not (Figure 3 and 
Figure 4). When grouping all studies, the suicide risk during the first year of follow-up after 
expression of suicidal ideation was 0.76% (95% CI = 0.33–1.77) (data not shown). The meta-





































Figure 3. Bar chart showing the suicide risk (%) during first year of follow-up.
Results specified separately for study participants who had expressed suicidal ideation and study participants 
who had not, stratified for psychiatric and non-psychiatric populations. Lines indicate 95% confidence interval. 
Percentages calculated using maximum likelihood meta-regression analyses with mean study follow-up time 
as determinant and loge-transformed rates of completed suicide as outcome (see Figure 4).
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Mean Study Follow-up Time (Years)
Mean Study Follow-up Time (Years)
Mean Study Follow-up Time (Years)
B Psychiatric patients; without si D Non-psychiatric participants; without si
A Psychiatric patients; with si C Non-psychiatric participants; with si




































Suicide rate at 1 year: 
12 / 1000 person-years
Suicide rate at 1 year: 
2.9 / 1000 person-years
Suicide rate at 1 year: 
2.7 / 1000 person-years
Suicide rate at 1 year: 
0.5 / 1000 person-years
Figure 4. Meta-regression of mean study follow-up time on suicide rate.
SI indicates suicidal ideation. Maximum likelihood meta-regression analyses with mean study follow-up time as 
determinant and loge-transformed rates of completed suicide as outcome presented on logarithmic scales. The 
bubble size is proportional to the study’s weight. Vertical line indicates 1-year follow-up.
The suicide risk can be calculated using the following formulas: suicide risk (during first year of follow-up)=1 – 
e(-rate per person-year at year 1). A and B: Psychiatric subgroup included: Bradvik and Berglund 1993;11 Coryell and Young 
2005;30 Dutta et al. 2007;31 Goldstein et al. 1991;33 Bioulac et al. 2000;39 Dingman and McGlashan 1986;40 Lin et al. 
2014;49 Park et al. 2013;50 Sani et al. 2011;52 Spiessl et al. 2002;54 Allebeck et al. 1987;56 de Hert et al. 2001;58 Drake 
and Cotton 1986;59 Dutta et al. 2011;60 Stephens et al. 1999;69 Kuo et al. 2011;76 Simon et al. 2013;78
C and D: Non-psychiatric subgroup included: Khang et al. 2010;83 Kleiman and Liu 2014;84 Brinkman et al. 
2014;89 Crandall et al. 2006;90 Hyman 2012;92 McEwan et al. 2010.94
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Risk of bias assessment & sensitivity analyses
Eighty-five percent of the studies adequately selected the study population, 68% adequately 
assessed the presence of suicidal ideation, 88% adequately assessed completed suicide, and 
66% had < 10% missing information (supplement S2 and supplementary Table 1 in supplement 
S3). When restricting the analyses to studies that scored ‘adequate’ on all four items (n = 31, 
42.5%), the pooled risk ratio (which was 4.41 in the main analysis) decreased slightly to 3.61 
(95% CI = 2.81–4.64) and the overall suicide risk during the first year of follow-up (which was 
0.76% in the main analysis) remained similar (risk during first year of follow-up = 0.78%; 95% CI 
= 0.29–2.12). In addition, restricting the primary analysis to cohort studies resulted in a slight 
decrease in the risk ratio (RR = 3.44; 95% CI = 2.35–5.03). Restricting the secondary analysis to 
studies that assessed suicidal ideation in the month around baseline resulted in a similar risk 
(risk during first year of follow-up = 0.75%; 95% CI = 0.31–1.84).
Is suicidal ideation an independent predictor of completed suicide?
Of all studies that used a multivariable model for the prediction of suicide and adjusted for 
(among other predictors) the presence of a previous suicide attempt (n = 26), only 12 reported 
the adjusted effect size of suicidal ideation. In 9 of these studies suicidal ideation was a 
significant independent predictor of completed suicide. The other 14 studies that included 
previous attempts in their multivariable model either did not include suicidal ideation as a 
separate predictor (n = 6), or did include suicidal ideation but did not report the adjusted effect 
size (n = 8), which was non-significant in 7 of these studies. While in at least 9 studies suicidal 
ideation was a significant independent predictor of completed suicide, which is significantly 
more than expected by chance, the 12 adjusted effect sizes were not pooled due to large 
underreporting of mainly non-significant results. 
Subgroup analyses
There was considerable heterogeneity (I2 for overall risk ratio = 86%), even when stratified 
for specific populations. Results of subgroup analyses regarding the timeframe between 
the expression of suicidal ideation and completed suicide and suicidal ideation assessment 
method can be found in supplementary Figure 1 in supplement S4, just like the results of the 
meta-regression analyses regarding age and gender. 
Publication bias
The funnel plot (supplementary Figure 2 in supplement S5) computed for the primary research 
question showed a rather symmetrical funnel plot. Egger’s test indicated no funnel plot 
asymmetry (2-tailed p-value = 0.82). 




Meta-analysing 73 eligible studies showed that overall, people expressing suicidal ideation are 
4 times more likely to die by suicide than people not expressing suicidal ideation, with a suicide 
risk during the first year of follow-up of 1.2% in psychiatric populations and 0.26% in non-
psychiatric populations. Effect estimates differed substantially among different populations: 
all in all, psychiatric populations showed the highest absolute suicide risks after expression of 
suicidal ideation but lowest relative risks, whereas the non-psychiatric populations showed the 
highest relative risks but lowest absolute risks.
The results of this meta-analysis are in line with previous meta-analyses on suicidal ideation and 
subsequent completed suicide.13-15;17;18 The highest relative risk was found in a meta-analysis 
restricted to schizophrenic patients15;18 followed by meta-analyses restricted to psychiatric 
inpatients13;14 and depressed patients.17;18 Remarkably one recent meta-analysis18 reported that 
the association between suicidal ideation and completed suicide was not significant in patients 
with a mood disorder, while the current meta-analysis reports a significant association. This 
is probably explained by the broader definition of suicidal ideation that was applied in the 
current study, also including expression of death ideation or suicide plans, and the fact that we 
excluded studies that compared expression of suicidal ideation in suicide completers versus 
attempters, while this previous meta-analysis included such studies.18 Unfortunately, none of 
the previous meta-analyses13-18 assessed the absolute risks of suicide.
The expression of suicidal ideation is also a significant independent predictor of completed 
suicide, given the high number of studies that reported this. However, the effect size remains 
unknown, as past suicide attempt-adjusted risk ratios could not be pooled. Underreporting 
of non-significant effect sizes would likely have yielded a biased overestimation of the risk 
ratio. Many studies included in our meta-analysis did develop a prediction model for suicide, 
although it is widely accepted that it is very difficult to accurately predict suicide for an 
individual patient,97 and there is a lot of debate on whether or not clinical risk categorization 
is helpful in preventing completed suicide.98;99 It was striking that only less than 60% of these 
studies included previous suicide attempts as a predictor, whereas this has been reported as 
one of the most important independent predictors of completed suicide.98 Future studies on 
suicide risk assessment should therefore include known predictors from the literature (e.g., 





A major strength of our paper was the attempt to provide risk estimates for different subgroups. 
Moreover, we strictly excluded studies that might have combined suicidal ideation with 
behaviour, and included many studies for the primary research aim. There are also limitations 
that need to be considered. First, the majority of studies only provided long-term follow-up 
results, while the short-term risk has most clinical value. Although the provided suicide risks 
should be interpreted with caution due to the declining rates over time and the limited number 
of studies, especially with short-term follow-up, that could be included in the meta-regression 
analyses, results clearly show the risk of suicide is higher after expression of suicidal ideation, 
especially in psychiatric patients. Future studies should focus on short-term suicide risk in 
the different psychiatric populations. Second, only part of the large amount of heterogeneity 
could be explained for; several patients characteristics that would be interesting in exploring/
explaining this heterogeneity, like duration of suicidal ideation101 or behavioural traits102 
were not provided in the studied articles. In addition, study level confounding103 might have 
influenced the results of our subgroup analyses, e.g. resulted in a significant effect of gender on 
the association between suicidal ideation and completed suicide, as the percentage of females 
was lower in certain high risk population subgroups like schizophrenia. Third, the varying 
or lacking definitions of suicidal ideation in the eligible studies might have been another 
source of unexplained and unmeasurable heterogeneity. Clear definitions of suicidal ideation 
are necessary,104 as different assessment methods may result in different suicide ideation 
prevalence numbers, even in the same population at the same time point.105 Also different 
studies assessed suicidal ideation during different time periods, but sensitivity analyses 
showed that restricting the meta-regression analysis to studies that assessed suicidal ideation 
at baseline or the month before resulted in a similar suicide risk. Fourth, some required study 
parameters could not be directly extracted from the original articles. For example the exposed 
person-years were conservatively estimated when possible, which could have resulted in an 
underestimation of the suicide risk.
Implications for clinical practice
For clinical psychiatric care, it is important to inquire about suicidal ideation in psychiatric 
patients given the substantial risk after expression of suicidal ideation, especially in the first 
period after expression. Although the relative risk was highest in non-psychiatric populations, 
the suicide risk after expression of suicidal ideation was lower than in psychiatric populations 
and decreased faster over time. However, even in psychiatric patients suicidal ideation 
assessment should be placed in perspective as the suicide risk during the first year of follow-
up among psychiatric patients who had not expressed suicidal ideation was 0.29%, which 
was similar to the suicide risk in non-psychiatric persons who had expressed suicidal ideation. 
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Clinicians know they should be alert when a psychiatric patient expresses suicidal ideation106 
and the suicide risks provided in this meta-analysis can help clinicians in their stepped care 
approach to decide whether the considered secondary prevention measure (ranging from 
further exploring suicidal thoughts to a compulsory admission) is proportionate to the risk of 
suicide.
In a patient who expresses suicidal ideation, follow-up inquiries are needed about the nature 
of these thoughts and the assessment of other known risk factors for suicide.107 As patients 
will not always express suicidal ideation spontaneously,97 it is important to ask them about 
suicidal thoughts. Actually, asking patients about suicidal ideation can reduce future suicidal 
ideation and follow-up inquiries can benefit long-term mental health.108 Patients often feel 
relieved by having an opportunity to talk about their suicidal ideas,109 especially if clinicians 
take time, show empathy, and acknowledge the suicidal feelings.110 Remarkably, in several of 
the included studies that assessed the presence of suicidal ideation in medical records, this 
information was missing. This means that it was unavailable to clinicians and appropriate care 
might have been unnecessarily withheld from these patients.48
Fortunately, the majority of patients with suicidal ideation do not die by suicide. Nevertheless, 
assessment of suicidal ideation is of priority in people with psychiatric illnesses and when a 
patient expresses suicidal ideation, prompt secondary prevention strategies are necessary to 
reduce their substantial increased risk of suicide.
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Supplement S1. Search strategy
The following search strategy was used in Pubmed on September 16th, 2014. Combining the 
results of search strategy part 1 and part 2 with OR resulted in 3416 references in PubMed. 
In addition, Embase, Web of Science, PsycINFO, PsycARTICLES, Psychology and Behavioural 
Sciences Collection, COCHRANE, CINAHL, Academic Search Premier, ScienceDirect were 
searched for eligible articles (total 4999 references). 
Search strategy part 1 focusing on prediction of suicide in adults
(((predict*[all fields] OR "predict"[all fields] OR "predictors"[all fields] OR "predictor"[all fields] 
OR "predictive"[all fields] OR "predicted"[all fields] OR "prediction"[all fields] OR "predictions"[all 
fields] OR predict*[all fields] OR traject*[all fields] OR "course"[all fields] OR "Time factors"[mesh] 
OR "Risk Factors"[mesh] OR "Risk"[mesh] OR "Probability"[mesh] OR "Prognosis"[mesh] OR 
prognos*[all fields] OR "time factors" [all fields] OR "risk factor"[all fields] OR "risk factors"[all 
fields]) AND ("Suicide"[majr:noexp] OR "Suicide, Attempted"[majr] OR "suicide"[ti] OR "completed 
suicide"[ti] OR "eventual suicide"[ti] OR "completed suicides"[ti] OR "eventual suicides"[ti] OR 
"later suicide"[ti] OR "later suicides"[ti] OR "subsequent suicide"[ti] OR "subsequent suicides"[ti] 
OR "suicide"[ti] OR "suicides"[ti] OR "suicidal behaviour"[ti] OR "suicidal behaviour"[ti] OR 
"suicidal behaviours"[ti] OR "suicidal behaviours"[ti] OR "suicide behaviour"[ti] OR "suicide 
behaviour"[ti] OR "suicide behaviours"[ti] OR "suicide behaviours"[ti]) AND ("Adult"[mesh] 
OR "adult"[all fields] OR "adults"[all fields])) OR ((predict*[all fields] OR "predict"[all fields] OR 
"predictors"[all fields] OR "predictor"[all fields] OR "predictive"[all fields] OR "predicted"[all 
fields] OR "prediction"[all fields] OR "predictions"[all fields] OR predict*[all fields] OR traject*[all 
fields] OR "course"[all fields] OR "Time factors"[mesh] OR "Risk Factors"[mesh] OR "Risk"[mesh] 
OR "Probability"[mesh] OR "Prognosis"[mesh] OR prognos*[all fields] OR "time factors" [all 
fields] OR "risk factor"[all fields] OR "risk factors"[all fields]) AND ("Suicide"[majr:noexp] OR 
"Suicide, Attempted"[majr] OR "suicide"[ti] OR "completed suicide"[ti] OR "eventual suicide"[ti] 
OR "completed suicides"[ti] OR "eventual suicides"[ti] OR "later suicide"[ti] OR "later suicides"[ti] 
OR "subsequent suicide"[ti] OR "subsequent suicides"[ti] OR "suicide"[ti] OR "suicides"[ti] OR 
"suicidal behaviour"[ti] OR "suicidal behaviour"[ti] OR "suicidal behaviours"[ti] OR "suicidal 
behaviours"[ti] OR "suicide behaviour"[ti] OR "suicide behaviour"[ti] OR "suicide behaviours"[ti] 
OR "suicide behaviours"[ti]) NOT ("Adolescent"[mesh] OR "Child"[mesh]) NOT "Adult"[mesh]))) 
AND ("Case-Control Studies"[mesh] OR "Case-Control"[all fields] OR "Case-Controlled"[all 
fields] OR "Retrospective"[all fields] OR Retrospectiv*[all fields] OR "Retrospective Studies"[all 
fields] OR "Retrospective Study"[all fields] OR "Cohort Studies"[mesh] OR "Cohort"[all fields] 
OR "Cohorts"[all fields] OR "Longitudinal Studies"[all fields] OR "Longitudinal Study"[all 
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fields] OR "Follow-Up Studies"[all fields] OR "Follow-Up Study"[all fields] OR "Follow-Up"[all 
fields] OR "Prospective Studies"[all fields] OR "Prospective Study"[all fields] OR "Multivariate 
Analysis"[Mesh] OR "Multivariate"[all fields])
Search strategy part 2 focusing on suicidal ideation and suicide in adults
((("Suicidal Ideation"[mesh] OR "suicide ideation"[all fields] OR "suicidal ideation"[all fields] OR 
"suicide thoughts"[all fields] OR "suicide thought"[all fields] OR "suicidal thoughts"[all fields] OR 
"suicidal thought"[all fields] OR "suicide idea"[all fields] OR "suicide ideas"[all fields] OR "suicide 
ideator"[all fields] OR "suicide ideators"[all fields] OR "suicidal idea"[all fields] OR "suicidal 
ideas"[all fields] OR "suicidal ideator"[all fields] OR "suicidal ideators"[all fields] OR "suicidality"[all 
fields] OR "suicidal tendencies"[all fields] OR "death wishes"[all fields] OR "suicidal tendency"[all 
fields] OR "death wish"[all fields] OR "talk of suicide"[all fields] OR "threat of suicide"[all fields] 
OR "suicidal communication"[all fields]) AND (predict*[all fields] OR "predict"[all fields] OR 
"predictors"[all fields] OR "predictor"[all fields] OR "predictive"[all fields] OR "predicted"[all 
fields] OR "prediction"[all fields] OR "predictions"[all fields] OR predict*[all fields] OR traject*[all 
fields] OR "course"[all fields] OR "Time factors"[mesh] OR "Risk Factors"[mesh] OR "Risk"[mesh] 
OR "Probability"[mesh] OR "Prognosis"[mesh] OR prognos*[all fields] OR "time factors" [all 
fields] OR "risk factor"[all fields] OR "risk factors"[all fields]) AND ("Suicide"[mesh:noexp] 
OR "Suicide, Attempted"[mesh] OR "suicide"[all fields] OR "completed suicide"[all fields] OR 
"eventual suicide"[all fields] OR "completed suicides"[all fields] OR "eventual suicides"[all fields] 
OR "later suicide"[all fields] OR "later suicides"[all fields] OR "subsequent suicide"[all fields] OR 
"subsequent suicides"[all fields] OR "suicide"[all fields] OR "suicides"[all fields] OR "suicidal 
behaviour"[all fields] OR "suicidal behaviour"[all fields] OR "suicidal behaviours"[all fields] OR 
"suicidal behaviours"[all fields] OR "suicide behaviour"[all fields] OR "suicide behaviour"[all fields] 
OR "suicide behaviours"[all fields] OR "suicide behaviours"[all fields]) AND ("Adult"[mesh] OR 
"adult"[all fields] OR "adults"[all fields])) OR (("Suicidal Ideation"[mesh] OR "suicide ideation"[all 
fields] OR "suicidal ideation"[all fields] OR "suicide thoughts"[all fields] OR "suicide thought"[all 
fields] OR "suicidal thoughts"[all fields] OR "suicidal thought"[all fields] OR "suicide idea"[all 
fields] OR "suicide ideas"[all fields] OR "suicide ideator"[all fields] OR "suicide ideators"[all 
fields] OR "suicidal idea"[all fields] OR "suicidal ideas"[all fields] OR "suicidal ideator"[all fields] 
OR "suicidal ideators"[all fields] OR "suicidality"[all fields] OR "suicidal tendencies"[all fields] OR 
"death wishes"[all fields] OR "suicidal tendency"[all fields] OR "death wish"[all fields] OR "talk of 
suicide"[all fields] OR "threat of suicide"[all fields] OR "suicidal communication"[all fields]) AND 
(predict*[all fields] OR "predict"[all fields] OR "predictors"[all fields] OR "predictor"[all fields] OR 
"predictive"[all fields] OR "predicted"[all fields] OR "prediction"[all fields] OR "predictions"[all 
fields] OR predict*[all fields] OR traject*[all fields] OR "course"[all fields] OR "Time factors"[mesh] 
OR "Risk Factors"[mesh] OR "Risk"[mesh] OR "Probability"[mesh] OR "Prognosis"[mesh] OR 
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prognos*[all fields] OR "time factors" [all fields] OR "risk factor"[all fields] OR "risk factors"[all 
fields]) AND ("Suicide"[mesh:noexp] OR "Suicide, Attempted"[mesh] OR "suicide"[all fields] 
OR "completed suicide"[all fields] OR "eventual suicide"[all fields] OR "completed suicides"[all 
fields] OR "eventual suicides"[all fields] OR "later suicide"[all fields] OR "later suicides"[all fields] 
OR "subsequent suicide"[all fields] OR "subsequent suicides"[all fields] OR "suicide"[all fields] 
OR "suicides"[all fields] OR "suicidal behaviour"[all fields] OR "suicidal behaviour"[all fields] OR 
"suicidal behaviours"[all fields] OR "suicidal behaviours"[all fields] OR "suicide behaviour"[all 
fields] OR "suicide behaviour"[all fields] OR "suicide behaviours"[all fields] OR "suicide 
behaviours"[all fields]) NOT ("Adolescent"[mesh] OR "Child"[mesh]) NOT "Adult"[mesh]))) 
AND ("Case-Control Studies"[mesh] OR "Case-Control"[all fields] OR "Case-Controlled"[all 
fields] OR "Retrospective"[all fields] OR Retrospectiv*[all fields] OR "Retrospective Studies"[all 
fields] OR "Retrospective Study"[all fields] OR "Cohort Studies"[mesh] OR "Cohort"[all fields] 
OR "Cohorts"[all fields] OR "Longitudinal Studies"[all fields] OR "Longitudinal Study"[all 
fields] OR "Follow-Up Studies"[all fields] OR "Follow-Up Study"[all fields] OR "Follow-Up"[all 
fields] OR "Prospective Studies"[all fields] OR "Prospective Study"[all fields] OR "Multivariate 
Analysis"[Mesh] OR "Multivariate"[all fields])
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Supplement S2. Risk of bias assessment 
Adapted from Newcastle-Ottawa scales24 and framework by Altman25
Case-control studies
1. Selection of study population 
(1) Adequate: Cases are a consecutive or obviously representative series of cases. 
Controls are a randomly selected sample from the cases’ source population. 
(2) Inadequate or not reported: Selected cases are not representative or controls are not 
randomly selected from cases’ source population. 
2. Assessment of determinant (presence of suicidal ideation) 
(1) Adequate: description of suicidal ideation assessment is provided and is the same for 
cases and controls, and information on presence of suicidal ideation is obtained from 
a source that was blind for the outcome (e.g. reported in medical record at time before 
suicide). 
(2) Inadequate or not reported: no description of suicidal ideation assessment provided, 
or assessment is different for cases and controls, or information on presence of suicidal 
ideation came from a source that was not blind for the outcome (e.g. asked to next of kin 
after suicide). 
3. Assessment of outcome (completed suicide) 
(1) Adequate: Use of death certificates/coroners verdicts/medical verdicts/registries to 
avoid misclassification of suicides. 
(2) Inadequate or not reported: No use of death certificates/coroners verdicts/medical 
verdicts/registries, misclassification of suicides likely. 
4. Missing information on determinant (presence of suicidal ideation) 
(1) Adequate: No or small number of participants with missing information on 
determinant: ≤ 10%. 
(2) Inadequate or not reported: Large number of participants with missing information 
on determinant: > 10%. Participants who were eligible for participation but had missing 
medical files or no informant that was willing to provide information on the presence of 
suicidal ideation were considered as participants with missing information. 
Cohort studies
1. Selection of study population 
(1) Adequate: Participants are a random (consecutive) sample of eligible patients, most 
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important aspect: non-exposed cohort drawn from same community as the exposed 
cohort and at the same time point in course of disease. 
(2) Inadequate or not reported: Participants are not a random sample of eligible patients, 
especially inadequate when non exposed cohort is drawn from different source or at 
different time point in course of disease.
2. Assessment of determinant (presence of suicidal ideation) 
(1) Adequate: description of suicidal ideation assessment provided.  
(2) Inadequate: no description of suicidal ideation assessment provided. 
3. Assessment of outcome (completed suicide) 
(1) Adequate: Use of death certificates/coroners verdicts/medical verdicts/registries to 
avoid misclassification of suicides.  
(2) Inadequate or not reported: No use of death certificates/coroners verdicts/medical 
verdicts/registries, misclassification of suicides likely.
4. Missing information on follow-up 
(1) Adequate: no or small number of participants lost to follow-up: ≤ 10%. If death 
registries were used with expected coverage > 90%, this item was scored adequate. 
(2) Inadequate or not reported: large number of participants lost to follow-up: >10%.
Scoring system
Total score is computed by adding scores on four items (range 0–4 points).  
Low risk of bias: total score 4 points 
Medium risk of bias: total score 5-6 points 
High risk of bias: total score 7-8 points









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Studies included in the meta-analysis
Log Risk Ratio
Supplement S5. Publication bias
Supplementary Figure 2. Funnel plot displaying effect estimates from included studies.
Egger’s test for funnel plot asymmetry: p = 0.82.
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In this thesis the epidemiology of suicidal ideation and suicide attempts (together referred 
to as ‘suicidality’) in Huntington’s disease (HD) is investigated, and coping styles and support 
strategies that may serve to help suicidal HD mutation carriers are explored. Prevalence and 
incidence, as well as sociodemographic, clinical and biological cross-sectional and longitudinal 
associations with suicidality were studied in a Dutch and in a European cohort of HD mutation 
carriers. In a qualitative study we explored how HD mutation carriers coped with suicidality and 
what their ideas and wishes were regarding how relatives and healthcare professionals could 
help them in coping with suicidality. Additionally, we examined how spouses of HD mutation 
carriers supported their partners with regard to suicidality. Finally, we examined whether the 
expression of suicidal ideation predicted subsequent completed suicide in various populations.
Previous studies showed an increased prevalence of suicidal ideation, suicide attempts and 
completed suicide in both pre-motor and motor symptomatic mutation carriers, compared 
with the general population (Chapter 1). Although various characteristics associated with 
suicidality and suicide have been reported, there appeared to be a lack of prospective studies 
to identify HD mutation carriers at highest risk of developing suicidality.
The results of the studies described in chapters 2 and 3 of this thesis confirm that suicidality 
frequently occurs in HD, with up to 20% of both pre-motor and motor symptomatic mutation 
carriers reporting suicidality in the month prior to the interview, compared with 0% of the 
controls. Mutation carriers who were most likely to currently experience suicidal ideation or 
suicidality had a shorter disease duration, were anxious, aggressive, previously attempted 
suicide, used antidepressants, and had a depressed mood. The presence of a depressed mood 
and the use of benzodiazepines were the only significant independent predictors of incident 
suicidal ideation or suicidality.
Apart from the sociodemographic and clinical associations, we also investigated cross-sectional 
biological associations of suicidality in HD, in particular the functioning of the immune system 
(Chapter 4) and the hypothalamus-pituitary-adrenal (HPA) axis (Chapter 5). In a Dutch cohort 
of HD mutation carriers, no cross-sectional associations were found between markers of the 
acute phase response (i.e. C-reactive protein and albumin) and suicidality. However, we did 
find associations between markers of the acute phase response proteins and several other 
clinical characteristics (e.g. disease stage), but these associations disappeared after adjusting 
for the use of antipsychotics (Chapter 4). Also, in the same cohort, it was shown that parameters 
of HPA axis activity were not associated with the severity of depressive symptoms or suicidality. 
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However, subgroup analyses revealed varying associations in pre-motor, early and late disease 
stages, with significantly higher morning cortisol levels in depressed pre-motor and early 
stage motor symptomatic HD mutation carriers, compared with non-depressed HD mutation 
carriers from these disease stages (Chapter 5).
Given the increased frequency of suicidality in HD compared with controls (Chapter 2) and 
the lack of treatment guidelines, we conducted a qualitative study in which HD mutation 
carriers who had experienced suicidal ideation or attempted suicide and their partners were 
interviewed (Chapter 6). HD mutation carriers generally used four strategies to cope with 
suicidality: talking about suicidality, employing self-management activities, using medication 
and discussing end-of-life wishes. Partners, relatives, and healthcare professionals can support 
suicidal HD mutation carriers in carrying out each of these strategies.
Suicidal ideation, sometimes combined with suicide attempts, was the outcome in all our 
studies. Therefore, the systematic review and meta-analysis described in chapter 7 examined 
whether the expression of suicidal ideation predicted subsequent completed suicide in 
different clinical and non-clinical populations. The risk of completed suicide was 3-8 times 
higher (depending on the population investigated) in individuals who had expressed suicidal 
ideation compared with individuals who had not. All in all, psychiatric populations showed the 
highest absolute suicide risks after expression of suicidal ideation but the lowest relative risks, 
whereas (vice versa) the non-psychiatric populations showed the highest relative risks but 
the lowest absolute risks. However, none of the included studies investigated the association 
between suicidal ideation and subsequent completed suicide in HD.
General discussion
Overall, we can conclude that suicidality frequently occurs in both pre-motor and motor 
symptomatic HD mutation carriers. Therefore, it is important to regularly assess HD mutation 
carriers for suicidality, especially when they have a depressed mood. Healthcare professionals 
can play a crucial role in supporting suicidal HD mutation carriers by providing an opportunity 
to talk about suicidality, providing psychoeducation on self-management, prescribing 
medication, and discussing end-of-life wishes.
Do HD mutation carriers at risk of suicidality differ from those at risk in non-HD populations?
The presence of psychiatric disorders and symptoms, in particular depression and a previous 
suicide attempt, are the most important associations and predictors of suicidality and suicide in 
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both the general population and other clinical populations.1-16 In the thesis, mainly psychiatric 
conditions, in particular the presence of a depressed mood, were shown to be associated with 
or predictive of suicidality in HD (Chapter 2 and 3), as well as in other HD studies.17-20 However, 
suicidality assessment in non-HD clinical populations mainly focuses on the presence of actual 
full-blown mood disorders, rather than on the presence of a depressed mood.21;22 We found 
that in HD a DSM-IV diagnosis of depression was no longer associated with suicidality after 
other psychiatric symptoms had been included in the regression model (Chapter 2). A possible 
explanation for this is the limited statistical power of the study. Also, an actual DSM diagnosis 
of depression might be less applicable in HD and less suited as a predictor of suicidality in HD, 
since several of the symptoms of a DSM diagnosis of depression (e.g. weight loss and sleep 
disturbance) also occur as physical symptoms of HD.23 Another discrepancy with results from 
non-HD studies is that a previous suicide attempt did not predict incident suicidal ideation, 
as described in chapter 3. This might be because suicidal ideation is clinically different from 
suicide attempts and completed suicide.22;24 Nevertheless, these three different aspects of the 
suicidality spectrum are associated but, for example, only 1.2% of the psychiatric patients who 
had expressed suicidal ideation actually died by suicide in the following year (Chapter 7). The 
clinical differences between individuals who think of, attempt, or die by suicide might explain 
why we found no sociodemographic associations of suicidality (Chapter 2 and 3). This is in 
contrast to studies on suicide in both HD and Western non-HD populations, which showed 
that being male was associated with a 2-4 times increased risk of completed suicide.12;25;26 In 
contrast, females were more likely to think of or attempt suicide, as shown in both one HD 
study19 and in various non-HD studies9;16;27-29 However, these latter associations were smaller 
and less consistent than those reported for male gender and suicide.
Moreover, some clinical characteristics known to be associated with suicidality in non-HD 
populations were not investigated in this thesis. For example, alcohol misuse is one of the 
most common psychiatric disorders in persons who die by suicide12 and increases the risk of 
suicidality.30 Also, HD mutation carriers with the most severe suicidal ideation were more likely 
to report alcohol abuse.18 Hopelessness and other psychological stressors are also prominent 
predictors of suicidal ideation and important in the risk of attempted and completed suicide 
in adults.31 Hopelessness in HD was shown to be increased in the first week after predictive 
testing and rose again 7-10 years after predictive testing, which could be the period when 
mutation carriers start to notice the first symptoms of the disease given their mean age of 
45 years.32 Feelings of hopelessness may also have resulted from the onset of HD in family 
members, loss of relatives, and a subsequent decrease in social support.32 The period around 
symptom onset was also identified as a high-risk period for suicidal ideation in HD.33 An 
association between hopelessness and both suicidality and suicide has not been found in HD; 
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however,  this was investigated in only one study with 13 suicidal events.19 Other personality 
traits (like impulsivity) might also be associated with suicidality in HD, as was found in non-
HD populations,12;31;34 given the disrupted frontal-subcortical circuits.18;35 While impulsivity was 
not investigated in this thesis or in other HD studies,18;19 suicidal ideation was associated with 
aggression (Chapter 3).18 Aggression is related to impulsivity and is even considered by some 
as a single phenotype.34
The only non-psychiatric characteristic we found to be associated with suicidality in HD was a 
shorter duration of HD (Chapter 3). This is in line with results from other HD studies showing 
that suicidal ideation and completed suicide occur more frequently in pre-motor, early 
symptomatic and middle symptomatic stages, than in later disease stages.25;33;36-38 Therefore, HD 
disease stage is an additional factor that should be taken into account when aiming to identify 
HD mutation carriers at highest risk of suicidality. Currently, a clinical diagnosis of HD is mainly 
based on motor symptoms.39 However, suicidality already occurs in 20% of the pre-motor 
symptomatic HD mutation carriers (Chapter 2) and up to 30% of the pre-motor symptomatic 
mutation carriers reported other neuropsychiatric symptoms.23;40 Many patients and their 
caregivers consider these symptoms to be the most distressing aspect of the disease.41 In case 
of such early neuropsychiatric symptoms, regular assessments and adequate symptomatic 
treatment are essential before motor symptoms become manifest. This questions whether 
the current criteria for a clinical HD diagnosis (that mainly rely on motor symptoms39) are 
adequate, or whether alternative criteria should be formulated which also take into account 
neuropsychiatric and cognitive symptoms.40;42
The associations between the immune system and HPA axis functioning on the one hand and 
suicidality on the other, as found in several studies on non-HD clinical populations,43-50 were 
not replicated in our Dutch HD cohort (Chapter 4 and 5). First of all, this could be explained 
by the fact that studies that previously reported on these associations in other populations 
often assessed other biological parameters or used different suicidality outcomes and 
assessment methods. For example, in non-HD populations, lower levels of interleukin 2 and 
4 were more consistently associated with suicidality than elevated CRP levels.43 Furthermore, 
the association between HPA axis functioning and completed suicide was more consistently 
reported in non-HD populations than its association with suicidality,46;48;51 whereas we assessed 
the association with suicidality using a single item of the Problem Behaviours Assessment.52 
Apart from these methodological considerations and other explanations discussed in the 
related chapters, it is possible that in HD, compared with non-HD populations, different 
mechanisms result in altered biological parameters or that these dysregulated systems have 
a different effect on clinical outcomes. Also within HD, there might be different mechanisms 
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for and influences of disturbed biological parameters in different disease stages. In chapter 
5 and in another HD study53 an association was shown between higher salivary morning 
cortisol concentrations and depressive symptoms in early disease stage mutation carriers, 
but not in the overall cohort. Causal relations between biological parameters and suicidality 
cannot be disentangled in observational studies due to the lack of consistency.54 Also from 
non-HD studies it is questionable whether the associations found between these biological 
characteristics and suicidality are causal. The use of biological markers for treatment, or for risk 
assessment purposes, is not recommended in clinical guidelines.21;22
Medication use and suicidality
In this thesis, several associations were found between medication use: specifically, 
antidepressants and benzodiazepines, and suicidality (Chapter 2 and 3). However, because 
we investigated associations, no conclusions can be drawn regarding causality. In non-HD 
studies, the debate continues about the efficacy and risk of antidepressant use and, to a lesser 
extent, about the risk of benzodiazepine use for attempted and completed suicide.55;56 Some 
studies and meta-analyses reported that attempted and completed suicide in adults can occur 
as a side-effect of benzodiazepine or antidepressant use;56-59 however, such conclusions are 
hampered by methodological limitations of these studies60-62 and results from other studies.62-64 
However, in several meta-analyses the efficacy of antidepressants in reducing repeated self-
harm or completed suicide could not be demonstrated.63-65
Whether antidepressants or benzodiazepines cause suicidality cannot be inferred from 
the few ecological and observational studies to date, e.g. due to simultaneous changes in 
other risk factors and confounding by indication.61;66;67 Also, causal inference is hindered by 
methodological limitations of the experimental clinical studies which assessed the efficacy and 
risks of antidepressants on suicide attempts and completed suicide.60;62;64;66 Lack of power due 
to the infrequent occurrence of these events is one of the limitations, which could not even 
be solved by conducting a meta-analysis, because 1.9 million participants would be needed 
in a trial to detect a 20% decrease in completed suicide risk.63 Given the low number of events 
in these studies, the overall outcome could be completely changed by an error in reporting 
or not reporting a few cases.60 Additionally, randomised controlled trials on the efficacy of 
antidepressants have a short follow-up (< 10 weeks) while in clinical practice the treatment 
may take 3-4 months to exert maximal benefit;66 also, there is a larger drop-out in the placebo 
group which might result in underreporting of suicidal events in this group,61 and information 




Thus, there is insufficient evidence to allow any causal conclusions to be drawn about 
associations between certain medication use and suicidality, mainly due to the methodological 
limitations of the studies. Nevertheless, the results of this thesis show that it is important for 
HD healthcare professionals to regularly assess suicidality in HD mutation carriers who use 
antidepressants and benzodiazepines, as they are a vulnerable group most likely to currently 
experience suicidality or develop suicidality in the future.
Prediction versus aetiology 
In chapters 2-5 of this thesis sociodemographic, clinical and biological characteristics 
associated with suicidality in HD were investigated. Two of these studies (Chapter 2 and 3) 
aimed to discover and evaluate characteristics that might be useful in identifying HD mutation 
carriers at highest risk of suicidality, while two other studies (Chapter 4 and 5) aimed to explain 
the occurrence of suicidality in HD.
The first steps in prediction research involve investigating the prognostic factors68 for suicidality 
in HD and determining which sociodemographic and clinical characteristics independently 
contribute to the estimation of the probability of suicidality, and to quantify to what extent.69;70 
Ideally, future studies can use such characteristics identified in previous research as building 
blocks for a prediction model. Chapter 7 shows that this is rarely done in studies that aim 
to predict suicide in non-HD populations. Most prediction studies in both HD and non-HD 
populations only determine which characteristics independently contribute to the suicidality 
or suicide risk, without taking it a step further by developing a prediction model and validating 
this in a different sample.71 If a prediction model is developed, it is essential that absolute risks 
of suicidality or suicide can be calculated. This is not always possible due to a missing intercept 
value, from which the probability of the outcome in an individual patient can be derived 
when the other variables in the model are set to zero.72 The development and validation of a 
prediction model was not pursued in this thesis. The limited number of suicidality cases in our 
studies together with the lack of previously identified predictors would likely have resulted in 
overly optimistic models. This optimism would probably be too large to be corrected for by 
shrinkage techniques, which reduce the regression coefficients to less extreme values. In such 
a case, the obtained prediction model cannot be generalised to other samples as the predicted 
probabilities will be too extreme in new samples, i.e. too high for the participants with the 
outcome and too low for those without the outcome.69;70;73
The value of a prediction model in estimating the absolute risk of future suicidal events for an 
individual patient is debatable.74-76 It is currently not possible to accurately predict the risk of 
suicide in an individual, even though there are characteristics associated with suicidality and 
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suicide at group level.22;77;78 The low base rate of suicide results in low positive predictive values 
and in the majority of the suicides occurring in the group that is classified as low-risk according 
to the prediction model.6;75;77;79;80 It is important to note that these studies are carried out in 
a clinical environment where interventions will be applied if a patient is considered to be at 
high risk of suicide, which might have resulted in an underestimation of the positive predictive 
value.6;22
Although checklists based on associations of suicidality and suicide cannot predict the 
long-term suicide risk in an individual, suicide risk assessment in clinical practice remains 
important.74;80;81 There are several important differences between prediction models for 
suicidality or suicide and clinical suicide assessment in clinical practice. First of all, the issue 
of imminent suicide risk in the patient’s current context is addressed in clinical practice,82 
while chapter 7 shows that studies which assessed the suicide risk had a follow-up of up to 
22 years, with only 22% of these studies assessing this risk within the first year of follow-up. 
Most importantly, suicide risk assessment in clinical practice should not merely be based on 
a ‘tick box’ approach74 that classifies patients as either high or low risk on the basis of a list 
of risk factors.22 Suicidality assessment in clinical practice should include a detailed analysis 
of current and previous suicidality using a systematic approach and investigation of relevant 
vulnerability and stress factors.22 In order to decide on the appropriate intervention, the 
healthcare professional has to clinically weigh all information obtained from the patient 
and relatives, which is most valid and reliable when the healthcare professional establishes 
a therapeutic alliance by actively listening and showing empathy and trust.22;83 This not only 
improves risk assessment, but talking about suicidality in a safe environment can help patients 
in coping with suicidality, as shown in chapter 6.
In contrast to prediction research, etiological research focuses on modifiable targets for 
treatment interventions. In chapters 4 and 5 of this thesis, biological associations of suicidality 
in HD were studied with the aim to explain the occurrence of suicidality in HD. If causes of 
suicidality are identified they can become targets for interventions. However, causality cannot 
be inferred from these cross-sectional studies, even though we corrected for confounders, 
e.g. due to lack of consistency54 and exchangeability.84 In chapter 4 an association was found 
between the use of antipsychotics and an elevated acute-phase response in HD, which remained 
significant after correction for confounders. However, confounding by indication is difficult 
to control for given the complexity of the indication. Mutation carriers using antipsychotics, 
which are prescribed for motor symptoms,85 were in a more severe disease stage, implying 
that they also have most immune activation86 and the most neuropsychiatric87 and cognitive 
symptoms. An additional problem for causal inference was the fact that there were hardly any 
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mutation carriers in the pre-motor or early disease stages who used antipsychotics.84
The causes of suicidality in HD remain elusive. With the use of observational aetiological 
research we will probably never be able to fully identify all causes of suicidality in HD. However, 
it is important that future studies focus on treatment strategies, so that effective strategies can 
be identified and provided to suicidal HD mutation carriers and HD mutation carriers at high 
risk of developing suicidality.
Recommendations for future research
Evidence-based treatment guidelines for suicidality in HD might be established faster if 
qualitative studies (like the study described in chapter 6) are considered as a starting point 
for future quantitative research, rather than first establishing possible causal determinants 
in observational research which are later examined and treated in experimental studies. 
The combination of the proposed strategies (talking about suicidality, self-management 
strategies, medication use, and discussing end-of-life wishes) are likely targets for (some of ) 
the multifactorial causes of suicidality in HD and should be investigated in future HD specific 
pragmatic trials. Additional support strategies for suicidal HD mutation carriers may also result 
from qualitative studies in other countries, where euthanasia is not possible.
In addition, future observational studies should focus on associations of completed suicide 
in HD, which might differ from associations of suicidality. Large observational cohort studies 
with regular assessments of clinical, motor, psychiatric, and cognitive signs and symptoms, like 
REGISTRY,88 COHORT,89 and especially ENROLL90 make such studies possible if causes of death 
are adequately registered. Such registries also allow to investigate which suicidal mutation 
carriers are most likely to act on their thoughts in the future.
Future studies that investigate suicidality in HD should also focus on characteristics that have 
not yet been investigated, such as impulsivity. We recommend to include different suicidality 
outcome measures, as non-HD studies have shown that different suicidality assessments can 
result in varying prevalence numbers even if administered to the same participants at the 
same time.91 So far, studies in HD assessed suicidality using one single item of the Unified 
Huntington’s Disease Rating Scale (Chapter 3)92 or Problem Behaviour Assessment (Chapter 
2 and 4-6).52 However, for more elaborate documentation and in clinic trials the use of the 
Columbia-Suicide Severity Rating Scale (C-SSRS)93 is recommended by the National Institute of 
Neurological Disorders and Stroke (NINDS).94 However, the C-SSRS has not yet been validated 
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in HD and to date has not been used to assess the frequency or associations of suicidality in HD.
Clinical recommendations
Although there is no turnkey solution for suicidality in HD, healthcare professionals can play an 
important role in the diagnostic process and treatment of suicidal HD mutation carriers. First 
of all, clinicians working with HD mutation carriers should be aware of the increased risk of 
suicidal ideation, suicide attempts, and completed suicide. Assessment of suicidality is already 
important in pre-motor symptomatic mutation carriers and should be introduced by asking 
about a depressed mood, which is the most important association and predictor of suicidality 
in HD. If a mutation carrier experiences suicidality they must be referred to a (preferably) HD-
related psychologist or psychiatrist for regular sessions to talk about suicidality. Listening to 
and taking the thoughts seriously are the most important factors to facilitate talking about 
suicidality. Apart from talking about suicidality, advice can be given on self-management 
activities, with the aim to maintain the balance between actively facing HD/suicidality and 
taking one’s mind off them. Medication, especially antidepressant use, may be effective in 
reducing suicidal thoughts, but should be combined with talking about suicidality; this was 
deeply appreciated by the participating suicidal HD patients. If a mutation carrier has a wish 
for euthanasia and this is legal in their country, the healthcare professional should provide 
adequate information about the legal requirements, regularly discuss the end-of-life wishes, 
and show a commitment of best intentions.95;96 Spouses should be involved in the supportive 
treatment, given the high burden of suicidality on spouses of HD mutation carriers and the 
support spouses can provide. Many spouses need guidance on talking about suicidality with 
their partner. Furthermore, suggestions for support strategies for the caregiver may help to 
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In dit proefschrift worden de resultaten beschreven van een onderzoek naar de epidemiologie 
van suïcidaliteit (suïcidale gedachten en suïcidepogingen) bij de ziekte van Huntington (ZvH) 
en naar copingstijlen en ondersteuningsstrategieën die suïcidale ZvH patiënten kunnen 
helpen. In een Nederlands en in een Europees cohort van ZvH gendragers werden, naast de 
prevalentie en incidentie van suïcidaliteit, de sociodemografische, klinische en biologische 
kenmerken die cross-sectioneel en longitudinaal geassocieerd zijn met suïcidaliteit 
onderzocht. In een kwalitatief onderzoek werd daarna geëxploreerd hoe ZvH gendragers 
zelf omgaan met suïcidaliteit en wat hun ideeën en wensen zijn ten aanzien van hoe naasten 
en gezondheidszorgprofessionals hen kunnen helpen bij het omgaan met suïcidaliteit. Ook 
werden de partners van deze ZvH gendragers geïnterviewd om te onderzoeken hoe zij 
hun partners ondersteunen bij het omgaan met suïcidaliteit. Tot slot werd in verschillende 
populaties onderzocht of het uiten van suïcidale gedachten voorspellend is voor een latere 
suïcide.
In de introductie (Hoofdstuk 1) wordt belicht dat de prevalentie van suïcidale gedachten, 
suïcidepogingen en suïcides bij zowel pre-motor als motor symptomatische ZvH gendragers 
hoger is dan in de algemene bevolking. Hoewel in een aantal eerdere onderzoeken de 
kenmerken die samenhangen met de aanwezigheid van suïcidaliteit en met suïcides bij 
ZvH gendragers werden nagegaan, bleek er een gebrek aan longitudinale studies waarin 
onderzocht wordt welke ZvH mutatiedragers de grootste kans hebben om suïcidaal te worden.
De in hoofdstuk 2 en 3 beschreven resultaten bevestigen dat suïcidaliteit frequent bij de ziekte 
van Huntington voorkomt. Tot 20% van zowel de pre-motor als motor symptomatische ZvH 
gendragers rapporteerde suïcidale gedachten in de maand voorafgaande aan het interview, 
vergeleken met 0% van de controle onderzoeksdeelnemers. ZvH gendragers die ten tijde van 
het interview suïcidale gedachten of suïcidaliteit ervoeren, hadden een kortere ziekteduur, 
waren vaker angstig en agressief, hadden vaker een eerdere suïcidepoging gedaan, gebruikten 
vaker antidepressiva en hadden vaker een depressieve stemming. De aanwezigheid van een 
depressieve stemming en het gebruik van benzodiazepines waren de enige onafhankelijke 
voorspellers van incidente suïcidale gedachten of suïcidaliteit.
Naast sociodemografische en klinische associaties hebben we ook associaties tussen 
biologische parameters en suïcidaliteit bij de ZvH onderzocht, in het bijzonder het functioneren 
van het immuunsysteem (Hoofdstuk 4) en de hypothalamus-hypofyse-bijnier (HHB) as 
(Hoofdstuk 5). Er werden geen cross-sectionele associaties gevonden tussen parameters van 
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de acute-fase-reactie (i.e. C-reactief proteïne en albumine) en suïcidaliteit in een Nederlands 
cohort van ZvH gendragers. We vonden wel associaties tussen parameters van de acute-
fase-reactie en verschillende andere klinische karakteristieken, zoals ziektestadium, maar 
deze associaties verdwenen na correctie voor het gebruik van antipsychotica (Hoofdstuk 4). 
Daarnaast bleek in ditzelfde cohort dat parameters van HHB as activiteit niet geassocieerd 
waren met de ernst van depressieve symptomen of suïcidaliteit. Subgroep analyses lieten 
echter zien dat de onderzochte associaties varieerden tussen pre-motor, en vroeg- en laat-
ziektestadium gendragers, waarbij depressieve gendragers uit het pre-motor en vroeg-motor 
symptomatische ziektestadium hogere ochtend cortisol niveaus hadden vergeleken met niet-
depressieve gendragers uit deze ziektestadia (Hoofdstuk 5).
Aangezien de prevalentie van suïcidaliteit bij de ZvH verhoogd is vergeleken met controle 
onderzoeksdeelnemers (Hoofdstuk 2) en er momenteel geen behandelrichtlijnen zijn voor 
suïcidaliteit bij de ZvH, hebben wij een kwalitatief onderzoek uitgevoerd (Hoofdstuk 6). In 
dit onderzoek werden ZvH gendragers die eerder suïcidale gedachten hadden gehad of een 
suïcidepoging hadden gedaan en hun partners geïnterviewd. ZvH gendragers gebruikten 
doorgaans vier strategieën om met suïcidaliteit om te gaan, namelijk: praten over suïcidaliteit, 
zelfmanagement activiteiten, gebruik van medicatie en het bespreken van levenseindewensen. 
Partners, naasten en gezondheidszorgprofessionals kunnen suïcidale ZvH gendragers 
ondersteunen bij elk van deze vier strategieën. 
De aanwezigheid van suïcidale gedachten, soms gecombineerd met suïcidepogingen, was 
de uitkomst variabele van al onze studies. Daarom hebben we een systematische review en 
meta-analyse uitgevoerd (Hoofdstuk 7), waarin werd onderzocht of het uiten van suïcidale 
gedachten voorspellend is voor een latere suïcide in verschillende klinische en niet-klinische 
populaties. Het risico op een suïcide was 3 tot 8 keer hoger (afhankelijk van de populatie 
die werd onderzocht) bij individuen die suïcidale gedachten hadden geuit, vergeleken 
met individuen die dat niet hadden gedaan. In psychiatrische populaties was het absolute 
suïciderisico na het uiten van suïcidale gedachten het hoogst maar het relatieve risico was hier 
het laagst, terwijl (vice versa) in niet-psychiatrische populaties het relatieve risico het hoogst 
was maar het absolute risico het laagst. Geen van de in de meta-analyse geïncludeerde studies 
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